GREEN JEREMY (US)
CHARIFSON PAUL (US)
GIROUX SIMON (US)
GRIFFIN ANDREW (CA)
WO2013049567A1 | 2013-04-04 | |||
WO2012137224A1 | 2012-10-11 |
US20100137371A1 | 2010-06-03 | |||
US20200031794A1 | 2020-01-30 |
Claims 1. A compound, or a pharmaceutically acceptable salt thereof, according to formula (I): wherein: W is C6-C10 aryl, C6-C10 cycloaryl, or 5-10 membered heteroaryl, any of which is optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, trifluoromethyl, difluoromethyl, cyano, hydroxyl, C1-C4 alkoxyl, and C1-C4 alkyl optionally substituted with one or more deuterium or hydroxyl; R is hydrogen, CH2CH2R2, 5- or 6-membered heterocyclyl optionally substituted with C1-C4 alkyl or C(O)R3, or C1-C6 alkyl optionally substituted with one or more groups, each independently selected from the group consisting of C1-C4 alkyl, 5- or 6- membered heterocyclyl, hydroxyl, cyano, fluoro, C1-C4 alkoxyl, C1-C4 haloalkoxyl, and NR3R4, or R is C6-C10 aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, C1-C4 haloalkoxyl, C1-C4 alkoxyl, and C(O)R3, provided that when R is hydrogen, then R1 is methyl and W is substituted, and further provided that when R is methyl, then W is disubstituted; R1 is hydrogen, fluoro, chloro, hydroxyl, cyano, C3-C4 cycloalkyl, C1-C2 alkoxyl, C1-C2 haloalkoxyl, or C1-C3 alkyl optionally substituted with one or more fluoro; R2 is C6-C10 aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, C1-C4 haloalkoxyl, and C1-C4 alkoxyl, OR3, NR3R4, C(O)R3, or C(O)NR3R4; each R3 is independently hydrogen or C1-C4 alkyl optio Cna1l-lCy4 substituted with one or more groups selected from the group consisting of fluoro, hydroxyl, C1-C4 haloalkoxyl, and C1-C4 alkoxyl; each R is independently R3, C(O)C1-C4 alkyl optionally substituted with one or more fluoro groups, or C(O)NHC1-C4 alkyl optionally substituted with one or more fluoro groups; or if R3 and R4 are attached to the same nitrogen atom, R3 and R4 together with their connecting nitrogen form a 5- or 6-membered heterocyclic ring optionally containing another heteroatom that is N, O, S, S(O), or S(O)NR3, and such heterocyclic ring is optionally substituted with one or more groups each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, C1-C4 alkoxyl, C1-C4 haloalkoxyl, carboxyl, and C1-C4 alkylcarboxylate; and R5 is hydrogen or C1-C4 alkyl. 2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein: W is C6 aryl, C6 cycloaryl, or a 5- or 6-membered heteroaryl, any of which is optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1 alkyl, trifluoromethyl, hydroxyl, and C1 alkoxyl; R is hydrogen, CH2CH2R2, C6 aryl, 5- or 6-membered heterocyclyl optionally substituted with C1 alkyl or C(O)R3, or C1-C4 alkyl optionally substituted with one or more groups, each independently selected from the group consisting of 6-membered heterocyclyl, hydroxyl, cyano, fluoro, C1 alkoxyl, and NR3R4; R1 is hydrogen or C1 alkyl; R2 is C6 aryl; each R3 is independently hydrogen or C1 alkyl; and each R4 is independently R3. 3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein: W is C6 aryl or 5-membered heteroaryl, any of which is optionally substituted with one or more groups, each independently selected from the group consisting of methyl, chloro, and fluoro; R is 6-membered heterocyclyl or C1-C4 alkyl optionally substituted with one or more groups independently selected from the group consisting of cyano, fluoro, and methoxyl; and R1 is hydrogen. 4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein: W is C6 aryl substituted with one or more methyl; R is C1-C4 alkyl optionally substituted with one or more groups independently selected from the group consisting of cyano and methoxyl; and R1 is hydrogen. 5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein: W is C6 aryl that is substituted with one or more methyl; R is C1-C2 alkyl that is substituted with cyano; and R1 is hydrogen. 6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein: W is C6 aryl that is substituted with two methyl; R is C1 alkyl substituted with cyano; and R1 is hydrogen. 7. A pharmaceutical composition comprising a compound according to claim 2, and a pharmaceutically acceptable excipient. 8. A pharmaceutical composition comprising a compound according to claim 3, and a pharmaceutically acceptable excipient. 9. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: 10. The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: 11. The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein the compound is: 12. The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein the compound is: 13. The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein the compound is: 14. The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: 15. A pharmaceutical composition comprising a compound according to claim 10, and a pharmaceutically acceptable excipient. 16. A method of inhibiting the activity of POLRMT with a compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein: W is C6-C10 aryl, C6-C10 cycloaryl, or 5-10 membered heteroaryl, any of which is optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, trifluoromethyl, difluoromethyl, cyano, hydroxyl, C1-C4 alkoxyl, and C1-C4 alkyl optionally substituted with one or more deuterium or hydroxyl; R is hydrogen, CH2CH2R2, 5- or 6-membered heterocyclyl optionally substituted with C1-C4 alkyl or C(O)R3, or C1-C6 alkyl optionally substituted with one or more groups, each independently selected from the group consisting of C1-C4 alkyl, 5- or 6- membered heterocyclyl, hydroxyl, cyano, fluoro, C1-C4 alkoxyl, C1-C4 haloalkoxyl, and NR3R4, or R is C6-C10 aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, C1-C4 haloalkoxyl, C1-C4 alkoxyl, and C(O)R3, provided that when R is hydrogen, then R1 is methyl and W is substituted, and further provided that when R is methyl, then W is disubstituted; R1 is hydrogen, fluoro, chloro, hydroxyl, cyano, C3-C4 cycloalkyl, C1-C2 alkoxyl, C1-C2 haloalkoxyl, or C1-C3 alkyl optionally substituted with one or more fluoro; R2 is C6-C10 aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, C1-C4 haloalkoxyl, and C1-C4 alkoxyl, OR3, NR3R4, C(O)R3, or C(O)NR3R4; each R3 is independently hydrogen or C1-C4 alkyl optionally substituted with one or more groups selected from the group consisting of fluoro, hydroxyl, C1-C4 haloalkoxyl, and C1-C4 alkoxyl; each R4 is independently R3, C(O) C1-C4 alkyl optio Cna1-lCly4 substituted with one or more fluoro groups, or C(O)NHC1-C4 alkyl optionally substituted with one or more fluoro groups; or if R3 and R4 are attached to the same nitrogen atom, R3 and R4 together with their connecting nitrogen form a 5- or 6-membered heterocyclic ring optionally containing another heteroatom that is N, O, S, S(O), or S(O)NR3, and such heterocyclic ring is optionally substituted with one or more groups each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, C1-C4 alkoxyl, C1-C4 haloalkoxyl, carboxyl, and C1-C4 alkylcarboxylate; and R5 is hydrogen or C1-C4 alkyl. 17. The method according to claim 16, wherein: W is C6 aryl, C6 cycloaryl, or a 5- or 6-membered heteroaryl, any of which is optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1 alkyl, trifluoromethyl, hydroxyl, and C1 alkoxyl; R is hydrogen, CH2CH2R2, C6 aryl, 5- or 6-membered heterocyclyl optionally substituted with C1 alkyl or C(O)R3, or C1-C4 alkyl optionally substituted with one or more groups, each independently selected from the group consisting of 6-membered heterocyclyl, hydroxyl, cyano, fluoro, C1 alkoxyl, and NR3R4; R1 is hydrogen or C1 alkyl; R2 is C6 aryl; each R3 is independently hydrogen or C1 alkyl; and each R4 is independently R3. 18. The method according to claim 16, wherein: W is C6 aryl or 5-membered heteroaryl, any of which is optionally substituted with one or more groups, each independently selected from the group consisting of methyl, chloro, and fluoro; R is 6-membered heterocyclyl or C1-C4 alkyl optionally substituted with one or more groups independently selected from the group consisting of cyano, fluoro, and methoxyl; and R1 is hydrogen. 19. The method according to claim 16, wherein the compound is selected from the group consisting of: 20. The method according to claim 16, wherein the compound is selected from the group consisting of: |
0146 Synthesis of ethyl 3-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate, Example 10 [Step 1]: A mixture of 7-hydroxy-4-(o-tolyl)-2H-chromen-2-one (Example 1, 200 mg, 0.793 mmol), ethyl prop-2-enoate (1.0 mL, 9.51 mmol) and DMAP (19 mg, 0.159 mmol) was heated to 100 °C for 24 h. The reaction temperature was increased to 120 °C and held there for another 24 h. Reaction was continued for another 48 h. at 130 °C. The mixture was cooled to ambient temperature and concentrated under reduced pressure. Purification by flash column chromatography on silica gel gave ethyl 3-((2-oxo- 4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (Example 10, 48 mg). 1 H NMR (400 MHz, DMSO-d6) δ 7.45-7.35 (m, 3H), 7.25 (d, 1H), 7.10 (m, 1H), 6.86 (m, 2H), 6.19 (s, 1H), 4.3 (t, 2H), 4.1 (q, 2H), 2.82 (t, 2H), 2.11 (s, 3H), 1.18 (t, 3H). LCMS (ESI) Calcd. for C21H20O5: 352, found [M+H] + = 353. 0147 Synthesis of 3-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoic acid, Example 11 [Step 2]: To a solution of ethyl 3-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate (Example 10, 45 mg, 0.128 mmol) in THF (4 mL) at ambient temperature was added a solution of LiOH∙H2O (27 mg, 0.639 mmol) in water (1 mL). The reaction mixture was stirred for 5 h., and concentrated under reduced pressure. The resulting mixture was acidified with saturated aqueous citric acid solution and extracted with EtOAc (twice). The combined organic extracts were washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 3-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoic acid (Example 11, 41 mg). LCMS (ESI) Calcd. for C19H16O5: 324, found [M+H] + = 325. 0148 Synthesis of N-methyl-3-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Example 12 [Step 3]: To a solution of 3-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanoic acid (Example 11, 41 mg, 0.126 mmol) in CH2Cl2 (4 mL) at ambient temperature and under an inert atmosphere was added methyl amine hydrochloride (10 mg, 0.152 mmol). The mixture was cooled to 0 °C and DIPEA (0.044 mL, 0.253 mmol) was added, followed by dropwise addition of T 3 P, 50 % in EtOAc (0.041 mL, 0.139 mmol). The resulting mixture was gradually warmed to ambient temperature and stirred for 2 h. The mixture was diluted with CH 2 Cl 2 , washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC to produce N-methyl-3-((2-oxo-4- (o-tolyl)-2H-chromen-7-yl)oxy)propanamide (Example 12, 7 mg). 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.92 (br s, 1H), 7.43-7.33 (m, 3H), 7.23 (d, 1H), 7.08 (s, 1H), 6.87 (m, 2H), 6.18 (s, 1H), 4.33 (t, 2H), 2.59-2.55 (m, 5H), 2.10 (s, 3H). LCMS Calcd. for C20H19NO4: 337, found [M+H] + = 338. Examples 13-14: 4-(2-chloro-4-fluorophenyl)-7-hydroxy-2H-chromen-2-one and methyl 2- ((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-m ethoxypropanoate 0149 Synthesis of ethyl 3-(2-chloro-4-fluorophenyl)-3-oxopropanoate, 4 [Step 1]: Sodium hydride (60 % dispersion in mineral oil) (12.11 g, 303 mmol) was charged in a 1 L round-bottom flask, washed with n-pentane, and dried under flow of nitrogen gas. Dry toluene (150 mL) was added and the resulting suspension was cooled to 0 °C. Diethyl carbonate (70 mL, 579 mmol) was then added dropwise, followed by 1-(2-chloro- 4-fluorophenyl)ethan-1-one (25.00 g, 145 mmol). The mixture was stirred for 30 min., then gradually warmed to 70 C, where it was stirred for 16 h. The reaction mixture was then cooled to 0 °C and quenched by dropwise addition of saturated aqueous NH 4 Cl solution. The resulting mixture was extracted with EtOAc (thrice). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by flash column chromatography on silica gel to give ethyl 3-(2-chloro-4-fluoro-phenyl)-3-oxo- propanoate (4, 14 g). LCMS (ESI) Calcd. for C11H10ClFO3: 244, found [M+H] + = 245. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.93-7.89 (m, 1H), 7.61-7.57 (m, 1H), 7.41-7.34 (m, 1H), 4.2 (s, 2H), 4.11 (q, 2H), 1.19 (t, 3H). 0150 Synthesis of 4-(2-chloro-4-fluorophenyl)-7-hydroxy-2H-chromen-2-one, Example 13 [Step 2]: To a mixture of ethyl 3-(2-chloro-4-fluoro-phenyl)-3-oxo- propanoate (4, 5 g, 20.4 mmol) and benzene-1,3-diol (2.25 g, 20.4 mmol) at ambient temperature was added methane sulphonic acid (13 mL, 204 mmol) dropwise. The mixture was stirred at 50 °C overnight, cooled to 10 °C, and quenched with water. The product was filtered, washed with water and n-pentane, and dried under reduced pressure to give 4-(2-chloro-4-fluorophenyl)-7-hydroxy-2H-chromen-2-one (Example 13, 5.8 g). LCMS (ESI) Calcd. for C15H8ClFO3: 290, found [M+H] + = 291. 1 H NMR (400 MHz, DMSO-d6) δ 10.68 (s, 1H), 7.70-7.67 (dd, 1H), 7.56-7.53 (m, 1H), 7.44-7.39 (dt, 1H), 6.87 (d, 1H), 6.80 (d, 1H), 6.75-6.73 (dd, 1H), 6.21 (s, 1H). 0151 Synthesis of methyl 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7- yl)oxy)-3-methoxypropanoate, Example 14 [Step 3]: To a stirred solution of 4-(2- chloro-4-fluorophenyl)-7-hydroxy-2H-chromen-2-one (Example 13, 200 mg, 0.688 mmol) in DMF (2 mL) at ambient temperature was added Cs 2 CO 3 (336.28 mg, 1.0321 mmol) followed by methyl 2-bromo-3-methoxy-propanoate (149.13 mg, 0.7569 mmol). The reaction mixture was stirred at ambient temperature for 18 h., then diluted with EtOAc, washed with water (thrice), brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to give methyl 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7- yl)oxy)-3-methoxypropanoate (Example 14, 152 mg). 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.70 (d, 1H), 7.56 (t, 1H), 7.46-7.42 (m, 1H), 7.09 (s, 1H), 6.96-6.90 (m, 2H), 6.33 (s, 1H), 5.36 (s, 1H), 3.89-3.79 (m, 2H), 3.70 (s, 3H), 3.28(s, 3H). LCMS Calcd. for C20H16ClFO6: 406, found [M+H] + = 407. Example 15: (R)-4-(2-chloro-4-fluorophenyl)-7-((3-hydroxy-1-oxo-1-(piper idin-1-yl)propan- 2-yl)oxy)-2H-chromen-2-one 0152 Synthesis of methyl (R)-3-(benzyloxy)-2-((4-(2-chloro-4-fluorophenyl)-2- oxo-2H-chromen-7-yl)oxy)propanoate, 5 [Step 1]: To a stirred solution of 4-(2-chloro- 4-fluorophenyl)-7-hydroxy-2H-chromen-2-one (Example 13, 280 mg, 1 mmol) in THF (2 mL) under an inert atmosphere were added triphenylphosphine (379 mg, 1.4 mmol) followed by methyl (S)-3-(benzyloxy)-2-hydroxypropanoate (200 mg, 1 mmol) and molecular sieves (4A°). The mixture was cooled to 0 °C and DIAD (0.6 mL, 3 mmol) was added dropwise. The reaction mixture was gradually warmed to 50 °C and stirred for 12 h. The reaction mixture was filtered and the product was purified by flash column chromatography on silica gel to give methyl (R)-3-(benzyloxy)-2-((4-(2-chloro-4- fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)propanoate (5, 150 mg). LCMS (ESI) Calcd. for C26H20ClFO6: 482, found [M+H] + = 483. 0153 Synthesis of (R)-3-(benzyloxy)-2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H- chromen-7-yl)oxy)propanoic acid, 6 [Step 2]: To a solution of methyl (R)-3- (benzyloxy)-2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen -7-yl)oxy)propanoate (5, 100 mg, 0.2 mmol) in THF (3 mL) at ambient temperature was added a solution of LiOH∙H 2 O (25 mg, 0.6 mmol) in water (0.6 mL). The reaction mixture was stirred for 16 h., then concentrated under reduced pressure. The product was diluted with water and washed with EtOAc. The aqueous layer was acidified (pH = 5-6) with 10M aqueous HCl solution and the product precipitated. The product was filtered, washed with water, and dried to give (R)-3-(benzyloxy)-2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-c hromen-7- yl)oxy)propanoic acid (6, 90 mg). LCMS (ESI) Calcd. for C25H18ClFO6: 468, found [M+H] + = 469. 0154 Synthesis of (R)-7-((3-(benzyloxy)-1-oxo-1-(piperidin-1-yl)propan-2- yl)oxy)-4-(2-chloro-4-fluorophenyl)-2H-chromen-2-one, 7 [Step 3]: To a solution of (R)-3-(benzyloxy)-2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-c hromen-7- yl)oxy)propanoic acid (6, 50 mg, 0.1 mmol) in CH 2 Cl 2 (4 mL) at ambient temperature was added piperidine (0.02 mL, 0.2 mmol) followed by DIPEA (0.04 mL, 0.3 mmol). The mixture was cooled 0 °C and T 3 P, 50 % in EtOAc (0.03 mL, 0.1 mmol) was added. The resulting mixture was stirred for 2 h. at ambient temperature and diluted with CH2Cl2. The product was washed with 10 % aqueous K 2 CO 3 solution, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by flash column chromatography on silica gel to give (R)-7-((3-(benzyloxy)-1- oxo-1-(piperidin-1-yl)propan-2-yl)oxy)-4-(2-chloro-4-fluorop henyl)-2H-chromen-2-one (7, 45 mg). LCMS (ESI) Calcd. for C 30 H 27 ClFNO 5 : 535, found [M+H] + = 536. 0155 Synthesis of (R)-4-(2-chloro-4-fluorophenyl)-7-((3-hydroxy-1-oxo-1- (piperidin-1-yl)propan-2-yl)oxy)-2H-chromen-2-one, Example 15 [Step 4]: To a stirred solution of (R)-7-((3-(benzyloxy)-1-oxo-1-(piperidin-1-yl)propan-2-yl)ox y)-4-(2- chloro-4-fluorophenyl)-2H-chromen-2-one (7, 40 mg, 0.1 mmol) in ethanol (5 mL) was bubbled nitrogen for 5 min.10 % Pd-C (10 mg) was added under an inert atmosphere and the reaction mixture was stirred under a hydrogen balloon pressure at ambient temperature for 2 h. The reaction mixture was filtered, concentrated under reduced pressure, purified by RP prep-HPLC, and lyophilized to give (R)-4-(2-chloro-4- fluorophenyl)-7-((3-hydroxy-1-oxo-1-(piperidin-1-yl)propan-2 -yl)oxy)-2H-chromen-2- one (Example 15, 2.5 mg). LCMS (ESI) Calcd. for C23H21ClFNO5: 445, found [M+H] + = 446. 1 H NMR (at 80 °C) (400 MHz, DMSO-d 6 ): δ 7.65 (d, 1H), 7.55 (t, 1H), 7.41 (t, 1H), 6.97-6.92 (m, 1H), 6.91 (s, 1H), 6.85-6.83 (m, 1H), 6.28 (s, 1H), 5.28 (br s, 1H), 5.08 (br s, 1H), 3.79 (s, 2H), 3.50 (br s, 6H), 1.59 (s, 2H), 1.47 (s, 2H). Examples 16-20: 4-(4-fluorophenyl)-7-hydroxy-5-methyl-2H-cheromen-2-one, ethyl (R)-2- ((4-(4-fluorophenyl)-5-methyl-2-oxo-2H-chromen-7-yl)oxy)prop anoate, (R)-2-((4-(4- fluorophenyl)-5-methyl-2-oxo-2H-chromen-7-yl)oxy)propanoic acid, 4-(4-fluorophenyl)-5- methyl-7-[(1R)-1-methyl-2-oxo-2-(1-piperidyl)ethoxy]chromen- 2-one, and (R)-2-((4-(4- fluorophenyl)-5-methyl-2-oxo-2H-chromen-7-yl)oxy)-N,N-dimeth ylpropanamide
0156 Synthesis of 3-(4-fluorophenyl)propiolic acid, 8 [Step 1]: To a stirred solution of methyl 3-(4-fluorophenyl)propiolate (1.00 eq, 750 mg, 4.2 mmol) in ethanol (15 mL) at ambient temperature was added 1N aqueous NaOH solution (7.5 mL), and the reaction mixture stirred for 2.5 h. The reaction mixture was concentrated under reduced pressure and the product was dissolved in water and extracted with EtOAc. The aqueous layer was separated and acidified with 1N aqueous HCl solution and extracted with EtOAc. The organic extract was washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford 3-(4- fluorophenyl)propiolic acid (8, 680 mg). LCMS (ESI) Calcd. for C9H5FO2: 164, found [M+H] + = 165. 1 H NMR (400 MHz, DMSO-d6) δ 13.93 (br s, 1H), 7.72-7.68 (m, 2H), 7.34-7.30 (m, 2H). 0157 Synthesis of 3-hydroxy-5-methylphenyl 3-(4-fluorophenyl)propiolate, 9 [Step 2]: To a stirred solution of 5-methylbenzene-1,3-diol (1.00 eq, 500 mg, 4.0 mmol) in CH2Cl2 (15 mL) at ambient temperature was added 3-(4-fluorophenyl)propiolic acid (8, 1.10 eq, 727 mg, 4.4 mmol), followed by DCC (1.50 eq, 1247 mg, 6.0 mmol) in a mixture of CH2Cl2 (10 mL) and DMAP (0.100 eq, 49 mg, 0.40 mmol). The resulting mixture was stirred at ambient temperature for 16 h. The reaction mixture was filtered and the filtrate was diluted with CH2Cl2, washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by flash column chromatography to afford 3-hydroxy-5-methylphenyl 3-(4- fluorophenyl)propiolate (9, 480 mg). LCMS (ESI) Calcd. for C 16 H 11 FO 3 : 270, found [M+H] + = 271. 1 H NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H), 7.83-7.79 (m, 2H), 7.38 (t, 2H), 6.54 (s, 1H), 6.50 (s, 1H), 6.44 (s, 1H), 2.24 (s, 3H). 0158 Synthesis of 4-(4-fluorophenyl)-7-hydroxy-5-methyl-2H-chromen-2-one, Example 16 [Step 3]: A solution of 3-hydroxy-5-methylphenyl 3-(4- fluorophenyl)propiolate (9, 1.00 eq, 487 mg, 1.8 mmol) in DCE (35 mL) was purged with argon for 10 min. (Acetonitrile)[(2-biphenyl)di-tert-butyl phosphine]gold(I) hexafluoroantimonate (0.100 eq, 140 mg, 0.18 mmol) was added and the reaction mixture was stirred at ambient temperature under an argon atmosphere for 16 h. The reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure. The product was purified by flash column chromatography to afford 4-(4- fluorophenyl)-7-hydroxy-5-methyl-2H-chromen-2-one (Example 16, 300 mg, 1.1 mmol). LCMS (ESI) Calcd. for C16H11FO3: 270, found [M+H] + = 271. 1 H NMR (400 MHz, DMSO-d 6 ) δ 10.56 (s, 1H), 7.44-7.40 (m, 2H), 7.34-7.29 (m, 2H), 6.66 (d, 1H), 6.56 (d, 1H), 5.95 (s, 1H), 1.68 (s, 3H). 0159 Synthesis of ethyl (R)-2-((4-(4-fluorophenyl)-5-methyl-2-oxo-2H-chromen- 7-yl)oxy)propanoate, Example 17 [Step 4]: To a stirred solution of 4-(4-fluorophenyl)- 7-hydroxy-5-methyl-2H-chromen-2-one (Example 16, 1.00 eq, 180 mg, 0.7 mmol) in dry THF (3 mL) at ambient temperature and under an argon atmosphere was added ethyl (S)-2-hydroxypropanoate (1.50 eq, 118 mg, 1.0 mmol), PPh 3 (3.00 eq, 524 mg, 2.0 mmol), and DIAD (3.00 eq, 0.39 mL, 2.00 mmol). The reaction mixture was heated to 50 °C for 16 h. and quenched with water and extracted with EtOAc. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by flash column chromatography to afford ethyl (R)-2- ((4-(4-fluorophenyl)-5-methyl-2-oxo-2H-chromen-7-yl)oxy)prop anoate (Example 17, 180 mg, 0.5 mmol). LCMS (ESI) Calcd. for C 21 H 19 FO 5 : 370, found [M+H] + = 371. 1 H NMR (400 MHz, DMSO-d6) δ 7.45-7.42 (m, 2H), 7.32 (t, 2H), 6.86 (d, 1H), 6.73 (d, 1H), 6.06 (s, 1H), 5.20-5.15 (m, 1H), 4.19-4.13 (m, 2H), 1.72 (s, 3H), 1.53 (d, 3H), 1.18 (t, 3H). 0160 Synthesis of (R)-2-((4-(4-fluorophenyl)-5-methyl-2-oxo-2H-chromen-7- yl)oxy)propanoic acid, Example 18 [Step 5]: To a stirred solution of ethyl (R)-2-((4-(4- fluorophenyl)-5-methyl-2-oxo-2H-chromen-7-yl)oxy)propanoate (Example 17, 1.00 eq, 200 mg, 0.5 mmol) in THF (4 mL) and water (1 mL) at ambient temperature was added LiOH∙H 2 O (3.00 eq, 68 mg, 1.6 mmol). The reaction mixture was stirred for 16 h., and concentrated under reduced pressure. The product was dissolved in water and washed with EtOAc. The aqueous layer was separated and acidified with citric acid to pH~5 and extracted with EtOAc. The organic extract was washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (R)- 2-((4-(4-fluorophenyl)-5-methyl-2-oxo-2H-chromen-7-yl)oxy)pr opanoic acid (Example 18, 180 mg, 0.5 mmol). LCMS (ESI) Calcd. for C 19 H 15 FO 5 : 342, found [M+H] + = 343. 0161 Synthesis of 4-(4-fluorophenyl)-5-methyl-7-[(1R)-1-methyl-2-oxo-2-(1- piperidyl)ethoxy]chromen-2-one, Example 19 [Step 6]: To a stirred solution of (R)-2- ((4-(4-fluorophenyl)-5-methyl-2-oxo-2H-chromen-7-yl)oxy)prop anoic acid (Example 18, 1.00 eq, 75 mg, 0.22 mmol) in CH2Cl2 (3 mL) at ambient temperature was added piperidine (1.20 eq, 22 mg, 0.3 mmol), DIPEA (3.00 eq, 0.11 mL, 0.7 mmol), T 3 P (1.50 eq, 0.19 mL, 0.33 mmol) and the reaction mixture stirred for 16 h. The mixture was concentrated under reduced pressure and the product purified by RP prep-HPLC to afford 4-(4-fluorophenyl)-5-methyl-7-[(1R)-1-methyl-2-oxo-2-(1-pipe ridyl)ethoxy]chromen-2- one (Example 19, 30 mg, 0.0731 mmol). LCMS (ESI) Calcd. for C 24 H 24 FNO 4 : 409, found [M+H] + = 410. 1 H NMR (400 MHz, DMSO-d6) δ 7.45-7.42 (m, 2H), 7.32 (t, 2H), 6.79 (d, 1H), 6.69 (d, 1H), 6.05 (s, 1H), 5.48-5.43 (m, 1H), 3.54-3.47 (m, 3H), 3.39-3.35 (m, 1H), 1.72 (s, 3H), 1.60-1.54 (m,4H), 1.43-1.41 (m, 5H). 0162 Synthesis of (R)-2-((4-(4-fluorophenyl)-5-methyl-2-oxo-2H-chromen-7- yl)oxy)-N,N-dimethylpropanamide, Example 20 [Step 7]: To a stirred solution of (R)- 2-((4-(4-fluorophenyl)-5-methyl-2-oxo-2H-chromen-7-yl)oxy)pr opanoic acid (Example 18, 1.00 eq, 75 mg, 0.22 mmol) in CH2Cl2 (3 mL) at ambient temperature was added N- methylmethanamine HCl (1.20 eq, 21 mg, 0.26 mmol), DIPEA (3.00 eq, 0.11 mL, 0.66 mmol), and T3P (1.50 eq, 0.19 mL, 0.34 mmol). The reaction mixture was stirred at ambient temperature for 16 h., and concentrated under reduced pressure. The product was purified by RP prep-HPLC to afford (R)-2-((4-(4-fluorophenyl)-5-methyl-2-oxo-2H- chromen-7-yl)oxy)-N,N-dimethylpropanamide (Example 20, 30 mg, 0.08 mmol). LCMS (ESI) Calcd. for C21H20FNO4: 369, found [M+H] + = 370. 1 H NMR (400 MHz, DMSO-d6) δ 7.45-7.42 (m, 2H), 7.32 (t, 2H), 6.77 (d, 1H), 6.69 (d, 1H), 6.04 (s, 1H), 5.43-5.42 (m, 1H), 3.09 (s, 3H), 2.85 (s, .3H), 1.72 (s, 3H), 1.42 (d, 3H). Example 21: 4-(2-chloro-4-fluorophenyl)-7-methoxy-2H-chromen-2-one 0163 Synthesis of 4-(2-chloro-4-fluorophenyl)-7-methoxy-2H-chromen-2-one, Example 21: To a stirred solution of compound 4-(2-chloro-4-fluorophenyl)-7-hydroxy- 2H-chromen-2-one (Example 13, 200 mg, 0.7 mmol) in dry DMF (5 mL) at 0 °C and under a nitrogen atmosphere was added NaH (60 % dispersion in mineral oil) (20 mg, 0.8 mmol) portion wise. The reaction mixture was slowly warmed to ambient temperature and stirred for 30 min. Methyl iodide (0.9 mL, 14 mmol) was added and mixture stirred for an additional 16 h. The reaction was quenched with saturated aqueous NH 4 Cl solution and extracted with EtOAc (thrice). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, then concentrated under reduced pressure. The product was purified by flash column chromatography on silica gel to give 4-(2-chloro-4-fluorophenyl)-7-methoxy-2H-chromen-2-one (Example 21, 96 mg). LCMS (ESI) Calcd. for C16H10ClFO3: 304, found [M+H] + = 305. 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.70 (dd, 1H), 7.59-7.55 (m, 1H), 7.44 (dt, 1H), 7.11 (d, 1H), 6.95 (d, 1H), 6.90 (dd, 1H), 6.31 (s, 1H), 3.87 (s, 3H). Examples 22-24: 7-hydroxy-5-methyl-4-phenyl-2H-chromen-2-one, 7-isopropoxy-5-methyl- 4-phenyl-2H-chromen-2-one, and 7-isobutoxy-5-methyl-4-phenyl-2H-chromen-2-one
0164 Synthesis of 3-hydroxy-5-methylphenyl-3-phenylpropiolate, 10 [Step 1]: To a stirred solution of 3-phenylpropiolic acid (194 mg, 1.33 mmol) and 5- methylbenzene-1,3-diol (150 mg, 1.21 mmol) in CH 2 Cl 2 (6 mL) at 0 °C was added a mixture of DCC (374 mg, 1.81 mmol) and DMAP (15 mg, 0.121 mmol) in CH2Cl2 (4 mL) dropwise. The mixture was gradually warmed to ambient temperature and stirred for 12 h. The mixture was concentrated under reduced pressure and the product was diluted with water and extracted with CH 2 Cl 2 (twice). The combined organic extracts were washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 3-hydroxy-5-methylphenyl 3-phenylpropiolate (10, 200 mg). LCMS (ESI) Calcd. for C16H12O3: 252, found [M+H] + = 253. 0165 Synthesis of 7-hydroxy-5-methyl-4-phenyl-2H-chromen-2-one, Example 22 [Step 2]: To a stirred solution of 3-hydroxy-5-methylphenyl 3-phenylpropiolate (10, 200 mg, 0.793 mmol) in DCE (5 mL) at ambient temperature and under an argon atmosphere was added (acetonitrile)[(2-biphenyl)di-tert-butyl phosphine]gold(I) hexafluoroantimonate (61 mg, 0.0793 mmol). The resulting mixture was stirred for 18 h and diluted with CH 2 Cl 2 , washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep- HPLC and lyophilized to give 7-hydroxy-5-methyl-4-phenyl-2H-chromen-2-one (Example 22, 90 mg). LCMS (ESI) Calcd. for C16H12O3: 252, found [M+H] + = 253. 1 H NMR (400 MHz, DMSO-d 6 ) δ 10.54 (br s, 1H), 7.49-7.47 (m, 3H), 7.37-7.35 (m, 2H), 6.67 (d, 1H), 6.55 (s, 1H), 5.93 (s, 1H), 1.67 (s, 3H). 0166 Synthesis of 7-isopropoxy-5-methyl-4-phenyl-2H-chromen-2-one, Example 23 [Step 3]: To a stirred solution of 7-hydroxy-5-methyl-4-phenyl-2H- chromen-2-one (Example 22, 40 mg, 0.159 mmol) in DMF (0.5 mL) was added K2CO3 (44 mg, 0.317 mmol) followed by 2-iodopropane (0.024 mL, 0.238 mmol). The resulting mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with EtOAc, washed with water (thrice), brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep- HPLC and lyophilized to give 7-isopropoxy-5-methyl-4-phenyl-2H-chromen-2-one (Example 23, 38 mg). LCMS (ESI) Calcd. for C19H18O3: 294, found [M+H] + = 295. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.49-7.47 (m, 3H), 7.38-7.36 (m, 2H), 6.93 (d, 1H), 6.69 (br s, 1H), 6.00 (s, 1H), 4.79-4.76 (m, 1H), 1.70 (s, 3H), 1.29 (d, 6H). 0167 Synthesis of 7-isobutoxy-5-methyl-4-phenyl-2H-chromen-2-one, Example 24 [Step 4]: To a stirred solution of 7-hydroxy-5-methyl-4-phenyl-2H-chromen-2-one (Example 22, 40 mg, 0.159 mmol) in DMF (0.5 mL) was added K 2 CO 3 (44 mg, 0.317 mmol) followed by isobutyl bromide (0.026 mL, 0.238 mmol). The mixture was stirred at ambient temperature for 16 h and diluted with EtOAc. The mixture was washed with water (thrice), brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford 7-isobutoxy-5-methyl-4-phenyl-2H-chromen-2-one (Example 24, 23 mg). LCMS (ESI) Calcd. for C20H20O3: 308, found [M+H] + = 309. 1 H NMR (400 MHz, DMSO-d6) δ 7.49-7.48 (m, 3H), 7.38-7.36 (m, 2H), 6.93 (d, 1H), 6.73 (d, 1H), 6.01 (s, 1H), 3.86 (d, 2H), 2.05-2.02 (m, 1H), 1.71 (s, 3H), 0.98 (d, 6H). Examples 25-27: 7-((1-methoxypropan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one, racemic and purified chiral analogs
0168 Synthesis of 7-((1-methoxypropan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2- one, Example 25 [Step 1]: To a stirred solution of 2-bromo-1-methoxy-propane (180 mg, 1.2 mmol) in MeCN (7 mL) was added K 2 CO 3 (270 mg, 2.0 mmol) and KI (200 mg, 1.2 mmol) followed by 7-hydroxy-4-(o-tolyl)-2H-chromen-2-one (Example 1, 250 mg, 1.0 mmol). The mixture was stirred at 70 °C for 48 h., and cooled to ambient temperature. The mixture was concentrated under reduced pressure and the product was partitioned between EtOAc and water. The organic layer was separated, washed with water (twice), brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford 7-((1- methoxypropan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one (Example 25, 100 mg). LCMS (ESI) Calcd. for C 20 H 20 O 4 : 323, found [M+H] + = 325. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.43-7.34 (m, 2H), 7.35 (t, 1H), 7.24 (d, 1H), 7.11 (d, 1H), 6.89-6.83 (m, 2H), 6.17 (s, 1H), 4.81-4.77 (m, 1H), 3.50 (t, 2H), 3.29 (d, 3H), 2.11 (s, 3H), 1.24 (d, 3H). 0169 Synthesis of chiral 7-((1-methoxypropan-2-yl)oxy)-4-(o-tolyl)-2H- chromen-2-one, Examples 26 and 27 [Step 2]: 7-((1-methoxypropan-2-yl)oxy)-4-(o- tolyl)-2H-chromen-2-one (Example 25, 80 mg) was purified by chiral prep-HPLC separation and the first product was isolated as 7-((1-methoxypropan-2-yl)oxy)-4-(o- tolyl)-2H-chromen-2-one, Peak 1 (Example 26, 30 mg) and the second product as 7-((1- methoxypropan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one, Peak 2 (Example 27, 25 mg). The absolute stereochemistries of these compounds were not determined. 0170 Example 26: [7-((1-methoxypropan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one, Peak 1]: LCMS (ESI) Calcd. for C 20 H 20 O 4 : 324, found [M+H] + = 325. 1 H NMR (400 MHz, DMSO-d6) δ 7.43-7.34 (m, 2H), 7.35 (t, 1H), 7.24 (d, 1H), 7.11 (s, 1H), 6.89-6.83 (m, 2H), 6.17 (s, 1H), 4.79 (d, 1H), 3.50 (t, 2H), 3.29 (d, 3H), 2.11 (s, 3H), 1.24 (d, 3H). 0171 Example 27: [(7-((1-methoxypropan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2- one, Peak 2]: LCMS (ESI) Calcd. for C 20 H 20 O 4 : 324, found [M+H] + = 325. 1 H NMR (400 MHz, DMSO-d6) δ 7.43-7.34 (m, 2H), 7.35 (t, 1H), 7.24 (d, 1H), 7.11 (s, 1H), 6.89-6.83 (m, 2H), 6.17 (s, 1H), 4.79 (d, 1H), 3.50 (t, 2H), 3.29 (d, 3H), 2.11 (s, 3H), 1.24 (d, 3H). 0172 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 21 mm), 5μ, operating at ambient temperature with flow rate of 21.0 mL/min. Mobile phase: 0.1 % isopropylamine in a mixture of 70 % hexane, 15 % of CH 2 Cl 2 and 15 % ethanol, held isocratic up to 25 min. with detection at 326 nm wavelength. Examples 28-29: 7-((tetrahydro-2H-pyran-4-yl)oxy)-4-(o-tolyl)-2H-chromen-2-o ne and 7- ((tetrahydro-2H-pyran-4-yl)methoxy)-4-(o-tolyl)-2H-chromen-2 -one 0173 Synthesis of 7-((tetrahydro-2H-pyran-4-yl)oxy)-4-(o-tolyl)-2H-chromen-2- one, Example 28 [Step 1]: To a solution of 7-hydroxy-4-(o-tolyl)-2H-chromen-2-one (Example 1, 300 mg, 1.2 mmol) in DMF (7 mL) was added Cs2CO3 (780 mg, 2.4 mmol) and KI (200 mg, 1.2 mmol) followed by 4-bromotetrahydropyran (300 mg, 1.8 mmol). The resulting mixture was stirred at 80 °C for 48 h. The mixture was cooled, concentrated under reduced pressure, and partitioned between EtOAc and water. The organic layer was separated, washed with water (twice), brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep- HPLC and lyophilized to afford 7-((tetrahydro-2H-pyran-4-yl)oxy)-4-(o-tolyl)-2H- chromen-2-one (Example 28, 130 mg). LCMS (ESI) Calcd. for C21H20O4: 336, found [M+H] + = 337. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.45-7.39 (m, 2H), 7.35 (t, 1H), 7.24 (d, 1H), 7.18 (d, 1H), 6.91-6.84 (m, 2H), 6.17 (s, 1H), 4.77-4.72 (m, 1H), 3.88-3.82 (m, 2H), 3.53-3.48 (m, 2H), 2.11 (S, 3H), 1.99 (d, 2H), 1.64-1.57 (m, 2H). 0174 Synthesis of 7-((tetrahydro-2H-pyran-4-yl)methoxy)-4-(o-tolyl)-2H- chromen-2-one, Example 29 [Step 2]: To a stirred solution of 7-hydroxy-4-(o-tolyl)-2H- chromen-2-one (Example 1, 200 mg, 0.8 mmol) in DMF (7 mL) was added Cs2CO3 (780 mg, 2.4 mmol) and KI (200 mg, 1.2 mmol) followed by 4-(bromomethyl)tetrahydropyran (210 mg, 1.2 mmol). The resulting mixture was stirred at 80 °C for 48 h, cooled, and concentrated under reduced pressure. The product was partitioned between EtOAc and water and the organic layer was separated, washed with water (twice), brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford 7-((tetrahydro-2H-pyran-4- yl)methoxy)-4-(o-tolyl)-2H-chromen-2-one (Example 29, 100 mg). LCMS (ESI) Calcd. for C22H22O4: 350, found [M+H] + = 351. 1 H NMR (400 MHz, DMSO-d6) δ 7.45-7.33 (m, 3H), 7.24 (d, 1H), 7.10 (s, 1H), 6.87 (t, 2H), 6.18 (s,1H), 4.02 (d, 2H), 3.96-3.85 (m, 2H), 3.35-3.28 (m, 2H), 2.11 (s, 3H), 2.07-1.94 (m, 1H), 1.66 (d, 2H), 1.38-1.31 (m, 2H). Examples 30-36: 7-propoxy-4-(2-(trifluoromethyl)phenyl)-2H-chromen-2-one, 4-(2-chloro-4- fluorophenyl)-7-propoxy-2H-chromen-2-one, 7-propoxy-4-(4-(trifluoromethyl)pyridin-3-yl)- 2H-chromen-2-one, 4-(4-methylthiophen-3-yl)-7-propoxy-2H-chromen-2-one, 4-(4-hydroxy- 2-methylphenyl)-7-propoxy-2H-chromen-2-one, 4-(2-methoxyphenyl)-7-propoxy-2H- chromen-2-one, and 4-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-7-propoxy-2H-chromen -2-one
0175 Synthesis of 1-(2-hydroxy-4-propoxyphenyl)ethan-1-one, 11 [Step 1]: To a solution of 1-(2,4-dihydroxyphenyl)ethan-1-one (8.0 g, 52.6 mmol) in acetone (520 mL) was added potassium carbonate (24 g, 174 mmol) followed by 1-iodopropane (5.1 mL, 52.6 mmol). The mixture was heated to 50 °C for 16 h., cooled, and concentrated under reduced pressure. The product was acidified using 2M aqueous HCl solution (pH = 3) and extracted with ethyl acetate (twice). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by flash column chromatography on silica gel to afford 1-(2-hydroxy-4- propoxyphenyl)ethan-1-one (11, 7.5 g). LCMS (ESI) Calcd. for C 11 H 14 O 3 : 194, found [M+H] + = 195. 0176 Synthesis of 4-hydroxy-7-propoxy-2H-chromen-2-one, 12 [Step 2]: To a stirred solution of 1-(2-hydroxy-4-propoxyphenyl)ethanone (11, 6 g, 30.9 mmol) in anhydrous toluene (90 mL) at 0 °C under an inert atmosphere was added diethyl carbonate (5.6 mL, 46.3 mmol), and sodium hydride (60 % dispersion in mineral oil) (3.7 g, 154 mmol). The mixture was heated to 100 °C and stirred for 4 h, then cooled to 0 °C and quenched with saturated aqueous ammonium chloride solution. The mixture was washed with diethyl ether (twice), and acidified with 2M aqueous HCl solution (pH = 3). The resulting precipitate was collected by filtration, washed with water, triturated with hexane, and dried to afford 4-hydroxy-7-propoxy-2H-chromen-2-one (12, 4.5 g). LCMS (ESI) Calcd. for C12H12O4: 220, found [M+H] + = 221. 0177 Synthesis of 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate, 13 [Step 3]: To a stirred solution of 4-hydroxy-7-propoxy- 2H-chromen-2-one (12, 2.0 g, 9.1 mmol) in CH 2 Cl 2 (40 mL) was added triethylamine (1.6 mL, 11.8 mmol) followed by trifluoromethanesulfonic anhydride (2.1 mL, 11.8 mmol). The mixture stirred at 0 °C for 1 h., then diluted with CH 2 Cl 2 , washed with water (twice), brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by flash column chromatography on silica gel to afford 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 2 g). LCMS (ESI) Calcd. for C 13 H 11 F 3 O 6 S: 352, found [M+H] + = 353. 1 H NMR (400 MHz, DMSO- d6): δ 7.60-7.57 (m, 1H), 7.17 (d, 1H), 7.11 (dd, 1H), 6.65 (s, 1H), 4.11-4.07 (m, 2H), 1.79-1.73 (m, 2H), 1.40-0.82 (m, 3H). 0178 General procedure for Suzuki coupling: An oven-dried tube was charged with 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 1.0 eq) followed by aryl boronic acid or aryl boronate ester (1.5 eq) and sodium carbonate (2.0 eq).1,4- Dioxane and water (4:1) were added and the mixture degassed with nitrogen for 10 min. by bubbling. Pd(PPh 3 ) 4 (0.1 eq) was then added and the tube was sealed and stirred at 80 °C for 1 h. The reaction mixture was then cooled to ambient temperature and partitioned between EtOAc and water. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford the desired product. 0179 Synthesis of 7-propoxy-4-(2-(trifluoromethyl)phenyl)-2H-chromen-2-one, Example 30 [Step 4]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 200 mg, 0.6 mmol) and [2-(trifluoromethyl)phenyl]boronic acid (160 mg, 0.9 mmol). Purification by RP prep-HPLC and lyophilization gave 7-propoxy-4-(2- (trifluoromethyl)phenyl)-2H-chromen-2-one (Example 30, 110 mg). LCMS (ESI) Calcd. for C19H15F3O3: 348, found [M+H] + = 349. 1 H NMR (400 MHz, DMSO-d6): δ 7.97-7.94 (d, 1H), 7.87-7.82 (t, 1H), 7.80-7.75 (t, 1H), 7.55-7.52 (d, 1H), 7.09-7.08 (m, 1H), 6.89- 6.85 (dd, 1H), 6.79-6.76 (d, 1H), 6.26 (s, 1H), 4.06-4.02 (m, 2H), 1.80-1.70 (m, 2H), 1.00-0.96 (m, 3H). 0180 Synthesis of 4-(2-chloro-4-fluorophenyl)-7-propoxy-2H-chromen-2-one, Example 31 [Step 5]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 200 mg, 0.6 mmol) and (2-chloro-4-fluoro-phenyl)boronic acid (150 mg, 0.9 mmol). Purification by RP prep-HPLC and lyophilization gave 4-(2-chloro-4-fluorophenyl)-7- propoxy-2H-chromen-2-one (Example 31, 69 mg). LCMS (ESI) Calcd. for C 18 H 14 ClFO 3 : 332, found [M+H] + = 333. 1 H NMR (400 MHz, DMSO-d6): δ 7.70 (dd, 1H), 7.56 (dd, 1H), 7.43 (dt, 1H), 7.08 (d, 1H), 6.94-6.90 (m, 2H), 6.30 (s, 1H), 4.05 (t, 2H), 1.75 (sextet, 2H), 0.98 (t, 3H). 0181 Synthesis of 7-propoxy-4-(4-(trifluoromethyl)pyridin-3-yl)-2H-chromen- 2-one, Example 32 [Step 6]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 30 mg, 0.08 mmol) and (4-(trifluoromethyl)pyridin-3-yl)boronic acid (30 mg, 0.1 mmol). Purification by RP prep-HPLC and lyophilization gave 7-propoxy-4-(4- (trifluoromethyl)pyridin-3-yl)-2H-chromen-2-one (Example 32, 11 mg). LCMS (ESI) Calcd. for C18H14F3NO3: 349, found [M+H] + = 350. 1 H NMR (400 MHz, DMSO-d6): δ 9.03 (d, 1H), 8.80 (s, 1H), 8.00 (d, 1H), 7.11 (s, 1H), 6.87 (s, 2H), 6.42 (s, 1H), 4.06 (t, 2H), 1.74 (sextet, 2H), 0.98 (t, 3H). 0182 Synthesis of 4-(4-methylthiophen-3-yl)-7-propoxy-2H-chromen-2-one, Example 33 [Step 7]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 250 mg, 0.7 mmol) and (4-methylthiophen-3-yl)boronic acid (151 mg, 1.06 mmol). Purification by RP prep-HPLC and lyophilization gave 4-(4-methylthiophen-3-yl)-7- propoxy-2H-chromen-2-one (Example 33, 77 mg). LCMS (ESI) Calcd. for C17H16O3S: 300, found [M+H] + = 301. 1 H NMR (400 MHz, DMSO-d 6 ): δ 7.69 (d, 1H), 7.43 (d, 1H), 7.13 (d, 1H), 7.06 (d, 1H), 6.92 (dd, 1H), 6.19 (s, 1H), 4.05 (t, 2H), 2.07 (s, 3H), 1.76 (sextet, 2H), 0.98 (t, 3H). 0183 Synthesis of 4-(4-hydroxy-2-methylphenyl)-7-propoxy-2H-chromen-2-one, Example 34 [Step 8]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 200 mg, 0.6 mmol) and (4-hydroxy-2-methylphenyl)boronic acid (130 mg, 0.9 mmol). Purification by RP prep-HPLC and lyophilization gave 4-(4-hydroxy-2- methylphenyl)-7-propoxy-2H-chromen-2-one (Example 34, 69 mg). LCMS (ESI) Calcd. for C19H18O4: 310, found [M+H] + = 311. 1 H NMR (400 MHz, DMSO-d6): δ 9.68(s, 1H), 7.04-7.02 (m, 2H), 6.97-6.94 (d, 1H), 6.89-6.85 (dd, 1H), 6.77-6.71 (m, 2H), 6.10 (s, 1H), 4.06-4.02 (m, 2H), 2.03 (s, 3H), 1.80-1.70 (m, 2H), 1.00-0.96 (m, 3H). 0184 Synthesis of 4-(2-methoxyphenyl)-7-propoxy-2H-chromen-2-one, Example 35 [Step 9]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 200 mg, 0.56 mmol) and (2-methoxyphenyl)boronic acid (130 mg, 0.9 mmol). Purification by RP prep-HPLC and lyophilization gave 4-(2-methoxyphenyl)-7-propoxy- 2H-chromen-2-one (Example 35, 58 mg). LCMS (ESI) Calcd. for C19H19O4: 310, found [M+H] + = 311. 1 H NMR (400 MHz, DMSO-d 6 ): δ 7.53 (t, 1H), 7.30-7.28 (m, 1H), 7.22 (d, 1H), 7.11 (t, 1H), 7.03-6.98 (m, 2H), 6.88-6.85 (m, 1H), 6.17 (s, 1H), 4.04 (t, 2H), 3.72 (s, 3H), 1.75 (sextet, 2H), 0.98 (t, 3H). 0185 Synthesis of 4-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-7-propoxy-2H- chromen-2-one, Example 36 [Step 10]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 50 mg, 0.14 mmol) and (2,3-dihydrobenzo[b][1,4]dioxin- 5-yl)boronic acid (38 mg, 0.2 mmol), Purification by RP prep-HPLC and lyophilization gave 4-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-7-propoxy-2H-chromen -2-one (Example 36, 33 mg). LCMS (ESI) Calcd. for C 20 H 18 O 5 : 338, found [M+H] + = 339. 1 H NMR (400 MHz, DMSO-d6): δ 7.17-7.13 (d, 1H), 7.05-7.02 (m, 2H), 7.00-6.94 (t, 1H), 6.90-6.84 (m, 2H), 6.20 (s, 1H), 4.29-4.27 (d, 2H), 4.21-4.18 (m, 2H), 4.06-4.02 (m, 2H), 1.80-1.70 (m, 2H), 1.00-0.96 (m, 3H). Example 37: 7-hydroxy-5-methyl-4-(o-tolyl)-2H-chromen-2-one
0186 Synthesis of 3-(o-tolyl)propiolic acid, 14 [Step 1]: To a stirred solution of 1- ethynyl-2-methylbenzene (2.4 g, 21 mmol) in THF (25 mL) at -78 °C was added n-butyl lithium, 1.8M in THF (13 mL, 23 mmol) dropwise. Carbon dioxide gas was then bubbled through the reaction mixture for 1 h. at -78 °C. The reaction mixture was then gradually warmed to ambient temperature and stirred for 16 h. The reaction was quenched with saturated aqueous NH 4 Cl solution and extracted with EtOAc. The aqueous layer was separated, acidified with 1N aqueous HCl solution, and extracted with EtOAc (thrice). Combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 3-(o-tolyl)propiolic acid (14, 1.8 g). LCMS Calcd. for C 10 H 8 O 2 : 160, found [M+H] + = 161. 1 H NMR (400 MHz, DMSO- d6) δ 7.54 (d, 1H), 7.41 (t, 1H), 7.35 (d, 1H), 7.26 (t, 1H), 2.41 (s, 3H). 0187 Synthesis of 3-hydroxy-5-methylphenyl 3-(o-tolyl)propiolate, 15 [Step 2]: To a stirred solution of 5-methylbenzene-1,3-diol (330 mg, 2.6 mmol) and 3-(o- tolyl)prop-2-ynoic acid (15, 450 mg, 2.5 mmol) in CH2Cl2 (15 mL) was added a solution of DCC (826 mg, 4 mmol) in CH 2 Cl 2 (10 mL) followed by DMAP (33 mg, 0.3 mmol). The resulting mixture was stirred at ambient temperature for 16 h., then filtered. The filtrate was washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by flash column chromatography on silica gel to afford 3-hydroxy-5-methylphenyl 3-(o-tolyl)propiolate (15, 230 mg). LCMS Calcd. for C17H14O3: 266, found [M+H] + = 267. 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.70 (s, 1H), 7.63 (d, 1H), 7.49 (t, 1H), 7.40 (d, 1H), 7.31 (t, 1H), 6.53 (d, 2H), 6.45 (s, 1H), 2.40 (s, 3H), 2.23 (s, 3H). 0188 Synthesis of 7-hydroxy-5-methyl-4-(o-tolyl)-2H-chromen-2-one, Example 37 [Step 3]: A solution of 3-hydroxy-5-methylphenyl 3-(o-tolyl)propiolate (15, 240 mg, 1 mmol) in DCE (15 mL) was degassed with nitrogen for 10 min. (Acetonitrile)[(2- biphenyl)di-tert-butylphosphine]gold(I) hexafluoroantimonate (70 mg, 0.1 mmol) was added and the mixture stirred at ambient temperature for 16 h. The mixture was filtered and the filtrate was concentrated under reduced pressure. Purification by flash column chromatography on silica gel gave 7-hydroxy-5-methyl-4-(o-tolyl)-2H-chromen-2-one (Example 37, 110 mg). LCMS Calcd. for C 17 H 14 O 3 : 266, found [M+H] + = 267. 1 H NMR (400 MHz, DMSO-d6) δ 10.54 (s, 1H), 7.37-7.35 (m, 1H), 7.32-7.28 (m, 2H), 7.20 (d, 1H), 6.68 (d, 1H), 6.53 (d, 1H), 5.89 (s, 1H), 2.07 (s, 3H), 1.58 (s, 3H). Examples 38-40: 7-((tetrahydro-2H-pyran-2-yl)methoxy)-4-(o-tolyl)-2H-chromen -2-one, racemic and purified chiral analogs 0189 Synthesis of 7-((tetrahydro-2H-pyran-2-yl)methoxy)-4-(o-tolyl)-2H- chromen-2-one, Example 38 [Step 1]: To a solution of 7-hydroxy-4-(o-tolyl)-2H- chromen-2-one (Example 1, 200 mg, 0.8 mmol) in DMF (5 mL) was added Cs2CO3 (780 mg, 2.4 mmol) and KI (200 mg, 1.2 mmol) followed by 2-(bromomethyl)tetrahydropyran (210 mg, 1.2 mmol). The mixture stirred at 80 °C for 12 h, and then cooled, diluted with ethyl acetate, washed water (thrice), brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford 7-((tetrahydro-2H-pyran-2-yl) methoxy)-4-(o-tolyl)-2H- chromen-2-one (Example 38, 100 mg). LCMS (ESI) Calcd. for C22H22O4: 349, found [M+H] + = 351. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.45-7.33 (m, 3H), 7.24 (d, 1H), 7.09 (d, 1H), 6.91-6.84 (m, 2H), 6.18 (s, 1H), 4.03 (d, 2H), 3.89 (d, 1H), 3.64 (t, 1H), 3.41- 3.35 (m, 1H), 2.11 (s, 3H), 1.82 (d, 1H), 1.65 (d, 1H), 1.52-1.14 (m, 3H), 1.34 (t, 1H). 0190 Synthesis of chiral 7-((tetrahydro-2H-pyran-2-yl)methoxy)-4-(o-tolyl)-2H- chromen-2-one, Examples 39 and 40 [Step 2]: 7-((tetrahydro-2H-pyran-2-yl) methoxy)- 4-(o-tolyl)-2H-chromen-2-one (Example 38, 90 mg) was purified by chiral prep-HPLC and lyophilized to afford the first product as 7-((tetrahydro-2H-pyran-2-yl)methoxy)-4-(o- tolyl)-2H-chromen-2-one, Peak 1 (Example 39, 22 mg) and the second product as 7- ((tetrahydro-2H-pyran-2-yl)methoxy)-4-(o-tolyl)-2H-chromen-2 -one, Peak 2 (Example 40, 17 mg). The absolute stereochemistries of the enantiomers were not determined. 0191 Example 39: 7-((tetrahydro-2H-pyran-2-yl)methoxy)-4-(o-tolyl)-2H- chromen-2-one, Peak 1: LCMS (ESI) Calcd. for C22H22O4: 350, found [M+H] + = 351. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.43-7.33 (m, 3H), 7.24 (d, 1H), 7.09 (d, 1H), 6.91-6.84 (m, 2H), 6.18 (s, 1H), 4.03 (d, 2H), 3.89 (d, 1H), 3.64 (t, 1H), 3.41-3.35 (m, 1H), 2.11 (s, 3H), 1.82 (d, 1H), 1.65 (d, 1H), 1.52-1.14 (m, 3H), 1.34 (t, 1H). 0192 Example 40: 7-((tetrahydro-2H-pyran-2-yl)methoxy)-4-(o-tolyl)-2H- chromen-2-one, Peak 2: LCMS (ESI) Calcd. for C22H22O4: 350, found [M+H] + = 351. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.43-7.33 (m, 3H), 7.24 (d, 1H), 7.09 (d, 1H), 6.91-6.86 (m, 2H), 6.18 (s, 1H), 4.03 (d, 2H), 3.89 (d, 1H), 3.64 (t, 1H), 3.41-3.35 (m, 1H), 2.11 (s, 3H), 1.82 (d, 1H), 1.65 (d, 1H), 1.52-1.14 (m, 3H), 1.34 (t, 1H). 0193 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 21 mm), 5μ, operating at ambient temperature with flow rate of 21.0 mL/min. Mobile phase: 0.1 % isopropylamine in a mixture of 60 % hexane, 20 % of CH 2 Cl 2 and 20 % ethanol, held isocratic up to 30 min. with detection at 326 nm wavelength. Examples 41-43: 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanenitrile, racemic and purified chiral analogs
0194 Synthesis of 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanenitrile, Example 41 [Step 1]: To a solution of 7-hydroxy-4-(o-tolyl)-2H-chromen-2-one (Example 1, 400 mg, 1.6 mmol) in DMF (8 mL) was added Cs 2 CO 3 (1550 mg, 4.8 mmol) and KI (390 mg, 2.4 mmol) followed by 2-bromopropanenitrile (320 mg, 2.4 mmol). The mixture was stirred at 80 °C for 48 h., then cooled and diluted with ethyl acetate. The mixture was washed water (thrice), brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl) oxy)propanenitrile (Example 41, 100 mg). LCMS (ESI) Calcd. for C 19 H 15 NO 3 : 305, found [M+H] + = 306. 1 H NMR (400 MHz, DMSO-d6) δ 7.46-7.34 (m, 3H), 7.31 (s, 1H), 7.26 (d, 1H), 7.02-6.94 (m, 2H), 6.28 (s, 1H), 5.63 (q, 1H), 2.12 (s, 3H), 1.73 (d, 3H). 0195 Synthesis of chiral 2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanenitrile, Examples 42 and 43 [Step 2]: 2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl) oxy)propanenitrile (Example 41, 70 mg) was purified by chiral prep- HPLC and lyophilized to afford the first product as 2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanenitrile, Peak 1 (Example 42, 35 mg) and the second product as 2-((2-oxo- 4-(o-tolyl)-2H-chromen-7-yl)oxy)propanenitrile, Peak 2 (Example 43, 30 mg). The absolute stereochemistries of the enantiomers were not determined. 0196 Example 42: 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanenitrile, Peak 1: LCMS (ESI) Calcd. for C 19 H 15 NO 3 : 305, found [M+H] + = 306. 1 H NMR (400 MHz, DMSO-d6) δ 7.46-7.40 (m, 2H), 7.36 (t, 1H) 7.31-7.26 (m, 2H), 7.02-6.94 (m, 2H), 6.28 (s, 1H), 5.63 (q, 1H), 2.12 (s, 3H), 1.73 (d, 3H). 0197 Example 43: 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanenitrile, Peak 2: LCMS (ESI) Calcd. for C 19 H 15 NO 3 : 305, found [M+H] + = 306. 1 H NMR (400 MHz, DMSO-d6) δ 7.43-7.37 (m, 2H), 7.33 (t, 1H) 7.28-7.22 (m, 2H), 7.00-6.92 (m, 2H), 6.25 (s, 1H), 5.60 (q, 1H), 2.10 (s, 3H), 1.71 (d, 3H). 0198 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 21 mm), 5μ, operating at ambient temperature with flow rate of 21.0 mL/min. Mobile phase: 0.1 % isopropylamine in a mixture of 90 % hexane, 10 % of CH 2 Cl 2 and 20 % ethanol, held isocratic up to 30 min. with detection at 210 nm wavelength. Examples 44-46: 7-((1-methoxybutan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one, racemic and purified chiral analogs 0199 Synthesis of 7-((1-methoxybutan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one, Example 44 [Step 1]: To a solution of 7-hydroxy-4-(o-tolyl)-2H-chromen-2-one (Example 1, 300 mg, 1.2 mmol) in dry THF (7 mL) at 0 °C under inert atmosphere was added 1-methoxybutan-2-ol (140 mg, 1.3 mmol) and PPh3 (340 mg, 1.3 mmol) followed by 4Å molecular sieves (500 mg). DEAD (diethyl azodicarboxylate) (0.2 mL, 1.3 mmol) was then added dropwise and the mixture stirred for 30 min. The mixture was gradually warmed to 50 °C and stirred for 12 h. The reaction mixture was diluted with ethyl acetate, washed water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford 7-((1-methoxybutan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one (Example 44, 140 mg). LCMS (ESI) Calcd. for C21H22O4: 337, found [M+H] + = 339. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.43-7.33 (m, 3H), 7.24 (d, 1H), 7.12 (d, 1H), 6.90-6.83 (m, 2H), 6.17 (s, 1H), 4.61 (t, 1H), 3.51 (t, 2H), 3.28 (d, 3H), 2.12 (s, 3H), 1.68-1.63 (m, 2H), 0.91 (t, 3H). 0200 Synthesis of chiral 7-((1-methoxybutan-2-yl)oxy)-4-(o-tolyl)-2H-chromen- 2-one, Examples 45 and 46 [Step 2]: 7-((1-methoxybutan-2-yl)oxy)-4-(o-tolyl)-2H- chromen-2-one (Example 44, 90 mg) was purified by chiral prep-HPLC and lyophilized to afford the first product as 7-((1-methoxybutan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2- one, Peak 1 (Examples 45, 32 mg) and the second product as 7-((1-methoxybutan-2- yl)oxy)-4-(o-tolyl)-2H-chromen-2-one, Peak 2 (Examples 46, 28 mg). The absolute stereochemistries of the enantiomers were not determined. 0201 Example 45: 7-((1-methoxybutan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one, Peak 1: LCMS (ESI) Calcd. for C21H22O4: 338, found [M+H] + = 339. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.43-7.39 (m, 2H), 7.35 (t, 1H), 7.24 (d, 1H), 7.12 (d, 1H), 6.90-6.83 (m, 2H), 6.17 (s, 1H), 4.61 (t, 1H), 3.51 (t, 2H), 3.28 (d, 3H), 2.12 (s, 3H), 1.68-1.60 (m, 2H), 0.91 (t, 3H). 0202 Example 46: 7-((1-methoxybutan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one, Peak 2: LCMS (ESI) Calcd. for C 21 H 22 O 4 : 338, found [M+H] + = 339. 1 H NMR (400 MHz, DMSO-d6) δ 7.43-7.33 (m, 3H), 7.24 (d, 1H), 7.12 (d, 1H), 6.90-6.83 (m, 2H), 6.17 (s, 1H), 4.61 (t, 1H), 3.51 (t, 2H), 3.28 (d, 3H), 2.12 (s, 3H), 1.68-1.60 (m, 2H), 0.91 (t, 3H). 0203 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 21 mm), 5μ, operating at ambient temperature with flow rate of 21.0 mL/min. Mobile phase: 95 % Hexane, 2.5 % Ethanol and 2.5 % THF, held isocratic up to 30 min. with detection at 325 nm wavelength. Examples 47-49: 7-((tetrahydro-2H-pyran-3-yl)oxy)-4-(o-tolyl)-2H-chromen-2-o ne, racemic and purified chiral analogs
0204 Synthesis of 7-((tetrahydro-2H-pyran-3-yl)oxy)-4-(o-tolyl)-2H-chromen-2- one, Example 47 [Step 1]: To a solution 7-hydroxy-4-(o-tolyl)-2H-chromen-2-one (Example 1, 500 mg, 2.0 mmol) in dry THF (10 mL) at 0 °C under inert atmosphere was added tetrahydropyran-3-ol (300 mg, 3.0 mmol) and PPh3 (780 mg, 3.0 mmol) followed by 4Å molecular sieves (1 g). Diethyl azodicarboxylate (0.5 mL, 3.0 mmol) was added and the mixture stirred at 50 °C for 12 h. The mixture was then diluted with ethyl acetate, washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford 7-((tetrahydro-2H-pyran-3-yl)oxy)-4-(o-tolyl)-2H-chromen-2-o ne (Example 47, 120 mg). LCMS (ESI) Calcd. for C21H20O4: 336, found [M+H] + = 337. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.45-7.39 (m, 2H), 7.-7.33 (m, 1H), 7.24 (d, 1H), 7.14 (d, 1H), 6.91- 6.84 (m, 2H), 6.18 (s, 1H), 4.58-4.55 (m, 1H), 3.81-3.78 (m, 1H), 3.64-3.52 (m, 3H), 2.11 (s, 3H), 2.05-2.00 (m, 1H), 1.80-1.70 (m, 2H), 1.57-1.51 (m, 1H). 0205 Synthesis of chiral 7-((tetrahydro-2H-pyran-3-yl)oxy)-4-(o-tolyl)-2H- chromen-2-one, Example 48 and Example 49 [Step 2]: 7-((tetrahydro-2H-pyran-3- yl)oxy)-4-(o-tolyl)-2H-chromen-2-one (Example 47, 120 mg) was purified by chiral- HPLC and lyophilized to afford the first product as 7-((tetrahydro-2H-pyran-3-yl)oxy)-4- (o-tolyl)-2H-chromen-2-one, Peak 1 (Example 48, 55 mg) and the second product as 7- ((tetrahydro-2H-pyran-3-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one , Peak 2 (Example 49, 50 mg). The absolute stereochemistries of the enantiomers were not determined. 0206 Example 48: 7-((tetrahydro-2H-pyran-3-yl)oxy)-4-(o-tolyl)-2H-chromen-2- one, Peak 1: LCMS (ESI) Calcd. for C 21 H 20 O 4 : 336, found [M+H] + = 337. 1 H NMR (400 MHz, DMSO-d6) δ 7.45-7.33 (m, 3H), 7.24 (d, 1H), 7.14 (d, 1H), 6.91-6.85 (m, 2H), 6.18 (s, 1H), 4.58-4.55 (m, 1H), 3.81-3.78 (m, 1H), 3.64-3.52 (m, 3H), 2.11 (s, 3H), 2.07-2.01 (m, 1H), 1.80-1.71 (m, 2H), 1.57-1.51 (m, 1H). 0207 Example 49: 7-((tetrahydro-2H-pyran-3-yl)oxy)-4-(o-tolyl)-2H-chromen-2- one, Peak 2: LCMS (ESI) Calcd. for C21H20O4: 336, found [M+H] + = 337. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.45-7.33 (m, 3H), 7.24 (d, 1H), 7.14 (d, 1H), 6.91-6.84 (m, 2H), 6.18 (s, 1H), 4.59-4.55 (m, 1H), 3.82-3.78 (m, 1H), 3.64-3.52 (m, 3H), 2.11 (s, 3H), 2.07-2.00 (m, 1H), 1.80-1.71 (m, 2H), 1.57-1.54 (m, 1H). 0208 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 21 mm), 5μ, operating at ambient temperature with flow rate of 21.0 mL/min. Mobile phase: 0.1 % isopropylamine in a mixture of 70 % hexane, 15 % of CH 2 Cl 2 and 15 % ethanol, held isocratic up to 25 min. with detection at 326 nm wavelength. Example 50: 7-hydroxy-4-(2-methoxyphenyl)-2H-chromen-2-one 0209 Synthesis of ethyl 3-(2-methoxyphenyl)-3-oxopropanoate, 20 [Step 1]: To a suspension of NaH (60 % dispersion in mineral oil) (2.9 g, 120 mmol) in toluene (40 mL) was added diethyl carbonate (15.8 g, 130 mmol) at ambient temperature. The mixture was stirred for 15 min., then 1-(2-methoxyphenyl)ethanone (5.0 g, 34.0 mmol) was added. The mixture was gradually warmed to 100 °C and stirred at 100 °C for 4 h. The reaction mixture was cooled to 0 °C and quenched with a saturated aqueous NH 4 Cl solution. The mixture was extracted with EtOAc (2 x 100 mL). The combined organic extracts were washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by flash column chromatography on silica gel to give ethyl 3-(2-methoxyphenyl)-3-oxopropanoate (20, 4.0 g). LCMS (ESI) Calcd. for C12H14O4: 222, found [M+H] + = 223. 1 H NMR (400 MHz, CDCl3) δ 7.87-7.85 (m, 1H), 7.51-7.47 (m, 1H), 7.02 (t, 1H), 6.96-6.86 (m, 1H), 4.24-4.14 (m, 2H), 3.95 (s, 2H), 3.88 (d, 3H), 1.22 (d, 3H). 0210 Synthesis of 7-hydroxy-4-(2-methoxyphenyl)-2H-chromen-2-one, Example 50 [Step 2]: Methanesulphonic acid (8.0 mL, 120.0 mmol) was added dropwise to a mixture of ethyl 3-oxo-3-(2-methoxyphenyl)-3-oxo-propanoate (20, 4.0 g, 18.0 mmol) and benzene-1,3-diol (2.0 g, 18.0 mmol) at ambient temperature. The reaction mixture was stirred for 16 h. and then quenched with ice water (40 mL). The resulting precipitate was filtered, washed with water (2 x 40 mL), then pentane. The solid was dried under reduced pressure to give 7-hydroxy-4-(2-methoxyphenyl)-2H-chromen-2-one (Example 50, 4 g). LCMS (ESI) Calcd. for C 16 H 12 O 4 : 268, found [M+H] + = 269. 1 H NMR (400 MHz, DMSO-d6) δ 10.56 (s, 1H), 7.53-7.49 (m, 1H), 7.27 (dd,1H), 7.20 (d, 1H), 7.09 (t, 1H), 6.92 (d, 1H), 6.76 (t, 1H), 6.73-6.69 (m, 1H), 6.09, (s, 1H), 3.71 (s, 3H). Examples 51-55: 4-(4,5-dimethylthiophen-3-yl)-7-propoxy-2H-chromen-2-one, 4-(3,5- dimethylisoxazol-4-yl)-7-propoxy-2H-chromen-2-one, 4-(2-methylpyridin-3-yl)-7-propoxy- 2H-chromen-2-one, 4-(3-methylpyridin-4-yl)-7-propoxy-2H-chromen-2-one, of 4-(6-chloro- 4-methylpyridin-3-yl)-7-propoxy-2H-chromen-2-one
66 0211 Synthesis of (4,5-dimethylthiophen-3-yl)boronic acid, 22 [Step 1A]: To an oven dried 2-neck round bottle flask was added 4-bromo-2,3-dimethylthiophene (21, 100 mg, 0.5 mmol) followed by triisopropyl borate (128 mg, 0.7 mmol) and THF (0.5 mL). The reaction mixture was treated with n-BuLi (1.6M in hexanes) (0.4 mL, 0.7 mmol) at - 78 °C under an argon atmosphere and stirred for 1 h. at the same temperature. The reaction mixture was gradually warmed to room temperature and quenched by the slow addition of 2N aq. HCl. The mixture was diluted with EtOAc, washed with brine and the organic layer was separated, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. Product 22 was used without further purification. 0212 Synthesis of 4-(4,5-dimethylthiophen-3-yl)-7-propoxy-2H-chromen-2-one, Example 51 [Step 1]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 100 mg) and (4,5-dimethylthiophen-3-yl)boronic acid (22, 66 mg). Purification by RP prep-HPLC and lyophilization gave 4-(4,5-dimethylthiophen-3-yl)-7-propoxy-2H- chromen-2-one (Example 51, 33 mg). LCMS (ESI) Calcd. for C18H18O3S: 314, found [M+H] + = 315. 1 H NMR (400 MHz, DMSO-d 6 ): δ 7.43 (s, 1H), 7.14 (d, 1H), 7.05 (d, 1H), 6.91 (dd, 1H), 6.14 (s, 1H), 4.05 (t, 2H), 2.39 (s, 3H), 1.92 (s, 3H), 1.80-1.70 (m, 2H), 0.98 (t, 3H). 0213 Synthesis of 4-(3,5-dimethylisoxazol-4-yl)-7-propoxy-2H-chromen-2-one, Example 52 [Step 2]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 100 mg) and (3,5-dimethylisoxazol-4-yl)boronic acid (23, 52 mg). Purification by RP prep-HPLC and lyophilization gave (Example 52, 38 mg). LCMS (ESI) Calcd. for C17H17NO4: 299, found [M+H] + = 300. 1 H NMR (400 MHz, DMSO-d6): δ 7.21 (d, 1H), 7.08-7.07 (m, 1H), 6.93-6.90 (m, 1H), 6.35 (s, 1H), 4.06 (t, 2H), 2.34 (s, 3H), 2.13 (s, 3H), 1.78-1.73 (m, 2H), 0.98 (t, 3H). 0214 Synthesis of 4-(2-methylpyridin-3-yl)-7-propoxy-2H-chromen-2-one, Example 53 [Step 3]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 70 mg) and (2-methylpyridin-3-yl)boronic acid (24, 49 mg). Purification by RP prep- HPLC and lyophilization gave 4-(2-methylpyridin-3-yl)-7-propoxy-2H-chromen-2-one (Example 53, 39 mg). LCMS (ESI) Calcd. for C18H17NO3: 295, found [M+H] + = 296. 1 H NMR (400 MHz, DMSO-d 6 ): δ 8.62-8.61 (m, 1H), 7.71-7.69 (m, 1H), 7.42-7.38 (m, 1H), 7.10 (s, 1H), 6.88 (s, 2H), 6.29 (s, 1H), 4.05 (t, 2H), 2.31 (s, 3H), 1.78-1.73 (m, 2H), 0.98 (t, 3H). 0215 Synthesis of 4-(3-methylpyridin-4-yl)-7-propoxy-2H-chromen-2-one, Example 54 [Step 4]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 30 mg) and (3-methylpyridin-4-yl)boronic acid (25, 21 mg). Purification by RP prep- HPLC and lyophilization gave 4-(3-methylpyridin-4-yl)-7-propoxy-2H-chromen-2-one, (Example 54, 15 mg). LCMS (ESI) Calcd. for C 18 H 17 NO 3 : 295, found [M+H] + = 296. 1 H NMR (400 MHz, DMSO-d6): δ 8.63 (s, 1H), 8.57-8.55 (m, 1H), 7.31-7.30 (m, 1H), 7.10 (s, 1H), 6.87-6.85 (m, 2H), 6.27 (s, 1H), 4.07-4.03 (m, 2H), 2.12 (s, 3H), 1.79-1.73 (m, 2H), 0.98 (t, 3H). 0216 Synthesis of 4-(6-chloro-4-methylpyridin-3-yl)-7-propoxy-2H-chromen-2- one, Example 55 [Step 5]: This compound was synthesized following general Suzuki coupling procedure from 2-oxo-7-propoxy-2H-chromen-4-yl trifluoromethanesulfonate (13, 100 mg) and 73 mg of (6-chloro-4-methylpyridin-3-yl)boronic acid (26, 73 mg). Purification by RP prep-HPLC and lyophilization gave 4-(6-chloro-4-methylpyridin-3- yl)-7-propoxy-2H-chromen-2-one (Example 55, 54 mg). LCMS (ESI) Calcd. for C18H16ClNO3: 329, found [M+H] + = 330. 1 H NMR (400 MHz, DMSO-d6): δ 8.29 (s, 1H), 7.64 (s, 1H), 7.09 (d, 1H), 6.95 (d, 1H), 6.86 (dd, 1H), 6.33 (s, 1H), 4.05 (t, 2H), 2.15 (s, 3H), 1.79-1.70 (m, 2H), 0.98 (t, 3H). Examples 56-57: 7-((1-acetylpiperidin-4-yl)oxy)-4-(2-chloro-4-fluorophenyl)- 2H-chromen-2- one, 7-((1-acetylpiperidin-3-yl)oxy)-4-(2-chloro-4-fluorophenyl)- 2H-chromen-2-one
0217 Synthesis of 7-((1-acetylpiperidin-4-yl)oxy)-4-(2-chloro-4-fluorophenyl)- 2H-chromen-2-one, Example 56 [Step 1]: In a dried 2-neck 50 mL flask was added a solution of 4-(2-chloro-4-fluoro-phenyl)-7-hydroxy-chromen-2-one (Example 13, 200 mg, 0.7 mmol) in dry THF (7 mL) followed by 1-(4-hydroxy-1-piperidyl)ethanone (27, 150 mg, 1.0 mmol) and PPh 3 (270 mg, 1.0 mmol) along with 4Å molecular sieves (400 mg) under an inert atmosphere. The reaction mixture was cooled to 0 °C, and DEAD (0.2 mL, 1.0 mmol) was added dropwise with stirring for 30 min. The reaction mixture was gradually warmed to ambient temperature and stirring was continued for 12 h., at 60 °C. The reaction mixture was diluted with ethyl acetate and the organic layer was washed with water (twice), brine (twice), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilization to afford 7-((1-acetylpiperidin-4-yl)oxy)-4-(2-chloro-4-fluorophenyl)- 2H-chromen-2-one (Example 56, 84 mg). LCMS (ESI) Calcd. for C 22 H 19 ClFNO 4 : 415, found [M+H] + = 416. 1 H NMR (400 MHz, DMSO-d6) δ 7.70 (dd, 1H), 7.58-7.55 (m, 1H), 7.46-7.41 (m, 1H), 7.21 (s, 1H), 6.95-6.90 (m, 2H), 6.30 (s, 1H), 4.82-4.76 (m, 1H), 3.89-3.85 (m, 1H), 3.70- 3.65 (m, 1H), 3.37-3.35 (m, 1H), 3.25-3.19 (m, 1H), 2.01 (s, 4H), 1.89 (d, 1H), 1.63 (d, 1H), 1.52 (d, 1H). 0218 Synthesis of 7-((1-acetylpiperidin-3-yl)oxy)-4-(2-chloro-4-fluorophenyl)- 2H-chromen-2-one, Example 57 [Step 2]: To a solution of 4-(2-chloro-4-fluoro- phenyl)-7-hydroxy-chromen-2-one (Example 13, 150 mg, 0.5 mmol) in dry THF (7 mL) was added 1-(3-hydroxy-1-piperidyl)ethanone (28, 220 mg, 1.6 mmol) and PPh3 (410 mg, 1.6 mmol) along with 4Å molecular sieves (300 mg) under inert atmosphere. The solution was cooled to 0 °C, and DIAD (270 mg, 1.6 mmol) was added dropwise and the reaction mixture was stirred for 30 min. The reaction mixture was gradually warmed to ambient temperature and continued stirring for 12 h. at 60 °C. The reaction mixture was diluted with ethyl acetate and the organic layer was washed with water (twice), brine (twice), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford 7-((1-acetylpiperidin-3-yl)oxy)-4-(2- chloro-4-fluorophenyl)-2H-chromen-2-one (Example 57, 60 mg). LCMS (ESI) Calcd. for C 22 H 19 ClFNO 4 : 415, found [M+H] + = 416. 1 H NMR (400 MHz, DMSO-d 6 ) (at 100 °C) δ 7.61-7.52 (m, 2H), 7.41-7.37 (m, 1H), 7.01 (s, 1H), 6.96 (d, 1H), 6.90 (t, 1H), 6.24 (s, 1H), 4.61 (d, 1H), 3.52-3.46 (m, 4H), 1.97 (s, 4H), 1.78 (s, 2H), 1.53 (s, 1H). Examples 58-60: 7-isopropoxy-5-methyl-4-(o-tolyl)-2H-chromen-2-one, 7-((1- methoxypropan-2-yl)oxy)-5-methyl-4-(o-tolyl)-2H-chromen-2-on e, racemic and purified chiral analogs
0219 Synthesis of 7-isopropoxy-5-methyl-4-(o-tolyl)-2H-chromen-2-one, Example 58 [Step 1]: To a solution of 7-hydroxy-5-methyl-4-(o-tolyl)chromen-2-one (Example 37, 50 mg, 0.2 mmol) in DMF (5 mL) was added Cs2CO3 (120 mg, 0.4 mmol), followed by 2-iodopropane (29, 50 mg, 0.3 mmol). The reaction mixture was stirred 80 °C for 12 h., and then concentration under reduced pressure at ambient temperature to obtain the product, which was extracted with EtOAc. The organic layer was washed twice with cold water, brine, and dried over anhydrous Na2SO4. The organic layer was concentrated under reduced pressure and purified via RP prep-HPLC and lyophilized to afford 7-isopropoxy-5-methyl-4-(o-tolyl)-2H-chromen-2-one (Example 58, 29 mg). LCMS (ESI) Calcd. for C 20 H 20 O 3 : 308, found [M+H] + = 309. 1 H NMR (400 MHz, DMSO-d6) δ 7.40-7.36 (m, 1H), 7.31 (t, 2H), 7.22 (d, 1H), 6.94 (d, 1H), 6.67 (d, 1H), 5.96 (s, 1H), 4.79-4.73 (m, 1H), 2.08 (s, 3H), 1.62 (s, 3H), 1.29 (d, 6H). 0220 Synthesis of 7-((1-methoxypropan-2-yl)oxy)-5-methyl-4-(o-tolyl)-2H- chromen-2-one, 31 [Step 2]: To a solution of 7-hydroxy-5-methyl-4-(o-tolyl)chromen-2- one (Example 37, 100 mg, 0.4 mmol) in DMF (5 mL) was added cesium carbonate (490 mg, 1.5 mmol) and KI (130 mg, 0.8 mmol) followed by 2-bromo-1-methoxy-propane (30, 120 mg, 0.8 mmol). The reaction mixture was stirred at 80 °C for 12 h, concentrated under reduced pressure, and the product was extracted with ethyl acetate. The organic layer was washed twice with cold water, brine, dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduce pressure and purified by column chromatography to obtain 7-((1-methoxypropan-2-yl)oxy)-5-methyl-4-(o-tolyl)-2H- chromen-2-one (31, 110 mg). LCMS (ESI) Calcd. for C 21 H 22 O 4 : 338, found [M+H] + = 339. 1 H NMR (400 MHz, CDCl3) δ 7.33 (t, 1H), 7.25 (t, 2H), 7.12 (d, 1H), 6.80 (d, 1H), 6.58 (s, 1H), 6.01 (s, 1H), 4.63-4.56 (m, 1H), 3.60-3.56 (m, 1H), 3.52-3.48 (m, 1H), 3.40 (s, 3H), 2.12 (d, 3H), 1.67 (s, 3H), 1.34 (d, 3H). 0221 Synthesis of chiral 7-((1-methoxypropan-2-yl)oxy)-5-methyl-4-(o-tolyl)- 2H-chromen-2-one, Examples 59 and 60 [Step 3]: 7-((1-methoxypropan-2-yl)oxy)-5- methyl-4-(o-tolyl)-2H-chromen-2-one (31, 110 mg) was purified by chiral prep-HPLC separation and the first product was isolated as 7-((1-methoxypropan-2-yl)oxy)-5-methyl- 4-(o-tolyl)-2H-chromen-2-one, Peak 1 (Example 59, 15 mg) and the second product as 7- ((1-methoxypropan-2-yl)oxy)-5-methyl-4-(o-tolyl)-2H-chromen- 2-one, Peak 2 (Example 60, 30 mg). The absolute stereochemistries of these compounds were not determined. 0222 Example 59: [7-((1-methoxypropan-2-yl)oxy)-5-methyl-4-(o-tolyl)-2H- chromen-2-one, Peak 1]: LCMS (ESI) Calcd. for C21H22O4: 338, found [M+H] + = 339. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.38 (t, 1H), 7.31 (t, 2H), 7.21 (d, 1H), 6.91 (d, 1H), 6.69 (s, 1H), 5.94 (s, 1H), 4.75 (q, 1H), 3.56-3.47 (m, 2H), 3.32 (s, 3H), 2.12 (s, 3H), 1.67 (s, 3H), 1.28 (d, 3H). 0223 Example 60: [7-((1-methoxypropan-2-yl)oxy)-5-methyl-4-(o-tolyl)-2H- chromen-2-one, Peak 2]: LCMS (ESI) Calcd. for C 21 H 22 O 4 : 338, found [M+H] + = 339. 1 H NMR (400 MHz, DMSO-d6) δ 7.38 (t, 1H), 7.31 (t, 2H), 7.21 (d, 1H), 6.91 (s, 1H), 6.69 (s, 1H), 5.94 (s, 1H), 4.75 (q, 1H), 3.56-3.47 (m, 2H), 3.32 (s, 3H), 2.12 (s, 3H), 1.67 (s, 3H), 1.28 (d, 3H). 0224 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 21 mm), 5μ, operating at ambient temperature with flow rate of 21.0 mL/min. Mobile phase: 85% hexane and 15% of ethanol, held isocratic up to 40 min. with detection at 210 nm wavelength. Examples 61-62: (S)-7-((1-acetylpyrrolidin-3-yl)oxy)-4-(o-tolyl)-2H-chromen- 2-one, (R)-7- ((1-acetylpyrrolidin-3-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one 0225 Synthesis of (S)-7-((1-acetylpyrrolidin-3-yl)oxy)-4-(o-tolyl)-2H-chromen- 2-one, Example 61 [Step 1]: To a stirred solution of 7-hydroxy-4-(o-tolyl)-2H-chromen- 2-one (Example 1, 200 mg, 0.8 mmol) and (R)-1-(hydroxypyrrolidin-1-yl)ethan-1-one (32, 155 mg, 1.2 mmol) in THF (3 mL) was added PPh 3 (625 mg, 2.4 mmol) followed by diisopropyl azodicarboxylate (0.5 mL, 2.4 mmol) and the reaction mixture was heated at 80 °C for 16 h. The reaction mixture was concentrated under reduced pressure to obtain the product, which was partitioned between EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure to obtain the product, which was purified by RP prep-HPLC chromatography and lyophilized to afford ethyl (S)-7-((1-acetylpyrrolidin-3-yl)oxy)-4-(o-tolyl)-2H- chromen-2-one as solid (Example 61, 159 mg). LCMS (ESI) Calcd. for C22H21NO4: 363, found [M+H] + = 364. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.43-7.33 (m, 3H), 7.23 (d, 1H), 7.15 (d, 1H), 6.89 (m, 2H), 6.19 (s, 1H), 5.23 (d, 1H), 3.86-3.52 (m, 4H), 2.33-2.11 (m, 5H), 1.97 (s, 3H). 0226 Synthesis of (R)-7-((1-acetylpyrrolidin-3-yl)oxy)-4-(o-tolyl)-2H-chromen- 2-one, Example 62 [Step 2]: To a stirred solution of 7-hydroxy-4-(o-tolyl)-2H-chromen- 2-one (Example 1, 200 mg, 0.8 mmol) and (S)-1-(hydroxypyrrolidin-1-yl)ethan-1-one (33, 155 mg, 1.2 mmol) in THF (3 mL) was added PPh 3 (625 mg, 2.4 mmol) followed by diisopropyl azodicarboxylate (0.5 mL, 2.4 mmol), and the reaction mixture was heated at 80 °C for 16 h. The reaction mixture was concentrated under reduced pressure and the product was partitioned between EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by RP prep-HPLC chromatography and lyophilized to afford ethyl (R)-7-((1-acetylpyrrolidin-3-yl)oxy)-4-(o-tolyl)-2H-chromen- 2-one (Example 62, 145 mg). LCMS (ESI) Calcd. for C22H21NO4: 363, found [M+H] + = 364. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.43-7.38 (m, 3H), 7.23 (d, 1H), 7.15 (d, 1H), 6.89 (m, 2H), 6.19 (s, 1H), 5.23 (d, 1H), 3.86-3.52 (m, 4H), 2.33-2.11 (m, 5H), 1.97 (s, 3H). Example 63: (S)-7-((1-methylpyrrolidin-3-yl)oxy)-4-(o-tolyl)-2H-chromen- 2-one 0227 Synthesis of (S)-7-((1-methylpyrrolidin-3-yl)oxy)-4-(o-tolyl)-2H-chromen- 2-one, Example 63 [Step 1]: To a stirred solution of 7-hydroxy-4-(o-tolyl)-2H-chromen- 2-one (Example 1, 200 mg, 0.8 mmol) in THF (5 mL) was added (R)-1-methylpyrrolidin- 3-ol (34, 120 mg, 1.2 mmol) followed by PPh3 (624 mg, 2.4 mmol). The reaction mixture was stirred at ambient temperature for 15 min., followed by the addition of diisopropyl azodicarboxylate (0.4 mL, 2.4 mmol) at 0 °C, and the reaction mixture was stirred at 80 °C for 16 h. The reaction mixture was concentrated under reduced pressure and the product was partitioned between EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The product was subjected to flash chromatography and then to RP prep-HPLC and lyophilized to afford (S)-7-((1-methylpyrrolidin-3-yl)oxy)-4-(o-tolyl)-2H-chromen- 2-one (Example 63, 120 mg). LCMS (ESI) Calcd. for C21H21NO3: 335, found [M+H] + = 336. 1H NMR (400 MHz, DMSO-d 6 ) δ 7.44-7.32 (m, 3H), 7.24 (d, 1H), 7.01 (d, 1H), 6.86- 6.81 (m, 2H), 6.17 (s, 1H), 4.98 (br s, 1H), 2.78-2.74 (m, 1H), 2.69-2.62 (m, 2H), 2.36- 2.32 (m, 2H), 2.25 (s, 3H), 2.11 (s, 3H), 1.83 (br s, 1H). Example 64: 4-(3-methylpyridin-2-yl)-7-propoxy-2H-chromen-2-one
0228 Synthesis of 4-(3-methylpyridin-2-yl)-7-propoxy-2H-chromen-2-one, Example 64 [Step 1]: To a mixture of THF (1.1 mL) and isopropylmagnesium chloride in 2M THF (0.6 mL, 1.3 mmol) under an argon atmosphere was added 2-bromo-3- methylpyridine (35, 200 mg, 1.2 mmol) dropwise at 25 °C. After 4 h., zinc chloride solution (0.7 mL, 1.9M in 2-MeTHF, 1.4 mmol) was added dropwise, and the reaction mixture was stirred for another hour at the same temperature. The organozinc reagent was kept under argon, and used in the next step. 0229 To a pressure tube was added Pd 2 (dba) 3 (20 mg, 23.2 µmol) and XPhos (17 mg, 34.9 µmol) in THF (1.5 mL) under argon, and the reaction mixture was heated at 65 °C for 10 min.4-Bromo-7-propoxy-2H-chromen-2-one (36, 200 mg, 0.7 mmol) was added and the reaction mixture was stirred for 15 min. at the same temperature. To the reaction mixture was added the previously prepared organozinc reagent and stirring was continued for 12 h. at 65 °C. The reaction mixture was filtered and concentrated under reduced pressure, and the product was purified by RP prep-HPLC to afford 4-(3- methylpyridin-2-yl)-7-propoxy-2H-chromen-2-one (Example 64, 19 mg). LCMS (ESI) Calcd. for C 18 H 17 NO 3 : 295, found [M+H] + = 296. 1 H NMR (400 MHz, DMSO-d 6 ): δ 8.55 (d, 1H), 7.85 (d, 1H), 7.48-7.45 (m, 1H), 7.08 (d, 1H), 6.88-6.86 (m, 2H), 6.29 (s, 1H), 4.06-4.03 (m, 2H) 2.19 (s, 3H) 1.78-1.72 (m, 2H), 0.98 (t, 3H). Example 65: 3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoi c acid 0230 Synthesis of methyl 3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 38 [Step 1]: To a stirred solution of 7-hydroxy-4-(o-tolyl)chromen- 2-one (Example 1, 1.0 g, 4 mmol) in DMF (5 mL) was added Cs2CO3 (2.6 g, 8 mmol). The reaction mixture was stirred at ambient temperature for 15 min., and methyl 2- bromo-3-methoxy-propanoate (37, 0.6 mL, 4 mmol) was added and the reaction mixture was stirred at ambient temperature for 18 h. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by flash column chromatography to obtain methyl 3-methoxy-2-((2-oxo-4-(o- tolyl)-2H-chromen-7-yl)oxy)propanoate (38, 1.3 g). LCMS (ESI) Calcd. for C 21 H 20 O 6 : 368, found [M+H] = 369. 0231 Synthesis of 3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, Example 65 [Step 2]: To a stirred solution of methyl 3-methoxy- 2-[4-(o-tolyl)-2-oxo-chromen-7-yl]oxy-propanoate (38, 300 mg, 0.8 mmol) in THF (3 mL) and water (0.3 mL) was added at LiOH (60 mg, 2.5 mmol). The reaction mixture was stirred for 16 h. at ambient temperature. The reaction mixture was concentrated under reduced pressure, diluted with water, and extracted with EtOAc. The aqueous layer was acidified to pH 5-6 with aqueous HCl (10M), filtered, and the precipitated solids were collected to afford the product. The product was purified by RP prep-HPLC and lyophilized to yield 3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy) propanoic acid (Example 65, 280 mg). LCMS (ESI) Calcd. for C 20 H 18 O 6 : 354, found [M+H] + = 355. 1 H NMR (400 MHz, DMSO-d6) (at 100 °C) δ 7.44-7.33 (m, 3H), 7.23 (d, 1H), 6.91 (br s, 1H), 6.86-6.81 (m, 2H), 6.1 (s, 1H), 4.78 (s, 1H), 3.79-3.77 (m, 2H), 3.32 (s, 3H), 2.14 (s, 3H). Example 66: (R)-7-((1-methylpyrrolidin-3-yl)oxy)-4-(o-tolyl)-2H-chromen- 2-one 0232 Synthesis of (R)-7-((1-methylpyrrolidin-3-yl)oxy)-4-(o-tolyl)-2H-chromen- 2-one, Example 66 [Step 1]: To a stirred solution of 7-hydroxy-4-(o-tolyl)-2H-chromen- 2-one (Example 1, 100 mg, 0.4 mmol) and (S)-1-methylpyrrolidin-3-ol (39, 60 mg, 0.6 mmol) in THF (3 mL) was added PPh3 (310 mg, 1.2 mmol) followed by diisopropyl azodicarboxylate (0.2 mL, 1.2 mmol) at 0 °C. The reaction mixture was stirred at 80 C for 16 h. and then concentrated under reduced pressure. The product was partitioned between EtOAc and water, and the organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford (R)-7-((1-methylpyrrolidin-3-yl)oxy)-4-(o- tolyl)-2H-chromen-2-one (Example 66, 30 mg). LCMS (ESI) Calcd. for C21H21NO3: 335, found [M+H] + = 336. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.43-7.38 (m, 2H), 7.36-7.33 (m, 1H), 7.24 (d, 1H), 7.01 (d, 1H), 6.87-6.81 (m, 2H), 6.17 (s, 1H), 5.00-4.98 (m, 1H), 2.78- 2.74 (m, 1H), 2.69-2.62 (m, 2H), 2.33-2.31 (m, 2H), 2.25 (s, 3H), 2.11 (s, 3H), 1.77 (d, 1H). Examples 67-68: 3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanam ide, racemic and purified chiral analogs 0233 Synthesis of methyl (S)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 41 [Step 1]: A stirred solution of methyl (S)-3-(benzyloxy)-2-((2- oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (40, 400 mg, 0.9 mmol) (7:3 (S:R) enantiomeric ratio) in ethanol (8 mL) was degassed with argon for 5 min. To the solution was added Pd/C (40 mg, 0.9 mmol) followed by hydrogen gas and stirring was continued at ambient temperature for 3 h. The reaction mixture was filtered through a celite bed using EtOH as eluent and concentrated under reduced pressure to afford methyl (S)-3- hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (41, 290 mg). LCMS (ESI) Calcd. for C20H18O6: 354, found [M+H] + = 355. 0234 Synthesis of methyl (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 42 [Step 2]: To a stirred solution of methyl (S)-3-hydroxy-2-((2-oxo- 4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (41, 350 mg, 1.0 mmol) was added methyl iodide (1.8 mL, 30 mmol) and Ag2O (460 mg, 2.0 mmol), and the reaction mixture was stirred at ambient temperature for 32 h. The reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure to give the product that was purified by flash chromatography to afford methyl (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)- 2H-chromen-7-yl)oxy)propanoate (42, 210 mg). LCMS (ESI) Calcd. for C21H20O6: 368, found [M+H] + = 369. 0235 Synthesis of (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, 43 [Step 3]: To a stirred solution of methyl (S)-3-methoxy-2- ((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (42, 210 mg, 0.6 mmol) in THF (4 mL) was added dropwise a solution of LiOH∙H20 (50 mg, 1.1 mmol) in water (1 mL) and the reaction mixture was stirred at ambient temperature for 2 h. The reaction mixture was concentrated under reduced pressure, diluted with water, acidified with citric acid, extracted with EtOAc, washed with brine, and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure to afford the (S)-3- methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoic acid (43, 200 mg). LCMS (ESI) Calcd. for C20H18O6: 354, found [M+H] + = 355. 0236 Synthesis of (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, 44 [Step 4]: To a stirred solution of (S)-3-methoxy-2-((2-oxo-4-(o- tolyl)-2H-chromen-7-yl)oxy)propanoic acid (43, 200 mg, 0.6 mmol) in DMF (3 mL) was added DIPEA (0.5 mL, 2.8 mmol) and (NH4)2CO3 (270 mg, 2.8 mmol), followed by the addition of T 3 P (50 % in EtOAc) (0.5 mL, 0.8 mmol) and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was quenched with ice-cold water, extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The product was purified by RP prep- HPLC to afford (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)prop anamide (44, 55 mg). LCMS (ESI) Calcd. for C 20 H 19 NO 5 : 353, found [M+H] + = 354. 0237 Synthesis of chiral 3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Examples 67 and 68 [Step 5]: (S)-3-methoxy-2-((2-oxo-4-(o- tolyl)-2H-chromen-7-yl)oxy)propenamide (44) (7:3 (S:R) enantiomeric ratio) was purified by chiral prep-HPLC separation and the first product was isolated as (S)-3- methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propenamid e, Peak 1 (Example 67, 30 mg) and the second product as (R)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Peak 2 (Example 68, 10 mg). 0238 Example 67: [(S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Peak 1]: LCMS (ESI) Calcd. for C20H19NO5: 353, found [M+H] + = 354. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.66 (br s, 1H), 7.44-7.40 (m, 3H), 7.38-7.34 (t, 1H), 7.24-7.22 (d, 1H), 7.03 (m, 1H), 6.91-6.86 (m, 2H), 6.20 (s, 1H), 4.92 (m, 1H), 3.75- 3.71 (m, 2H), 3.30 (s, 3H) , 2.11 (s, 3H). 0239 Example 68: [(R)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Peak 2]: LCMS (ESI) Calcd. for C 20 H 19 NO 5 : 353, found [M+H] + = 354. 1 H NMR (400 MHz, DMSO-d6) δ 7.66 (br s, 1H), 7.44-7.40 (m, 3H), 7.38-7.33 (m, 1H), 7.24-7.22 (d, 1H), 7.03 (m, 1H), 6.93-6.86 (m, 2H), 6.20 (s, 1H), 4.92 (m, 1H), 3.77- 3.69 (m, 2H), 3.30 (s, 3H), 2.11 (s, 3H). 0240 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 20 mm), 5μ, operating at ambient temperature with flow rate of 18.0 mL/min. Mobile phase: Hexane, dichloromethane, and ethanol (70/15/15), held isocratic up to 33 min. with detection at 322 nm wavelength. Examples 69-70: 3-methoxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanamide, racemic and purified chiral analogs
0241 Synthesis of (R)-3-(benzyloxy)-2-hydroxypropanoic acid, 40-2 [Step 1]: A stirred solution of (2R)-2-amino-3-benzyloxy-propanoic acid (40-1, 2.0 g, 10.2 mmol) in 2N H2SO4 (10 mL) was cooled to 0 °C. Then a solution of NaNO2 (1.28 g, 18.6 mmol) in water was added to the mixture over 1.5 h. and the temperature was maintained at 0 to 5 °C. The reaction mixture was stirred at 5 °C for 6 h. and it was gradually warmed to ambient temperature and stirred for another 3 h. A solution of 50% NaOH was added dropwise to the reaction mixture at 0 °C until pH 4, and the mixture was extracted with ethyl acetate. The aqueous layer was acidified to pH 2 with the addition of 2N H 2 SO 4 and extracted several times with EtOAc. The combined organic layer was dried over anhydrous Na 2 SO 4 , filter, and concentrated under reduced pressure to obtain (R)-3- (benzyloxy)-2-hydroxypropanoic acid (40-2, 1.4 g). LCMS (ESI): Calcd. for C10H12O4: 196, found [M+NH 4 ] + = 214. 0242 Synthesis of methyl (R)-3-(benzyloxy)-2-hydroxypropanoate, 40-4 [Step 2]: To a stirred mixture of (R)-3-(benzyloxy)-2-hydroxypropanoic acid (40-2, 5.3 g, 27.0 mmol) in methanol (35 mL) was added a freshly prepared solution of methanolic HCl 1M (25 mL) at ambient temperature and the mixture was stirred for 1 h. To the mixture was added trimethyl orthoformate (40-3, 17.2 g, 162 mmol) and the mixture was stirred for 18 h. at ambient temperature. The mixture was concentrated under reduced pressure, and the product was purified by column chromatography to afford methyl (R)-3-(benzyloxy)-2- hydroxypropanoate (40-4, 3.4 g). 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.34- 7.24 (m, 5H), 4.61-4.51 (m, 2H), 4.33-4.30 (m, 1H), 3.77 (s, 3H), 3.74 (m, 2H). 0243 Synthesis of methyl 3-(benzyloxy)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 40 [Step 3]: To a stirred solution of 7-hydroxy-4-(o-tolyl)-2H- chromen-2-one (Example 1, 1 g, 4 mmol) and methyl (R)-3-(benzyloxy)-2- hydroxypropanoate (40-4, 1.2 g, 6 mmol) in THF (25 mL) was added PPh3 (3.1 g, 12 mmol). The reaction mixture was cooled to 0 °C, and DIAD (2.3 mL, 12 mmol) was added and the reaction mixture was stirred for 5 min., and gradually heated to 80 °C and stirred for 16 h. The reaction mixture was diluted with ethyl acetate, washed with water, brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified through combi-flash chromatography to afford methyl 3- (benzyloxy)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propan oate (40, 582 mg). LCMS Calcd. for C27H24O6: 444, found [M+H] + = 445. 1 H NMR (400 MHz, DMSO-d6) δ 7.39- 7.27 (m, 8H), 7.15 (d, 1H), 6.97 (d, 1H), 6.83-6.81 (m, 1H), 6.79-6.75 (m, 1H), 6.16 (s, 1H), 4.98 (m, 1H), 4.67 (s, 2H), 3.99-3.92 (m, 2H), 3.79 (s, 3H), 2.16 (s, 3H). 0244 Synthesis of methyl (S)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 41 [Step 4]: To a stirred solution of methyl (S)-3-benzyloxy-2-[4-(o- tolyl)-2-oxo-chromen-7-yl]oxy-propanoate (40, 520 mg, 1.17 mmol) in ethanol (10 mL) under argon, was added Pd/C (30 mg, 0.117 mmol) and the reaction mixture was subjected to hydrogenolysis using a H 2 balloon for 2 h. The reaction mixture was filtered through a celite bed and concentrated under reduced pressure. The product was purified through column chromatography to obtain methyl (S)-3-hydroxy-2-[4-(o-tolyl)-2-oxo- chromen-7-yl]oxy-propanoate (41, 280 mg). LCMS Calcd. for C20H18O6: 354, found [M+H] + = 355. 0245 Synthesis of methyl (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 42 [Step 5]: To a stirred solution of methyl (S)-3-hydroxy-2-[4-(o- tolyl)-2-oxo-chromen-7-yl]oxy-propanoate (41, 210 mg, 0.593 mmol) in methyl iodide (1.1 mL, 17.8 mmol) at 0 o C under argon, was added Ag 2 O (275 mg, 1.19 mmol) portion wise, and the reaction mixture was stirred at ambient temperature overnight. The reaction mixture was diluted with ethyl acetate and filtered through a celite bed, and concentrated under reduced pressure to afford methyl (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanoate (42, 215 mg) which was used for next without further purification. LCMS Calcd. for C21H20O6: 368, found [M+H] + = 369. 0246 Synthesis of (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, 43 [Step 6]: To a stirred solution of methyl (S)-3-methoxy-2-[4- (o-tolyl)-2-oxo-chromen-7-yl]oxy-propanoate (42, 200 mg, 0.543 mmol) in THF (6 mL) and water (1.5 mL) was added LiOH ^H2O (68 mg, 1.63 mmol). The reaction mixture was stirred for 6 h. at ambient temperature, and concentrated under reduced pressure to obtain (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)prop anoic acid (43, 160 mg). The product was used in the next step without further purification. LCMS Calcd. for C20H18O6: 354, found [M+H] + = 355. 0247 Synthesis of (S)-3-methoxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, 45 [Step 7]: To a stirred solution of (S)-3-methoxy-2-[4-(o-tolyl)- 2-oxo-chromen-7-yl]oxy-propanoic acid (43, 150 mg, 0.423 mmol) and methylamine hydrochloride (171 mg, 2.54 mmol) in DCM (10 mL) was added N,N- diisopropylethylamine (0.52 mL, 2.96 mmol) at 0 o C under argon, and the reaction mixture was stirred for 10 min. A solution of T 3 P (0.20 mL, 0.635 mmol) was added dropwise in ice-cold conditions and the mixture was stirred for 18 h. at ambient temperature. The reaction mixture was diluted with DCM, washed with water, concentrated under reduced pressure, and subjected to RP prep-HPLC to afford (S)-3- methoxy-N-methyl-2-[4-(o-tolyl)-2-oxo-chromen-7-yl]oxy-propa namide (45, 110 mg). LCMS Calcd. for C21H21NO5: 367, found [M+H] + = 368. Enantiomeric ratio was 7:3. 0248 Synthesis of (S)-3-methoxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Example 69, and (R)-3-methoxy-N-methyl-2-((2-oxo-4-(o-tolyl)- 2H-chromen-7-yl)oxy)propenamide, Example 70 [Step 8]: Enantio-enriched (7:3) (S)- 3-methoxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy )propanamide (45, 110 mg) was purified by chiral prep-HPLC separation and the first product was isolated as (S)-3-methoxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl )oxy)propenamide, Peak 1 (Example 69, 59 mg) and the second product as (R)-3-methoxy-N-methyl-2-((2-oxo-4- (o-tolyl)-2H-chromen-7-yl)oxy)propenamide, Peak 2 (Example 70, 21 mg). 0249 Example 69: [(S)-3-methoxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Peak 1]: LCMS (ESI) Calcd. for C21H21NO5: 367, found [M+H] + = 368. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.16 (br s, 1H), 7.44-7.41 (m, 2H), 7.35 (t, 1H), 7.24 (d, 1H), 7.05-7.04 (m, 1H), 6.92-6.89 (m, 2H), 6.21 (s, 1H), 4.98 (s, 1H), 3.74-3.71 (m, 2H), 3.28 (s, 3H), 2.61 (d, 3H), 2.12 (s, 3H). 0250 Example 70: [(R)-3-methoxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Peak 2]: LCMS (ESI) Calcd. for C 21 H 21 NO 5 : 367, found [M+H] + = 368. 1 H NMR (400 MHz, DMSO-d6) δ 8.16 (br s, 1H), 7.44-7.41 (m, 2H), 7.35 (t, 1H), 7.24 (d, 1H), 7.05-7.04 (m, 1H), 6.92-6.89 (m, 2H), 6.21 (s, 1H), 4.97 (s, 1H), 3.74-3.71 (m, 2H), 3.28 (s, 3H), 2.61 (d, 3H), 2.12 (s, 3H). 0251 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 20 mm), 5μ, operating at ambient temperature with flow rate of 18.0 mL/min. Mobile phase: Hexane, dichloromethane, and ethanol (65/17.5/17.5), held isocratic up to 20 min. with detection at 322 nm wavelength. Examples 71-72: 3-methoxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, racemic and purified chiral analogs
Synthesis of (S)-3-(benzyloxy)-2-hydroxypropanoic acid, 46-2 [Step 1]: To stirred a solution of O-benzyl-L-serine (46-1, 10 g, 51.2 mmol) in 2N H2SO4 (30 mL) at 0 °C was added an aqueous solution of NaNO 2 (6.3 g, 92 mmol) over a period of 2 h. The reaction mixture was stirred at the same temperature for 6 h. and then allowed to warm to ambient temperature and stirred for 12 h. The reaction mixture was cooled and a solution of 50% NaOH was added slowly to adjust to pH ~4, and the reaction mixture was stirred for 10 min. EtOAc (100 mL) was added and the reaction mixture was stirred for another 10 min., cooled to 0 °C, and acidified with 2N H2SO4 to pH ~2. The organic layer was separated and the aqueous layer was re-extracted with EtOAc (twice). The combined organic layer was washed with cold water, brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure to afford (S)-3-(benzyloxy)-2-hydroxypropanoic acid (46-2, 7 g). H NMR (400 MHz, DMSO-d6) δ 12.51 (s, 1H), 7.33-7.22 (m, 5H), 5.32 (s, 1H), 4.54-4.47 (m, 2H), 4.15 (t, 1H), 3.60 (d, 2H). 0252 Synthesis of methyl (S)-3-(benzyloxy)-2-hydroxypropanoate, 46-4 [Step 2]: To a stirred solution of (S)-3-(benzyloxy)-2-hydroxypropanoic acid (46-2, 4.5 g, 13.7 mmol) in MeOH (50 mL) was added 1M methanolic HCl (8.1 mL, 8.1 mmol), and the reaction mixture was allowed to stir for 1.5 h. at ambient temperature. To the reaction mixture was added trimethyl orthoformate (46-3, 4.9 g, 46 mmol) and stirring was continued for 18 h. at ambient temperature. The reaction mixture was concentrated under reduced pressure and the product was purified by flash column chromatography to afford methyl (S)-3-(benzyloxy)-2-hydroxypropanoate (46-4, 2.2 g). 1 H NMR (400 MHz, DMSO-d6) δ 7.36-7.26 (m, 5H), 5.58 (d, 1H), 4.53-4.45 (m, 2H), 4.27-4.23 (m, 1H), 3.66- 3.60 (m, 5H). 0253 Synthesis of methyl (R)-3-(benzyloxy)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 46 [Step 3]: To a stirred solution of methyl (S)-3-(benzyloxy)-2- hydroxypropanoate (46-4, 1.8 g, 8.7 mmol) in THF (10 mL) was added 7-hydroxy-4-(o- tolyl)chromen-2-one (Example 1, 1 g, 4 mmol), PPh 3 (3.1 g, 11.9 mmol), and the reaction mixture was cooled 0 °C. To the reaction mixture was added DIAD (2.4 mL, 11.9 mmol) and the reaction mixture was allowed to warm to ambient temperature and then heated at 80 o C for 16 h. The reaction mixture was concentrated under reduced pressure and the product was diluted with EtOAc, washed with water, brine and dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified through combi-flash chromatography to afford methyl (R)-3-(benzyloxy)-2-((2- oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (46, 1.20 g). LCMS (ESI) Calcd. for C27H24O6: 444, found [M+H] + = 445. The enantiomeric ratio was determined to be approximately 8:2 of R:S enantiomers. 0254 Synthesis of methyl (R)-3-(benzyloxy)-2-(2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, 47 [Step 4]: To stirred a solution of methyl (R)-3-(benzyloxy)-2- ((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (46, 200 mg, 0.45 mmol) in THF (4 mL) and water (1 mL), was added LiOH∙H 2 O (75 mg, 1.79 mmol) and the reaction mixture was stirred for 16 h. at ambient temperature. The reaction mixture was acidified with 1N HCl to pH ~5 and extracted with EtOAc. The organic layer was washed with water, brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The product was purified by combi-flash chromatography to afford methyl (R)-3-(benzyloxy)- 2-(2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoic acid (47, 150 mg, 75%). LCMS (ESI) Calcd. for C 26 H 22 O 6 : 430, found [M+H] + = 431. 0255 Synthesis of (R)-3-(benzyloxy)-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propenamide, 48 [Step 5]: To a stirred solution of methyl (R)-3- (benzyloxy)-2-(2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propano ic acid (47, 1.4 g, 3.2 mmol) in DCM (10 mL) was added N-methylmethanamine hydrochloride (1.6 g, 19.5 mmol) and DIPEA (3.1 mL, 22.8 mmol). The reaction mixture was cooled to 0 °C and T 3 P (50 % in EtOAc) (1.3 mL, 4.9 mmol) was added, and the reaction mixture was allowed to warm to ambient temperature and stirred for 16 h. The reaction mixture was diluted with DCM and washed with water, brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by flash column chromatography to afford (R)-3-(benzyloxy)-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanamide (48, 0.5 g). LCMS (ESI) Calcd. for C28H27NO5: 457, found [M+H] + = 458. 0256 Synthesis of (R)-3-hydroxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propenamide, 49 [Step 6]: A stirred solution of (R)-3-(benzyloxy)- N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propa namide (48, 600 mg, 1.3 mmol) in ethanol (7 mL) was degassed with argon for 10 min. and then Pd/C (70 mg, 0.1 mmol) was added under an argon atmosphere. The reaction mixture was subjected to hydrogenolysis using a hydrogen balloon for 1 h., filtered through a celite bed, and the filtrate was concentrated under reduced pressure. The product was purified by flash column chromatography to afford (R)-3-hydroxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanamide (49, 80 mg). LCMS (ESI) Calcd. for C 21 H 21 NO 5 : 367, found [M+H] + = 368. 0257 Synthesis of (R)-3-methoxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propenamide, 50 [Step 7]: To a stirred solution of (R)-3-hydroxy- N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propa namide (49, 80 mg, 0.2mmol) was added MeI (0.41 mL, 6.5 mmol) at 0 °C under an argon atmosphere. Ag2O (101 mg, 0.4mmol) was added to the reaction mixture and stirring was continued at ambient temperature for 12 h. The reaction mixture was filtered through a celite bed and concentrated under reduce pressure. The product was purified by RP prep-HPLC to afford (R)-3-methoxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H-chromen- 7- yl)oxy)propanamide (50, 60 mg). LCMS (ESI) Calcd. for C22H23NO5: 381, found [M+H] = 382. The enantiomeric ratio was approximately 8:2 R:S enantiomers. 0258 Synthesis of chiral 3-methoxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propenamide, Examples 71 and 72 [Step 8]: Enantio-enriched (8:2) (R)-3-methoxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H-chromen- 7-yl)oxy)propanamide (50, 60 mg) was purified by chiral prep-HPLC separation and the first product was isolated as (R)-3-methoxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H-chromen- 7- yl)oxy)propenamide, Peak 1 (Example 71, 27 mg) and the second peak as (S)-3- methoxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)o xy)propenamide, Peak 2 (Example 72, 6 mg). 0259 Example 71: (R)-3-methoxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propenamide, Peak 1: LCMS (ESI) Calcd. for C 22 H 23 NO 5 : 382, found [M+H] + = 382. 1 H NMR (400 MHz, DMSO-d6) δ 7.40-7.32 (m, 3H), 7.24 (m, 1H), 6.91- 6.80 (m, 3H), 6.19 (s, 1H), 5.53 (m, 1H), 3.73 (m, 2H), 3.32 (s, 3H), 3.13 (s, 3H), 2.83 (s, 3H), 2.11 (s, 3H). 0260 Example 72: (S)-3-methoxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propenamide, Peak 2: LCMS (ESI) Calcd. for C22H23NO5: 382, found [M+H] + 382. 1 H NMR (400 MHz, DMSO-d6) δ 7.43-7.34 (m, 3H), 7.24 (m, 1H), 6.91- 6.83 (m, 3H), 6.19 (s, 1H), 5.50 (m, 1H), 3.73 (m, 2H), 3.31 (s, 3H), 3.13 (s, 3H), 2.83 (s, 3H), 2.11 (s, 3H). 0261 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 20 mm) 5μ, operating at ambient temperature with flow rate of 18.0 mL/min. Mobile phase: 0.1 % isopropylamine in a mixture of hexane, dichloromethane, and ethanol (70/15/15), held isocratic up to 17 min. with detection at 324 nm wavelength. Examples 73-75: 2-[4-(2-chloro-4-fluoro-phenyl)-2-oxo-2H-chromen-7-yl]oxy-3- methoxy- propanoic acid, and chiral analogs of 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7- yl)oxy)-3-methoxypropanamide
0262 Synthesis of methyl 3-(4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7- yl)-2-(methoxymethyl)propanoate, 51 [Step 1]: To a stirred solution of 4-(2-chloro-4- fluorophenyl)-7-hydroxy-2H-chromen-2-one (Example 13, 200 mg, 0.7 mmol) in DMF (5 mL) was added K2CO3 (561 mg, 1.7 mmol) followed by methyl 2-bromo-3- methoxypropanoate (37, 0.1 mL, 0.83 mmol). To the reaction mixture was added EtOAc and water, and the organic layer was extracted and washed with brine, ice-cold water, dried over anhydrous Na 2 SO 4 , and concentrated under reduce pressure. The product was purified by combi-flash chromatography to afford methyl 3-(4-(2-chloro-4-fluorophenyl)- 2-oxo-2H-chromen-7-yl)-2-(methoxymethyl)propanoate (51, 260 mg). LCMS (ESI) Calcd. for C20H16ClFO6: 406, found [M+H] + = 407. 0263 Synthesis of 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)- 3-methoxypropanoic acid, Example 73 [Step 2]: To a stirred solution of methyl 2-[4-(2- chloro-4-fluoro-phenyl)-2-oxo-2H-chromen-7-yl]oxy-3-methoxy- propanoate (51, 600 mg, 1.5 mmol) in THF (3 mL) and water (1 mL) was added LiOH∙H 2 O (153 mg, 6.4 mmol) at ambient temperature and the reaction mixture was allowed to stir at the same temperature for 2 h. The reaction mixture was concentrated under reduced pressure and the product was diluted with a minimum amount of water and slowly acidified with citric acid until pH 4-5. The product was extracted with ethyl acetate and the combined organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The product was purified by RP prep-HPLC to afford 2-[4-(2-chloro-4- fluoro-phenyl)-2-oxo-2H-chromen-7-yl]oxy-3-methoxy-propanoic acid (Example 73, 300 mg). LCMS (ESI) Calcd. for C 19 H 14 ClFO 6 : 392, found [M+H] + = 393. 1 H NMR (400 MHz, DMSO-d6) δ 7.71-7.68 (m, 1H), 7.57-7.53 (m, 1H), 7.44-7.40 (m, 1H), 6.90-6.87 (m, 2H), 6.84-6.81 (m, 1H), 6.26 (s, 1H), 4.79 (m, 1H), 3.74 (m, 2H), 3.32 (s, 3H). 0264 Synthesis of 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)- 3-methoxypropanamide, 52 [Step 3]: To a stirred solution of 2-[4-(2-chloro-4-fluoro- phenyl)-2-oxo-2H-chromen-7-yl]oxy-3-methoxy-propanoic acid (Example 73, 260 mg, 0.7 mmol) in DMF (5 mL) was added (NH 4 ) 2 CO 3 (254 mg, 2.7 mmol), DIPEA (0.58 mL, 3.3 mmol), and then T3P (0.58 mL, 1 mmol). The reaction mixture was allowed to stir at ambient temperature for 4 h., and then concentrated under reduced pressure. Water was added to the product and the mixture was extracted with EtOAc (three times). The combined organic layers were washed with aq. NaHCO3 solution, brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The product was purified by flash chromatography to afford 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H- chromen-7-yl)oxy)-3-methoxypropanamide (52, 150 mg). 0265 Synthesis of chiral 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7- yl)oxy)-3-methoxypropanamide, Examples 74 and 75 [Step 4]: 2-[4-(2-chloro-4- fluoro-phenyl)-2-oxo-2H-chromen-7-yl]oxy-3-methoxy-propanami de (52, 150 mg, 0.4 mmol) was purified by chiral prep-HPLC separation and the first product was isolated as 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3 -methoxypropanamide, Peak 1 (Example 74, 50 mg) and the second peak as 2-((4-(2-chloro-4-fluorophenyl)-2- oxo-2H-chromen-7-yl)oxy)-3-methoxypropanamide, Peak 2 (Example 75, 40 mg). The absolute stereochemistries of these compounds were not determined. 0266 Example 74: 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)- 3-methoxypropanamide, Peak 1: LCMS (ESI) Calcd. for C 19 H 15 ClFNO 5 : 391, found [M+H] = 392. H NMR (400 MHz, DMSO-d6) δ 7.72-7.67 (m, 2H), 7.57-7.54 (m, 1H), 7.46-7.41 (m, 2H), 7.04 (s, 1H), 6.97-6.91 (m, 2H), 6.33 (s, 1H), 4.94-4.92 (m, 1H), 3.78-3.69 (m, 2H), 3.31 (s, 3H). 0267 Example 75: 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)- 3-methoxypropanamide, Peak 2: LCMS (ESI) Calcd. for C19H15ClFNO5: 391, found [M+H] + = 392. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.72-7.67 (m, 2H), 7.57-7.54 (m, 1H), 7.46-7.41 (m, 2H), 7.04 (s, 1H), 6.97-6.91 (m, 2H), 6.33 (s, 1H), 4.94-4.92 (m, 1H), 3.78-3.69 (m, 2H), 3.31 (s, 3H). 0268 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 21 mm) 5μ, operating at ambient temperature with flow rate of 21.0 mL/min. Mobile phase: 0.1 % isopropylamine in hexane, dichloromethane, and ethanol (50/25/25), held isocratic up to 24 min. with detection at 325 nm wavelength. Examples 76-77: 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3 - methoxypropanamide, racemic and purified chiral analogs 0269 Synthesis of 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)- 3-methoxypropanamide, 53 [Step 1]: To a stirred solution of 2-[4-(4-chloro-2-fluoro- phenyl)-2-oxo-2H-chromen-7-yl]oxy-3-methoxy-propanoic acid (Example 73, 261 mg, 0.7 mmol) in DCM (5 mL) was added DIPEA (0.58 mL, 3.3 mmol), methylamine hydrochloride (224 mg, 3.3 mmol), T 3 P (0.59 mL, 1 mmol), and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with DCM and washed with water, brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure to obtain the product. The product was purified by flash chromatography to afford 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3 - methoxypropanamide (53, 220 mg). LCMS Calcd. for C20H17ClFNO5: 405, found [M+H] + = 406. 0270 Synthesis of chiral 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7- yl)oxy)-3-methoxypropanamide, Examples 76 and 77 [Step 2]: 2-((4-(2-chloro-4- fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxypropanamid e (53, 250 mg, 0.616 mmol) was purified by chiral prep-HPLC separation and the first product was isolated as 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3 -methoxypropanamide, Peak 1 (Example 76, 90 mg) and the second peak as 2-((4-(2-chloro-4-fluorophenyl)-2- oxo-2H-chromen-7-yl)oxy)-3-methoxypropanamide, Peak 2 (Example 77, 100 mg). The absolute stereochemistries of these compounds were not determined. 0271 Example 76: 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)- 3-methoxypropanamide, Peak 1: LCMS (ESI) Calcd. for C20H17ClFNO5: 405, found [M+H] + = 406. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.17-8.15 (m, 1H), 7.72-7.69 (m, 1H), 7.57-7.54 (m, 1H), 7.46-7.41 (m, 1H), 7.06-7.05 (m, 1H), 6.97-6.92 (m, 2H), 6.33 (s, 1H), 4.97 (m, 1H), 3.77-3.68 (m, 2H), 3.31 (s, 3H), 2.61 (d, 3H). 0272 Example 77: 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)- 3-methoxypropanamide, Peak 2: LCMS (ESI) Calcd. for C 20 H 17 ClFNO 5 : 405, found [M+H] + = 406. 1 H NMR (400 MHz, DMSO-d6) δ 8.18-8.16 (m, 1H), 7.71-7.69 (m, 1H), 7.57-7.54 (m, 1H), 7.46-7.41 (m, 1H), 7.06-7.05 (m, 1H), 6.97-6.92 (m, 2H), 6.33 (s, 1H), 4.99 (m, 1H), 3.77-3.68 (m, 2H), 3.31 (s, 3H), 2.61 (d, 3H). 0273 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 21 mm) 5μ, operating at ambient temperature with flow rate of 21.0 mL/min. Mobile phase: 0.1 % isopropylamine in a mixture of hexane, dichloromethane, and ethanol (50/25/25), held isocratic up to 40 min. with detection at 325 nm wavelength. Examples 78-79: 3-hydroxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanamide, racemic and purified chiral analogs *First peak from chiral separation. **Second peak from chiral separation. Absolute stereochemistry not determined 0274 Synthesis of 3-(benzyloxy)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, 54 [Step 1]: To a stirred solution of methyl 3-(benzyloxy)-2-((2- oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (40, 400 mg, 0.9 mmol) in THF (6 mL) and water (1.5 mL) was added LiOH∙H 2 O (113 mg, 2.7 mmol) at ambient temperature and the reaction mixture was stirred for 16 h. The mixture was concentrated under reduced pressure to obtain the product, to which water was added and the mixture was acidified with 1N HCl to pH 5. The mixture was extracted with EtOAc, and the organic layer was washed with water, brine, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to afford 3-(benzyloxy)-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanoic acid (54, 320 mg). LCMS Calcd. for C 26 H 22 O 6 : 430, found [M+H] + = 431. 0275 Synthesis of 3-(benzyloxy)-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propenamide, 55 [Step 2]: To a stirred solution of 3-(benzyloxy)-2- ((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoic acid (54, 320 mg, 0.7 mmol) and N- methylmethanamine hydrochloride (364 mg, 4.5 mmol) in DCM (10 mL), was added DIPEA (0.7 mL, 5.2 mmol) and the reaction mixture was cooled to 0 °C. Then T 3 P (0.3 mL, 1.1 mmol) was added dropwise at 0 °C and the reaction mixture was allowed to warm up to ambient temperature and stirred for 16 h. The reaction mixture was diluted with DCM and washed with water and brine. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the product, which was purified by combi-flash chromatography to afford 3-(benzyloxy)-N,N-dimethyl-2-((2- oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanamide (55, 170 mg). LCMS Calcd. for C 28 H 27 NO 5 : 457, found [M+H] + = 458. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.43-7.22 (m, 9H), 6.94 (m, 1H), 6.86 (m, 2H), 6.19 (s, 1H), 5.58 (m, 1H), 4.59 (s, 2H), 3.83 (m, 2H), 3.09 (s, 3H), 2.83 (s, 3H), 2.11 (s, 3H). 0276 Synthesis of 3-hydroxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, 56 [Step 3]: A stirred solution of 3-benzyloxy-N,N-dimethyl-2-[4- (o-tolyl)-2-oxo-2H-chromen-7-yl]oxy-propanamide (55, 170 mg, 0.372 mmol) in ethanol (5 mL) was purged with argon for 5 min. To the solution was added Pd-C (25 mg, 0.04 mmol) and the reaction mixture was subjected to hydrogenolysis using a hydrogen balloon for 4 h. The reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure to obtain the product, which was purified by RP prep-LC to afford 3-hydroxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H-chr omen-7- yl)oxy)propanamide (56, 60 mg). LCMS Calcd. for C21H21NO5: 367, found [M+H] + = 368. 0277 Synthesis of chiral 3-hydroxy-N,N-dimethyl-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propenamide, Examples 78 and 79 [Step 4]: 3-hydroxy-N,N- dimethyl-2-[4-(o-tolyl)-2-oxo-2H-chromen-7-yl]oxy-propanamid e (56, 60 mg, 0.163 mmol) was purified by chiral prep-HPLC separation and the first product was isolated as 3-hydroxy-N,N-dimethyl-2-[4-(o-tolyl)-2-oxo-2H-chromen-7-yl] oxy-propanamide (56, 60 mg, 0.163 mmol), Peak 1 (Example 78, 10 mg) and the second product as 3-hydroxy- N,N-dimethyl-2-[4-(o-tolyl)-2-oxo-2H-chromen-7-yl]oxy-propan amide, Peak 2 (Example 79, 25 mg). The absolute stereochemistries of these compounds were not determined. 0278 Example 78: [3-hydroxy-N,N-dimethyl-2-[4-(o-tolyl)-2-oxo-2H-chromen-7- yl]oxy-propanamide, Peak 1]: LCMS Calcd. for C21H21NO5: 367, found [M+H] + = 368. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.43-7.33 (m, 3H), 7.24 (m, 1H), 6.88 (m, 2H), 6.82- 6.80 (m, 1H), 6.19 (s, 1H), 5.28-5.22 (m, 2H), 3.77 (m, 2H), 3.14 (s, 3H), 2.84 (s, 3H), 2.11 (s, 3H). 0279 Example 79: [3-hydroxy-N,N-dimethyl-2-[4-(o-tolyl)-2-oxo-2H-chromen-7- yl]oxy-propanamide, Peak 2]: LCMS Calcd. for C 21 H 21 NO 5 : 367, found [M+H] + = 368. H NMR (400 MHz, DMSO-d6) δ 7.43- 7.34 (m, 3H), 7.24 (m, 1H), 6.88-6.86 (m, 2H), 6.82 (m, 1H), 6.19 (s, 1H), 5.28-5.23 (m, 2H), 3.77 (m, 2H), 3.14 (s, 3H), 2.83 (s, 3H), 2.11 (s, 3H). 0280 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 20 mm), 5μ, operating at ambient temperature with flow rate of 18.0 mL/min. Mobile phase: 0.1 % isopropylamine in a mixture of 60 % hexane, 20 % of CH2Cl2 and 20 % ethanol, held isocratic up to 15 min. with detection at 324 nm wavelength. Examples 80-81: N-ethyl-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanamide, racemic and purified chiral analogs 0281 Synthesis of N-ethyl-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, 57 [Step 1]: To a stirred solution of 3-methoxy-2-[4-(o-tolyl)-2- oxo-2H-chromen-7-yl]oxy-propanoic acid (Example 65, 150 mg, 0.4 mmol) and ethylamine (29 mg, 0.6 mmol) in DCM (4 mL) was added DIPEA (0.2 mL, 1.3 mmol) followed by T3P, 50 % in EtOAc (0.2 mL, 0.6 mmol) at 0 ° C, and the reaction mixture was stirred at ambient temperature for 2 h. The reaction mixture was diluted with DCM, washed with water, brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The product was purified by flash column chromatography to afford N- ethyl-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)pr opanamide (57, 120 mg). 0282 Synthesis of chiral N-ethyl-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen- 7-yl)oxy)propanamide, Examples 80 and 81 [Step 2]: N-ethyl-3-methoxy-2-((2-oxo-4- (o-tolyl)-2H-chromen-7-yl)oxy)propanamide (57, 120 mg) was purified by chiral prep- HPLC separation and the first product was isolated as N-ethyl-3-methoxy-2-((2-oxo-4-(o- tolyl)-2H-chromen-7-yl)oxy)propanamide, Peak 1 (Example 80, 48 mg) and the second product as N-ethyl-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy) propanamide, Peak 2 (Example 81, 36 mg). The absolute stereochemistries of these compounds were not determined. 0283 Example 80: [N-ethyl-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanamide, Peak 1]: LCMS (ESI) Calcd. for C 22 H 23 NO 5 : 381, found [M+H] + = 382. 1 H NMR (400 MHz, DMSO-d6) δ 8.25 (s, 1H), 7.43-7.33 (m, 3H), 7.24 (d, 1H), 7.04 (d, 1H), 6.93-6.87 (m, 2H), 6.21 (s, 1H), 4.94 (t, 1H), 3.76-3.67 (m, 2H), 3.32 (s, 3H), 3.12 (q, 2H), 2.11 (s, 3H), 1.01 (q, 3H). 0284 Example 81: [N-ethyl-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanamide, Peak 2]: LCMS (ESI) Calcd. for C22H23NO5: 381, found [M+H] + = 382. 1 H NMR (400 MHz, DMSO-d6) δ 8.25 (s, 1H), 7.43-7.33 (m, 3H), 7.24 (d, 1H), 7.04 (d, 1H), 6.93-6.87 (m, 2H), 6.21 (s, 1H), 4.94 (t, 1H), 3.76-3.67 (m, 2H), 3.32 (s, 3H), 3.12 (q, 2H), 2.11 (s, 3H), 1.01 (q, 3H). 0285 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 21 mm), 5μ, operating at ambient temperature with flow rate of 21.0 mL/min. Mobile phase: 0.1 % isopropylamine in a mixture of 40 % hexane, 30 % of CH2Cl2 and 30 % ethanol, held isocratic up to 12 min. with detection at 322 nm wavelength. Examples 82-83: 3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-N-(2,2, 2- trifluoroethyl)propanamide, racemic and purified chiral analogs
0286 Synthesis of 3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-N- (2,2,2 trifluoroethyl) propenamide, 58 [Step 1]: To a stirred solution of 3-methoxy-2- [4-(o-tolyl)-2-oxo-2H-chromen-7-yl]oxy-propanoic acid (Example 65, 150 mg, 0.4 mmol) and 2,2,2-trifluoroethan-1-amine (63 mg, 0.6 mmol) in DCM (4 mL) was added DIPEA (0.3 mL, 1.3 mmol) followed by T3P, 50 % in EtOAc (0.2 mL, 0.6 mmol) at 0 ° C, and the reaction mixture was stirred at ambient temperature for 2 h. The reaction mixture was diluted with DCM, washed with water, brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by flash chromatography to afford 3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-N- (2,2,2-trifluoroethyl)propanamide (58, 120 mg). 0287 Synthesis of chiral 3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)- N-(2,2,2-trifluoroethyl)propanamide, Examples 82 and 83 [Step 2]: 3-methoxy-2-((2- oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-N-(2,2,2-trifluoroethyl )propanamide (58, 120 mg) was purified by chiral prep-HPLC separation and the first product was isolated as 3- methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-N-(2,2,2- trifluoroethyl)propanamide, Peak 1 (Example 82, 40 mg) and the second product as 3- methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-N-(2,2,2- trifluoroethyl)propanamide, Peak 2 (Example 83, 40 mg). The absolute stereochemistries of these compounds were not determined. 0288 Example 82: [3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-N- (2,2,2-trifluoroethyl)propanamide, Peak 1]: LCMS (ESI) Calcd. for C 22 H 20 F 3 NO 5 : 435, found [M+H] + = 436. 1 H NMR (400 MHz, DMSO-d6) (at 100 °C) δ 8.57 (br s, 1H), 7.43- 7.33 (m, 3H), 7.24 (d, 1H), 7.03 (s, 1H), 6.91 (s, 2H), 6.15 (s, 1H), 5.05 (s, 1H), 3.96-3.89 (m, 2H), 3.83-3.75 (m, 2H), 3.33 (s, 3H), 2.13 (s, 3H). 0289 Example 83: [3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-N- (2,2,2-trifluoroethyl)propanamide, Peak 2]: LCMS (ESI) Calcd. for C22H20F3NO5: 435, found [M+H] + = 436. 1 H NMR (400 MHz, DMSO-d 6 ) (at 100 °C) δ 8.56 (br s, 1H), 7.45- 7.33 (m, 3H), 7.24 (d, 1H), 7.03 (s, 1H), 6.91 (s, 2H), 6.15 (s, 1H), 5.05 (s, 1H), 3.96-3.89 (m, 2H), 3.80-3.75 (m, 2H), 3.33 (s, 3H), 2.13 (s, 3H). 0290 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 21 mm), 5μ, operating at ambient temperature with flow rate of 21.0 mL/min. Mobile phase: 0.1 % isopropylamine in a mixture of 60 % hexane, 20 % of CH 2 Cl 2 and 20 % ethanol, held isocratic up to 24 min. with detection at 322 nm wavelength. Example 84: 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxyp ropanoic acid 0291 Synthesis of 4-(2-chlorophenyl)-7-hydroxy-2H-chromen-2-one, 61 [Step 1]: To a mixture of ethyl 3-(2-chlorophenyl)-3-oxo-propanoate (59, 2.0 g, 8.8 mmol) and benzene-1,3-diol (60, 1 g, 8.8 mmol) was added methanesulphonic acid (5 mL) and the reaction mixture was heated at 50 °C for 16 h. The reaction mixture was cooled and poured into ice-water and the precipitate was filtered and dried to yield 4-(2- chlorophenyl)-7-hydroxy-2H-chromen-2-one (61, 2.0 g). LCMS (ESI): Calcd. for C15H9ClO3: 272, found [M+H] + = 272. 0292 Synthesis of methyl 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)- 3-methoxypropanoate, 63 [Step 2]: To a stirred solution of 4-(2-chlorophenyl)-7- hydroxy-2H-chromen-2-one (61, 1.0 g, 3.7 mmol) in DMF (5 mL) was added Cs 2 CO 3 (2.4 g, 7.3 mmol) and the reaction mixture was stirred at ambient temperature for 15 min. To the reaction mixture was added methyl 2-bromo-3-methoxypropanoate (62, 0.5 mL, 4.0 mmol) and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with EtOAc and washed with water, brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to yield methyl 2- ((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxypro panoate (63, 1.30 g). LCMS (ESI): Calcd. for C20H17ClO6: 388, found [M+H] + = 389. 0293 Synthesis of 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxypropanoic acid, Example 84 [Step 3]: To an ice-cooled solution of methyl 2- ((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxypro panoate (63, 150 mg, 0.4 mmol) in a mixture of THF:methanol:water (5:3:1, 1 mL) was added LiOH∙H2O (15 mg, 0.6 mmol) and the reaction mixture was allowed to warm to ambient temperature and stirred for 16 h. The reaction mixture was concentrated under reduced pressure and the resulting material was dissolved in water, acidified with 1N HCl (pH = 3), and extracted with EtOAc (3 x 30 mL). The organic phase was combined and washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford the product, which was purified by RP prep-HPLC and lyophilized to yield 2-((4-(2- chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxypropanoic acid (Example 84, 80 mg). LCMS (ESI): Calcd. for C 19 H 15 ClO 6 : 374, found [M+H] + = 375. 1 H NMR (400 MHz, DMSO-d6) at δ 7.66 (d, 1H), 7.59-7.47 (m, 3H), 7.21 (br s, 1H), 6.93 (br s, 1H), 6.88-6.83 (m, 2H), 6.26 (br s, 1H), 4.90 (br s, 1H), 3.76 (d, 2H), 3.29 (s, 3H). Examples 85-86: 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3 -methoxy- N,N-dimethylpropanamide, racemic and purified chiral analogs
0294 Synthesis of 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)- 3-methoxy-N,N-dimethylpropanamide, 64 [Step 1]: To a stirred solution of 2-[4-(4- chloro-2-fluoro-phenyl)-2-oxo-2H-chromen-7-yl]oxy-3-methoxy- propanoic acid (Example 73, 261 mg, 0.7 mmol) in DCM (5 mL) was added DIPEA (0.7 mL, 4 mmol), N-methylmethanamine hydrochloride (270 mg, 3.3 mmol) and T 3 P (0.6 mL, 1 mmol), and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with DCM and washed with water, brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The resulting product was purified by flash chromatography to afford 2-[4-(4-chloro-2-fluoro-phenyl)-2-oxo-2H-chromen-7- yl]oxy-3-methoxy-N,N-dimethyl-propanamide (64, 150 mg). LCMS Calcd. for C 21 H 19 ClFNO 5 : 419, found [M+H] + = 420. 0295 Synthesis of chiral 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7- yl)oxy)-3-methoxy-N,N-dimethylpropanamide, Examples 85 and 86 [Step 2]: 2-((4- (2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-metho xy-N,N- dimethylpropanamide (64, 150 mg) was purified by chiral prep-HPLC separation and the first product was isolated as 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7- yl)oxy)-3-methoxy-N,N-dimethylpropanamide, Peak 1 (Example 85, 65 mg) and the second product as 2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3 - methoxy-N,N-dimethylpropanamide, Peak 2 (Example 86, 70 mg). The absolute stereochemistries of these compounds were not determined. 0296 Example 85: [2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)- 3-methoxy-N,N-dimethylpropanamide, Peak 1]: LCMS (ESI) Calcd. for C 21 H 19 ClFNO 5 : 419, found [M+H] + = 420. 1 H NMR (400 MHz, DMSO-d6) δ 7.71-7.69 (m, 1H), 7.58- 7.53 (m, 1H), 7.45-7.41 (m, 1H), 6.94-6.92 (m, 2H), 6.86-6.82 (m, 1H), 6.31 (s, 1H), 5.54 (m, 1H), 3.76-3.72 (m, 2H), 3.33 (s, 3H), 3.13 (s, 3H), 2.84 (s, 3H). 0297 Example 86: [2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)- 3-methoxy-N,N-dimethylpropanamide, Peak 2]: LCMS (ESI) Calcd. for C21H19ClFNO5: 419, found [M+H] + = 420. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.71-7.69 (m, 1H), 7.58- 7.53 (m, 1H), 7.45-7.41 (m, 1H), 6.94-6.92 (m, 2H), 6.88-6.82 (m, 1H), 6.32 (s, 1H), 5.54 (m, 1H), 3.73 (m, 2H), 3.33 (s, 3H), 3.13 (s, 3H), 2.84 (s, 3H). 0298 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 21 mm), 5μ, operating at ambient temperature with flow rate of 21.0 mL/min. Mobile phase: mixture of 65 % hexane, 17.5 % of CH2Cl2 and 17.5 % ethanol, held isocratic up to 30 min. with detection at 325 nm wavelength. Examples 87-88: 3-methoxy-N-(2-methoxyethyl)-2-((2-oxo-4-(o-tolyl)-2H-chrome n-7- yl)oxy)propanamide, racemic and purified chiral analogs
0299 Synthesis of 3-methoxy-N-(2-methoxyethyl)-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propenamide, 65 [Step 1]: To a stirred solution of 3-methoxy-2-[4- (o-tolyl)-2-oxo-2H-chromen-7-yl]oxy-propanoic acid (Example 65, 130 mg, 0.4 mmol) and 2-methoxyethylamine (0.06 mL, 0.7 mmol) in DCM (3 mL) was added DIPEA (0.3 mL, 1.5 mmol) followed by T 3 P (50 % in EtOAc) (0.2 mL, 0.6 mmol) at 0 °C and the reaction mixture was stirred at ambient temperature for 4 h. The reaction mixture was diluted with DCM and washed with water. The organic layer was collected, washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The product was purified by flash column chromatography to afford 3-methoxy-N-(2- methoxyethyl)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)prop anamide (65, 120 mg). 0300 Synthesis of chiral 3-methoxy-N-(2-methoxyethyl)-2-((2-oxo-4-(o-tolyl)- 2H-chromen-7-yl)oxy)propanamide, Examples 87 and 88 [Step 2]: 3-methoxy-N-(2- methoxyethyl)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)prop anamide (65, 120 mg) was purified by chiral prep-HPLC separation and the first product was isolated as 3- methoxy-N-(2-methoxyethyl)-2-((2-oxo-4-(o-tolyl)-2H-chromen- 7-yl)oxy)propanamide, Peak 1 (Example 87, 60 mg) and the second product as 3-methoxy-N-(2-methoxyethyl)- 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanamide, Peak 2 (Example 88, 55 mg). The absolute stereochemistries of these compounds were not determined. 0301 Example 87: [3-methoxy-N-(2-methoxyethyl)-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanamide, Peak 1]: LCMS (ESI) Calcd. for C 23 H 25 NO 6 : 411, found [M+H] + = 412. 1 H NMR (400 MHz, DMSO-d6) δ 8.34 (t , 1H), 7.43-7.33 (m, 3H), 7.24 (d , 1H), 7.04-7.02 (m, 1H), 6.92-6.86 (m, 2H), 6.20 (s, 1H), 4.99 (s, 1H), 3.76-3.71 (m, 1H), 3.69-3.66 (m, 1H), 3.32 (s, 1H), 3.29 (s, 4H), 3.27-3.24 (m, 2H), 3.19 (s, 3H), 2.10 (s, 3H). 0302 Example 88: [3-methoxy-N-(2-methoxyethyl)-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanamide, Peak 2]: LCMS (ESI) Calcd. for C 23 H 25 NO 6 : 411, found [M+H] + = 412. 1 H NMR (400 MHz, DMSO-d6) δ 8.34 (t , 1H), 7.43-7.33 (m, 3H), 7.24 (d , 1H), 7.04-7.02 (m, 1H), 6.92-6.86 (m, 2H), 6.20 (s, 1H), 4.99 (s, 1H), 3.76-3.71 (m, 1H), 3.69-3.66 (m, 1H), 3.32 (s, 1H), 3.29 (s, 4H), 3.27-3.24 (m, 2H), 3.19 (s, 3H), 2.10 (s, 3H). 0303 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 20 mm), 5μ, operating at ambient temperature with flow rate of 18.0 mL/min. Mobile phase: mixture of 60 % hexane, 20 % of CH2Cl2 and 20 % ethanol, held isocratic up to 25 min. with detection at 332 nm wavelength. Examples 89-90: 7-((1-(azetidin-1-yl)-3-methoxy-1-oxopropan-2-yl)oxy)-4-(o-t olyl)-2H- chromen-2-one, racemic and purified chiral analogs 0304 Synthesis of 7-((1-(azetidin-1-yl)-3-methoxy-1-oxopropan-2-yl)oxy)-4-(o- tolyl)-2H-chromen-2-one, 66 [Step 1]: To a stirred solution of 3-methoxy-2-[4-(o-tolyl)- 2-oxo-2H-chromen-7-yl]oxy-propanoic acid (Example 65, 150 mg, 0.4 mmol) and azetidine hydrochloride (59 mg, 0.7 mmol) in DCM (4 mL) was added DIPEA (0.3 mL, 1.7 mmol) followed by T3P, 50 % in EtOAc (0.2 mL, 0.7 mmol) and the reaction mixture was stirred at ambient temperature for 4 h. The reaction mixture was diluted with DCM and washed with water. The organic layer was collected, washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by flash column chromatography to afford 7-((1-(azetidin-1-yl)-3-methoxy-1-oxopropan- 2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one (66, 120 mg). 0305 Synthesis of chiral 7-((1-(azetidin-1-yl)-3-methoxy-1-oxopropan-2-yl)oxy)- 4-(o-tolyl)-2H-chromen-2-one, Examples 89 and 90 [Step 2]: 7-((1-(azetidin-1-yl)-3- methoxy-1-oxopropan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one (66, 120 mg) was purified by chiral prep-HPLC separation and the first product was isolated as 7-((1- (azetidin-1-yl)-3-methoxy-1-oxopropan-2-yl)oxy)-4-(o-tolyl)- 2H-chromen-2-one, Peak 1 (Example 89, 30 mg) and the second product as 7-((1-(azetidin-1-yl)-3-methoxy-1- oxopropan-2-yl)oxy)-4-(o-tolyl)-2H-chromen-2-one, Peak 2 (Example 90, 22 mg). The absolute stereochemistries of these compounds were not determined. 0306 Example 89: [7-((1-(azetidin-1-yl)-3-methoxy-1-oxopropan-2-yl)oxy)-4-(o- tolyl)-2H-chromen-2-one, Peak 1]: LCMS (ESI) Calcd. for C23H23NO5: 393, found [M+H] + = 394. 1 H NMR (400 MHz, DMSO-d 6 ) : δ 7.46-7.36 (m, 3H), 7.28 (d, 1H), 7.02- 7.00 (m, 1H), 6.94-6.89 (m, 2H), 6.24 (s, 1H), 5.10-5.08 (m, 1H), 4.49 (t, 1H), 4.16 (t, 1H), 3.95 (d, 1H), 3.87 (d, 1H), 3.79-3.71 (m, 2H), 3.34 (s, 3H), 2.25-2.18 (m, 2H), 2.15 (s, 3H). 0307 Example 90: [7-((1-(azetidin-1-yl)-3-methoxy-1-oxopropan-2-yl)oxy)-4-(o- tolyl)-2H-chromen-2-one, Peak 2]: LCMS (ESI) Calcd. for C23H23NO5: 393, found [M+H] + = 394. 1 H NMR (400 MHz, DMSO-d 6 ) : δ 7.46-7.36 (m, 3H), 7.28 (d, 1H), 7.02- 7.00 (m, 1H), 6.94-6.89 (m, 2H), 6.24 (s, 1H), 5.10-5.08 (m, 1H), 4.49 (t, 1H), 4.16 (t, 1H), 3.95 (d, 1H), 3.87 (d, 1H), 3.79-3.71 (m, 2H), 3.34 (s, 3H), 2.25-2.18 (m, 2H), 2.15 (s, 3H). 0308 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: Chiralpak IC (250 x 20 mm), 5μ, operating at ambient temperature with flow rate of 18.0 mL/min. Mobile phase: 0.1 % isopropylamine in a mixture of 65 % hexane, 17.5 % of CH2Cl2 and 17.5 % ethanol, held isocratic up to 40 min. with detection at 324 nm wavelength. Examples 91-92: 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxy- N- methylpropanamide, racemic and purified chiral analogs 0309 Synthesis of 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxy-N-methylpropanamide, 67 [Step 1]: To a stirred solution of 2-((4-(2- chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxypropanoic acid (Example 84, 300 mg, 0.8 mmol) in DCM (10 mL), was added HATU (610 mg, 1.6 mmol) and N,N- diisopropylethylamine (0.7 mL, 4.0 mmol) at 0 o C and the reaction mixture was stirred for 30 min. Methanamine (25 mg, 0.8 mmol) was added and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with EtOAc and washed with 5 % aq. Na2CO3, water, brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to yield 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxy- N- methylpropanamide (67, 200 mg). LCMS (ESI): Calcd. for C 20 H 18 ClNO 5 : 387, found [M+H] + = 387. 0310 Synthesis of chiral 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxy-N-methylpropanamide, Examples 91 and 92 [Step 2]: 2-((4-(2- chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxy-N-methylp ropanamide (67, 200 mg) was purified by chiral prep-HPLC separation and the first product was isolated as 2- ((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxy-N- methylpropanamide, Peak 1 (Example 91, 92 mg) and the second product as 2-((4-(2-chlorophenyl)-2-oxo- 2H-chromen-7-yl)oxy)-3-methoxy-N-methylpropanamide, Peak 2 (Example 92, 90 mg). The absolute stereochemistries of these compounds were not determined. 0311 Example 91: [2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxy-N-methylpropanamide, Peak 1]: LCMS (ESI): Calcd. for C 20 H 18 ClNO 5 : 387, found [M+H] + = 388. 1 H NMR (400 MHz, DMSO-d6) δ 8.16 (t, 1H), 7.67 (d, 1H), 7.61- 7.47 (m, 3H), 7.59 (q, 1H), 6.96-6.90 (m, 2H), 6.32 (s, 1H), 4.98 (br s, 1H), 3.77-3.68 (m, 2H), 3.28 (s, 3H), 2.62 (d, 3H). 0312 Example 92: [2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxy-N-methylpropanamide, Peak 2: LCMS (ESI): Calcd. for C20H18ClNO5: 387, found [M+H] + = 388. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.16 (t, 1H), 7.67 (d, 1H), 7.61- 7.47 (m, 3H), 7.59 (q, 1H), 6.96-6.90 (m, 2H), 6.32 (s, 1H), 4.98 (br s, 1H), 3.77-3.68 (m, 2H), 3.28 (s, 3H), 2.62 (d, 3H). 0313 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: (R,R) WHELK-01 (250 x 21.1 mm), 5μ, operating at 35 °C with flow rate of 60 g/min. Mobile phase: 65 % CO 2 + 35 % (0.3 % Ipamine in MeOH) at 100 bar with detection at 320 nm wavelength. Examples 93-94: 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxy- N,N- dimethylpropanamide, racemic and purified chiral analogs
0314 Synthesis of 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxy-N,N-dimethylpropanamide, 68 [Step 1]: To a stirred solution of 2-((4-(2- chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxypropanoic acid (Example 84, 300 mg, 0.8 mmol) in DCM (10 mL) was added HATU (610 mg, 1.6 mmol) and N,N- diisopropylethylamine (0.7 mL, 4.0 mmol) at 0 o C and the reaction mixture was stirred for 30 min. To the reaction mixture was added N-methylmethanamine (1M in THF) (0.8 mL, 0.8 mmol) and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with EtOAc and washed with 5 % aq. Na 2 CO 3 , water, brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC chromatography and lyophilized to yield 2-((4- (2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxy-N,N-di methylpropanamide (68, 200 mg). LCMS Calcd. for C 21 H 20 ClNO 5 : 402, found [M+H] + = 403. 0315 Synthesis of chiral 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxy-N,N-dimethylpropanamide, Examples 93 and 94 [Step 2]: 2-((4-(2- chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxy-N,N-dimet hylpropanamide (68, 200 mg) was purified by chiral prep-HPLC separation and the first product was isolated as 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxy- N,N- dimethylpropanamide, Peak 1 (Example 93, 60 mg) and the second product as 2-((4-(2- chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxy-N,N-dimet hylpropanamide, Peak 2 (Example 94, 72 mg). The absolute stereochemistries of these compounds were not determined. 0316 Example 93: [2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxy-N,N-dimethylpropanamide, Peak 1]: LCMS (ESI): Calcd. for C21H20ClNO5: 401, found [M+H] + = 402. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.67 (d, 1H), 7.60-7.47 (m, 3H), 6.94-6.85 (m, 3H), 6.31 (s, 1H), 5.53 (q, 1H), 3.73 (d, 2H), 3.33 (s, 3H), 3.13 (s, 3H), 2.84 (s, 3H). 0317 Example 94: [2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxy-N,N-dimethylpropanamide, Peak 2]: LCMS (ESI): Calcd. for C 21 H 20 ClNO 5 : 402, found [M+H] + = 402. 1 H NMR (400 MHz, DMSO-d6) δ 7.67 (d, 1H), 7.60-7.47 (m, 3H), 6.94-6.85 (m, 3H), 6.31 (s, 1H), 5.53 (q, 1H), 3.73 (d, 2H), 3.33 (s, 3H), 3.13 (s, 3H), 2.84 (s, 3H). 0318 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: (R,R) WHELK-01 (250 x 21.1 mm), 5μ, operating at 35 °C with flow rate of 60 g/min. Mobile phase: 65 % CO 2 + 35 % (0.3 % isopropylamine in MeOH) at 100 bar with detection at 320 nm wavelength. Examples 95-96: 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxypropanamide, racemic and purified chiral analogs
0319 Synthesis of 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxypropanamide, 69 [Step 1]: To a stirred solution of 2-((4-(2-chlorophenyl)-2- oxo-2H-chromen-7-yl)oxy)-3-methoxypropanoic acid (Example 84, 300 mg, 0.8 mmol) in DMF (3 mL) was added HOBt (160 mg, 1.2 mmol), EDC HCl (230 mg, 1.2 mmol), DIPEA (0.4 mL, 3.2 mmol), and (NH 4 ) 2 CO 3 (310 mg, 3.2 mmol) and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to yield 2-((4-(2-chlorophenyl)-2-oxo- 2H-chromen-7-yl)oxy)-3-methoxypropanamide (69, 200 mg). LCMS (ESI): Calcd. for C 19 H 16 ClNO 5 : 374, found [M+H] + = 374. 0320 Synthesis of chiral 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxypropanamide, Examples 95 and 96 [Step 2]: 2-((4-(2-chlorophenyl)-2-oxo- 2H-chromen-7-yl)oxy)-3-methoxypropanamide (69, 160 mg) was purified by chiral prep- HPLC separation and the first product was isolated as 2-((4-(2-chlorophenyl)-2-oxo-2H- chromen-7-yl)oxy)-3-methoxypropanamide, Peak 1 (Example 95, 60 mg) and the second product as 2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3-methoxyp ropanamide, Peak 2 (Example 96, 55 mg). The absolute stereochemistries of these compounds were not determined. 0321 Example 95: [2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxypropanamide, Peak 1]: LCMS (ESI): Calcd. for C 19 H 16 ClNO 5 : 374, found [M+H] + = 374. 1 H NMR (400 MHz, DMSO-d6) δ 7.67 (d, 2H), 7.61-7.46 (m, 4H), 7.05- 7.04 (m, 1H), 6.96-6.90 (m, 2H), 6.32 (s, 1H), 4.95-4.92 (m, 1H), 3.78-3.69 (m, 2H), 3.31 (d, 3H). 0322 Example 96: [2-((4-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)-3- methoxypropanamide, Peak 2]: LCMS (ESI): Calcd. for C19H16ClNO5: 374, found [M+H] + = 374. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.67 (d, 2H), 7.61-7.46 (m, 4H), 7.05- 7.04 (m, 1H), 6.96-6.90 (m, 2H), 6.32 (s, 1H), 4.95-4.92 (m, 1H), 3.78-3.69 (m, 2H), 3.31 (d, 3H). Examples 97-98: 3-hydroxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, racemic and chiral forms 0323 Synthesis (S)-3-(benzyloxy)-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen- 7- yl)oxy)propenamide, 70 [Step 1]: To a stirred solution of (S)-3-(benzyloxy)-2-((2-oxo- 4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoic acid (47, 180 mg, 0.4 mmol) in DCM (7 mL) was added DIPEA (0.46 mL, 3.3 mmol) and methanamine hydrochloride (198 mg, 2.9 mmol), and the reaction mixture was cooled to 0 °C. T 3 P (50% in EtOAc, 0.4 mL, 0.6 mmol) was added, and the reaction mixture was allowed to warm to room temperature and stirred for 16 h. The reaction mixture was diluted with DCM, washed with water, brine, dried over anhydrous Na2SO4, and concentrated to afford (S)-3-(benzyloxy)-N- methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanamide (70, 130 mg). LCMS (ESI): Calcd. for C27H25NO5: 443, found: [M +H] + = 444. 0324 Synthesis of (S)-3-hydroxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, 71 [Step 2]: A stirred solution of (S)-3-(benzyloxy)-N-methyl-2- ((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanamide (70, 130 mg, 0.3 mmol) in ethanol (5 mL) was purged with argon for 5 min. To the mixture was added Pd/C (10 mg, 0.03 mmol) and the reaction mixture was subjected to hydrogenolysis for 3 h. The reaction mixture was filtered through a celite bed and the filtrate was concentrated to obtain the product that was purified by RP prep HPLC to afford (S)-3-hydroxy-N- methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanamide (71, 70 mg). LCMS (ESI): Calcd. for C 20 H 19 NO 5 : 353, found: [M+H] + = 354. 0325 Synthesis of chiral 3-hydroxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen- 7-yl)oxy)propenamide, Examples 97 and 98 [Step 3]: (S)-3-hydroxy-N-methyl-2-((2- oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanamide (71, 70 mg, 0.2 mmol) was purified by chiral prep-HPLC separation and the first product isolated as 3-hydroxy-N-methyl-2- ((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propenamide, Peak 1 (Example 97, 12 mg) and the second product as 3-hydroxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Peak 2 (Example 98, 28 mg). The absolute stereochemistries of these compounds were not determined. 0326 Example 97: [3-hydroxy-N-methyl-2-[4-(o-tolyl)-2-oxo-chromen-7-yl]oxy- propanamide, Peak 1]: LCMS (ESI) Calcd. for C20H19NO5: 353, found: [M+H] + = 354. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.11 (m, 1H), 7.43-7.39 (m, 2H), 7.36-7.33 (m, 1H), 7.24 (d, 1H), 7.02 (m, 1H), 6.91-6.87 (m, 2H), 6.20 (s, 1H), 5.15-5.12 (m, 1H), 4.76 (m, 1H), 3.76 (m, 2H), 2.61 (d, 3H), 2.11 (s, 3H). 0327 Example 98: [3-hydroxy-N-methyl-2-[4-(o-tolyl)-2-oxo-chromen-7-yl]oxy- propanamide, Peak 2]: LCMS (ESI) Calcd. for C 20 H 19 NO 5 : 353, found: [M+H] + = 354. 1 H NMR (400 MHz, DMSO-d6) δ 8.11 (m, 1H), 7.43- 7.40 (m, 2H), 7.38-7.35 (m, 1H), 7.24 (d, 1H), 7.02 (m, 1H), 6.91-6.87 (m, 2H), 6.20 (s, 1H), 5.15-5.12 (m, 1H), 4.76 (m, 1H), 3.76 (m, 2H), 2.61 (d, 3H), 2.11 (s, 3H). 0328 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: CHIRALPAK IC (250 X 20 mm), 5μ, operating at ambient temperature with flow of 18.0 mL/min. Mobile phase: 65 % hexane, 17.5 % dichloromethane, and 17.5 % ethanol with run time up to 20 min. and detection at 324 nm wavelength. Examples 99-100: 3-ethoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propenami de, racemic and purified chiral analogs 0329 Synthesis of ethyl (S)-3-ethoxy-2-hydroxypropanoate, 76 [Step 1]: To a stirred solution of methyl (S)-oxirane-2-carboxylate (75, 2.0 g, 19.6 mmol) in ethanol (10 mL) was added magnesium triflate (1.6 g, 4.9 mmol) at ambient temperature. The reaction mixture was stirred at 50 °C for 40 h., and then concentrated under reduced pressure and diluted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and the filtrate was concentrated under reduced pressure. The product was purified by column chromatography to afford ethyl (S)-3- ethoxy-2-hydroxypropanoate (76, 950 mg). 1 H NMR (400 MHz, CDCl 3 ) δ 4.28-4.20 (m, 3H), 3.73-3.67 (m, 2H), 3.59-3.47 (m, 2H), 3.01 (d, 1H), 1.29 (t, 3H), 1.17 (t, 3H). 0330 Synthesis of ethyl (R)-3-ethoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 77 [Step 2]: To a stirred solution of 7-hydroxy-4-(o-tolyl)-2H- chromen-2-one (76, 0.5 g, 2.0 mmol) and ethyl (S)-3-ethoxy-2-hydroxypropanoate (0.5 g, 3.0 mmol) in THF was added PPh3 (1.6 g, 6.0 mmol). The reaction mixture was cooled to 0 °C and DIAD (1.2 mL, 6.0 mmol) was added. The reaction mixture was stirred for 5 min., and then gradually heated to 80 °C and stirred at this temperature for 16 h. The reaction mixture was diluted with ethyl acetate, washed with water, brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The product was purified by column chromatography to afford ethyl (R)-3-ethoxy-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanoate (77, 350 mg). LCMS (ESI) Calcd. for C23H24O6 = 396, found [M+H] + = 397. 0331 Synthesis of (R)-3-ethoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, 78 [Step 3]: To a stirred solution of ethyl (R)-3-ethoxy-2-((2- oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (77, 350 mg, 0.9 mmol) in THF (6 mL) and water (1.5 mL), was added LiOH ^H2O (111 mg, 2.7 mmol). The reaction mixture was stirred for 16 h. at ambient temperature, and concentrated under reduced pressure to give (R)-3-ethoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propa noic acid (78, 300 mg). The product was carried forward without further purification. LCMS (ESI) Calcd. for C21H20O6 = 368, found [M+H] + = 369. 0332 Synthesis of (R)-3-ethoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, 79 [Step 4]: To a stirred solution of (R)-3-ethoxy-2-((2-oxo-4-(o- tolyl)-2H-chromen-7-yl)oxy)propanoic acid (78, 200 mg, 0.6 mmol) and ammonium carbonate (380 mg, 4.0 mmol) in DMF was added N,N-diisopropylethylamine (0.8 mL, 4.5 mmol) at 0 °C under an argon atmosphere. The reaction was stirred for 10 min., followed by the dropwise addition of T3P in EtOAc (50%, 0.3 mL, 0.8 mmol). The reaction mixture was then warmed to ambient temperature and stirred for 18 h. The product was diluted with DCM, washed with water, and concentrated under reduced pressure. The product was purified by RP prep HPLC to afford (R)-3-ethoxy-2-((2-oxo-4- (o-tolyl)-2H-chromen-7-yl)oxy)propanamide (79, 50 mg). 0333 Synthesis of chiral 3-ethoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Examples 99 and 100 [Step 5]: 3-ethoxy-2-((2-oxo-4-(o-tolyl)- 2H-chromen-7-yl)oxy)propanamide (50 mg) was purified by chiral prep-HPLC and the first product isolated as 3-ethoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Peak 1 (Example 99, 7 mg) and the second product as 3-ethoxy-2- ((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propenamide, Peak 2 (Example 100, 32 mg). The absolute stereochemistries of these compounds were not determined. 0334 Example 99: [3-ethoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Peak 1]: LCMS (ESI) Calcd. for C21H21NO5 = 367, found [M+H] + = 368. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.67 (s, 1H), 7.45-7.39 (m, 3H), 7.35 (t, 1H), 7.24 (d, 1H), 7.03 (t, 1H), 6.94-6.87 (m, 2H), 6.20 (s, 1H), 4.90 (s, 1H), 3.77 (d, 2H), 3.52 (q, 2H), 2.12 (s, 3H), 1.09 (t, 3H). 0335 Example 100: [3-ethoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propenamide, Peak 2]: LCMS (ESI) Calcd. for C 21 H 21 NO 5 = 367, found [M+H] + = 368. 1 H NMR (400 MHz, DMSO-d6) δ 7.67 (s, 1H), 7.45-7.39 (m, 3H), 7.35 (t, 1H), 7.23 (d, 1H), 7.03 (s, 1H), 6.94-6.87 (m, 2H), 6.20 (s, 1H), 4.88 (t, 1H), 3.80 (d, 2H), 3.54 (q, 2H), 2.14 (s, 3H), 1.09 (t, 3H). 0336 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: CHIRALPAK IC (250 X 20 mm), 5μ, operating at ambient temperature with flow of 18.0 mL/min. Mobile phase: 60 % hexane, 20 % dichloromethane, and 20 % ethanol with run time up to 18 min. and detection at 322 nm wavelength. Examples 101: (R)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)prop anoic acid
0337 Synthesis of methyl (R)-3-(benzyloxy)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 80 [Step 1]: To a stirred solution of methyl (S)-3-(benzyloxy)-2- hydroxypropanoate (46-4, 1.83 g, 8.7 mmol) in THF (10 mL) was added 7-hydroxy-4-(o- tolyl)-2H-chromen-2-one (Example 1, 1.00 g, 4 mmol) and PPh 3 (3.12 g, 11.9 mmol). To the reaction mixture was slowly added DIAD (2.4 mL, 11.9 mmol) at 0 °C, and the reaction mixture was stirred for 10 min. before it was gradually heated to 80 °C and stirred for 16 h. The reaction mixture was diluted with ethyl acetate, washed with water, brine, and dried over anhydrous Na 2 SO 4 . The mixture was concentrated under reduced pressure to get the product that was purified by combi-flash chromatography to afford methyl (R)-3-(benzyloxy)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy) propanoate (80, 1.20 g). LCMS (ESI) Calcd. for C 27 H 24 O 6 : 444, found [M+H] + = 445. 0338 Synthesis of methyl (R)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 81 [Step 2]: A stirred solution of methyl (R)-3-(benzyloxy)-2-((2- oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (80, 700 mg, 1.6 mmol) in ethanol (7 mL) was degassed for 10 min., followed by the addition of Pd-C (17 mg, 0.2 mmol), and the reaction mixture was subjected to hydrogenolysis for 2 h. The reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure to obtain the product, which was purified by combi-flash chromatography to afford methyl (R)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)prop anoate (81, 200 mg) as a liquid. LCMS (ESI) Calcd. for C 20 H 18 O 6 : 354, found: [M+H] + = 355. 1 H NMR (400 MHz, DMSO-d6) δ 7.41-7.33 (m, 3H), 7.25-7.23 (m, 1H), 7.03 (s, 1H), 6.88 (m, 2H), 6.20 (s, 1H), 5.33-5.20 (m, 1H), 5.12 (m, 1H), 3.88-3.86 (m, 2H), 3.68 (s, 3H), 2.11 (s, 3H). 0339 Synthesis of methyl (R)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 82, and methyl (S)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen- 7-yl)oxy)propanoate, 83 [Step 3]: Methyl (R)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanoate (81, 200 mg, 0.6 mmol) was subjected to normal phase chiral prep chromatography to afford methyl (R)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanoate, 82, and methyl (S)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanoate, 83. The major product was assumed to have the desired R- stereochemistry. 0340 Methyl (R)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)prop anoate (82, 120 mg). LCMS (ESI) Calcd. for C 20 H 18 O 6 : 354, found: [M+H] + = 355. Chiral purity: 100% ee. 0341 Methyl (S)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)prop anoate (83, 60 mg). LCMS (ESI) Calcd. for C 20 H 18 O 6 : 354, found: [M+H] + = 355. Chiral purity: 99% ee. 0342 Synthesis of methyl (R)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 84 [Step 4]: A stirred solution of methyl (R)-3-hydroxy-2-((2-oxo-4- (o-tolyl)-2H-chromen-7-yl)oxy)propanoate (82, 120 mg, 0.3 mmol) in MeI (0.63 mL, 10.2 mmol) was cooled to 0 °C, and Ag2O (157 mg, 0.7 mmol) was added portion wise under an argon atmosphere. The reaction mixture was allowed to warm to ambient temperature and stirred for 12 h. The reaction mixture was filtered through a celite bed and the filtrate was evaporated under reduced pressure to afford methyl (R)-3-methoxy-2- ((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (84, 110 mg). LCMS (ESI) Calcd. for C 21 H 20 O 6 : 368, found: [M+H] + = 369. 0343 Synthesis of (R)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, Example 101 [Step 5]: To a stirred solution of methyl (R)-3- methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (84, 110 mg, 0.3 mmol) in THF (4 mL) and water (1 mL) was added LiOH H 2 O (50 mg, 1.2 mmol), and the reaction mixture was stirred at ambient temperature for 4 h. The reaction mixture was concentrated under reduced pressure and the product was dissolved in water and acidified with 1N HCl, and then extracted with EtOAc. The organic layer was washed with water, brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford (R)-3-methoxy-2-((2- oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoic acid (Example 101, 69 mg). LCMS (ESI) Calcd. for C20H18O6: 354, found [M+H] + = 355. 1 H NMR (400 MHz, DMSO-d6) δ 7.44-7.38 (m, 2H), 7.36-7.32 (m, 1H), 7.24-7.22 (d, 1H), 6.90 (m, 1H), 6.82 (m, 2H), 6.14 (s, 1H), 4.84 (m, 1H), 3.75-3.73 (d, 2H), 3.28 (s, 3H), 2.11 (s, 3H). Example 102-103: 3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoi c acid, racemic and purified chiral analogs 0344 Synthesis of (R)-3-(benzyloxy)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, 85 [Step 1]: To a stirred solution of methyl (R)-3-(benzyloxy)-2- ((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (80, 500 mg, 1.1 mmol) in THF (4 mL) and water (1 mL), was added LiOH H 2 O (190 mg, 4.5 mmol) at ambient temperature. The reaction mixture was allowed to stir for 4 h., and then concentrated under reduced pressure. The product was diluted with EtOAc, washed with water, brine, dried over Na2SO4, and concentrated under reduced pressure to afford (R)-3-(benzyloxy)- 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoic acid (85, 450 mg). LCMS (ESI) Calcd. for C26H22O6: 430, found [M+H] + = 431. 0345 Synthesis of (R)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, 86 [Step 2]: A stirred solution of (R)-3-(benzyloxy)-2-((2-oxo-4- (o-tolyl)-2H-chromen-7-yl)oxy)propanoic acid (85, 300 mg, 0.7 mmol) in ethanol (7 mL) was degassed with argon for 10 min. To the reaction mixture was added Pd-C 10% (50 mg) and the reaction mixture was subjected to hydrogenolysis at ambient temperature for 2 h. The reaction mixture was filtered through a celite bed and the filtrate was concentrated to obtain the product that was purified by RP prep-HPLC and lyophilized to afford (R)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)prop anoic acid (86, 104 mg). LCMS (ESI) Calcd. for C19H16O6: 340 found: [M+H] + = 341. 0346 Synthesis of chiral 3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, Example 102 and 103 [Step 3]: 3-hydroxy-2-((2-oxo-4-(o- tolyl)-2H-chromen-7-yl)oxy)propanoic acid (86, 104 mg) was separated by normal phase chiral prep-HPLC to afford 3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid (Example 102, 45 mg) and 3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanoic acid (Example 103, 9.0 mg). The absolute stereochemistries of these compounds were not determined. 0347 Example 102: 3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, Peak 1: LCMS (ESI) Calcd. for C19H16O6: 340, found: [M-H]-: 339. 1 H NMR (400 MHz, DMSO-d 6 ) δ 13.18 (br s, 1H), 7.45-7.33 (m, 3H), 7.25 (d, 1H), 6.98 (s, 1H), 6.88 (s, 2H), 6.19 (s, 1H), 4.98 (br s, 1H), 3.86 (br s, 2H), 2.11 (s, 3H). 0348 Example 103: (S)-3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, Peak 2: LCMS (ESI) Calcd. for C19H16O6: 340, found [M-H]-: 339. 1 H NMR (400 MHz, DMSO-d 6 ) δ 13.18 (br s, 1H), 7.45-7.33 (m, 3H), 7.25 (d, 1H), 6.98 (s, 1H), 6.88 (s, 2H), 6.19 (s, 1H), 4.98 (br s, 1H), 3.86 (br s, 2H), 2.11 (s, 3H). 0349 Chiral prep-HPLC: Chiral separation was performed on an Agilent 1200 series instrument. Column: CHIRALPAK IG (250 X 21 mm), 5μ, operating at ambient temperature with flow of 21.0 mL/min. Mobile phase: 70 % hexane, 15 % dichloromethane, 15 % ethanol, and 0.1% trifluoroacetic acid, with a run time up to 28 min. and detection at 324 nm wavelength. Example 104: (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)prop anoic acid
0350 Synthesis of methyl (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 90 [Step 1]: To a stirred solution of methyl (S)-3-hydroxy-2-((2-oxo- 4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (83, 60 mg, 0.2 mmol) in methyl iodide (0.3 mL, 5.1 mmol) was added Ag 2 O (78 mg, 0.4 mmol), and the reaction mixture stirred at ambient temperature for 32 h. The reaction mixture was filtered through a celite bed and the filtrate was concentrated under reduced pressure to afford the product that was purified by flash chromatography to afford methyl (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)- 2H-chromen-7-yl)oxy)propanoate (90, 60 mg). LCMS (ESI) Calcd. for C 21 H 20 O 6 : 368, found [M+H] + = 369. 0351 Synthesis of (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid, Example 104 [Step 2]: To a stirred solution of methyl (S)-3- methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (90, 60 mg, 0.2 mmol) in THF (3 mL) was dropwise added an aqueous solution of LiOH H2O (21 mg, 0.5 mmol, 0.75 mL). The reaction mixture was stirred for 2 h. at ambient temperature and concentrated under reduced pressure to afford the product that was diluted with water, acidified with citric acid, and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 , concentrated under reduced pressure and purified by RP prep-HPLC to afford (S)-3-methoxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoic acid (Example 104, 20 mg). LCMS (ESI) Calcd. for C 20 H 18 O 6 : 354, found [M+H] + = 355. 1 H NMR (400 MHz, DMSO-d6) δ 13.48 (br s, 1H), 7.44-7.32 (m, 3H), 7.24-7.22 (d, 1H), 6.97 (s, 1H), 6.85 (m, 2H), 6.17 (s, 1H), 5.05 (m, 1H), 3.80-3.75 (m, 2H), 3.34 (s, 3H), 2.11 (s, 3H). Examples 105-106: Methyl 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-3- (trifluoromethoxy)propanoate, 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-3- (trifluoromethoxy)propanoic acid, ammonia salt
0352 Synthesis of 3-(benzyloxy)-2-hydroxypropanoic acid, 96 [Step 1]: A stirred solution of O-benzylserine (95, 10.0 g, 51.2 mmol) in 2N H 2 SO 4 (50 mL) was cooled to 0 °C. Then a solution of NaNO2 (6.4 g, 92.2 mmol) in water (10 mL) was added to the mixture over 1.5 h. at a temperature of 0-5 °C. The reaction mixture was stirred at 5 °C for 6 h., and gradually warmed to ambient temperature and stirred for another 6 h. The reaction mixture was adjusted to pH 4 with 50% NaOH solution at 0 °C. Ethyl acetate (300 mL) was added and the reaction was stirred vigorously and the aqueous layer was adjusted to pH 2 with the addition of 2N H 2 SO 4 . The aqueous layer was extracted with EtOAc and the combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain 3-(benzyloxy)-2-hydroxypropanoic acid (96, 9.5 g). LCMS (ESI): Calcd. for C10H12O4: 196, found [M-H]- = 195. 0353 Synthesis of methyl 3-(benzyloxy)-2-hydroxypropanoate, 97 [Step 2]: To a stirred mixture of 3-(benzyloxy)-2-hydroxypropanoic acid (96, 5.0 g, 25.5 mmol) in methanol (50 mL), was added freshly prepared methanolic HCl (25 mL, 1 M) at ambient temperature over 1.5 h. To the reaction mixture was added trimethyl orthoformate (17.2 g, 162 mmol) and the reaction mixture was stirred at ambient temperature for 18 h. The reaction mixture was concentrated under reduced pressure and purified by column chromatography to afford methyl 3-(benzyloxy)-2-hydroxypropanoate (97, 5.0 g). 1 H NMR (400 MHz, DMSO-d6) δ 7.36-7.28 (m, 5H), 5.59 (br s, 1H), 4.54-4.46 (m, 2H), 4.25 (br s, 1H), 3.64-3.60 (m, 5H). 0354 Synthesis of methyl 3-(benzyloxy)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 98 [Step 3]: To a stirred solution of 7-hydroxy-4-(o-tolyl)-2H- chromen-2-one (Example 1, 1.0 g, 3.9 mmol) and methyl 3-(benzyloxy)-2- hydroxypropanoate (97, 1.25 g, 5.9 mmol) in THF (30 mL) was added PPh 3 (3.1 g, 11.9 mmol). The reaction mixture was cooled to 0 °C and DIAD (2.3 mL, 11.9 mmol) was added and the reaction mixture was stirred for 5 min., then gradually heated to 80 °C and stirred for 18 h. The reaction mixture was diluted with ethyl acetate, washed with water, brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by column chromatography to afford methyl 3-(benzyloxy)-2-((2- oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (98, 950 mg). LCMS (ESI) Calcd. for C27H24O6: 444, found [M+H] + = 445. 0355 Synthesis of methyl 3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 99 [Step 4]: A stirred solution of methyl 3-(benzyloxy)-2-((2-oxo-4- (o-tolyl)-2H-chromen-7-yl)oxy)propanoate, (98, 950 mg, 2.1 mmol) in ethanol (20 mL) was purged with argon for 5 min. To the mixture was added 10% Pd/C (200 mg, 0.2 mmol) and the mixture was subjected to hydrogenolysis at ambient temperature for 4 h. The reaction mixture was filtered through a celite bed and concentrated under reduced pressure, and the product was purified by column chromatography to afford methyl 3- hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoate (99, 400 mg). LCMS (ESI) Calcd. for C20H18O6: 354, found [M+H] + = 355. 0356 Synthesis of methyl 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-3- (trifluoromethoxy)propanoate, Example 105 [Step 5]: In a sealed vessel, dry potassium fluoride (490 mg, 8.5 mmol), silver trifluoromethanesulphonate (1.7 g, 6.8 mmol), 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (1.2 g, 3.4 mmol), and methyl 3-hydroxy-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate (99, 600 mg, 1.7 mmol) were added successively under an argon atmosphere. To the mixture was successively added dry ethyl acetate (10 mL), 2- fluoropyridine (0.6 mL, 6.8 mmol), and (trifluoromethyl)trimethylsilane (1.0 mL, 6.8 mmol) under argon and the reaction mixture was stirred at ambient temperature for 18 h. The reaction mixture was diluted with ethyl acetate and filtered through a celite bed and the filtrate was dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by column chromatography to give methyl 2-((2-oxo-4-(o- tolyl)-2H-chromen-7-yl)oxy)-3-(trifluoromethoxy)propanoate (Example 105, 170 mg). LCMS (ESI) Calcd for C21H17F3O6: 422, found [M+H] + = 423. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.46-7.39 (m, 2H), 7.35 (t, 1H), 7.25 (d, 1H), 7.18 (s, 1H), 6.95 (d, 1H), 6.90 (t, 1H), 6.23 (s, 1H), 5.61 (t, 1H), 4.58 (d, 2H), 3.75 (s, 3H), 2.15 (s, 3H). 0357 Synthesis of 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-3- (trifluoromethoxy)propanoic acid, ammonia salt, Example 106 [Step 6]: Methyl 2- ((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-3-(trifluoromethoxy )propanoate (Example 105, 90 mg, 0.2 mmol), water (0.6 mL, 33.3 mmol), and 12N HCl (4.0 mL, 132 mmol) were added to a sealed tube. The reaction mixture was heated to 110 °C for 2 h, and then concentrated under reduced pressure. The product was purified by RP prep-HPLC to afford 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-3-(trifluorometho xy)propanoic acid, ammonia salt (Example 106, 30 mg). LCMS (ESI) Calcd. for C20H15F3O6: 408, found [M+H] + = 409. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.45-7.38 (m, 2H), 7.35 (t, 1H), 7.23 (d, 1H), 7.14 (br s, 3H), 6.91 (s, 1H), 6.83 (s, 2H), 6.15 (s, 1H), 4.99-4.88 (m, 1H), 4.48 (d, 1H), 4.41-4.36 (m, 1H), 2.15 (s, 3H). Example 107: 2-((4-(2,6-dimethylphenyl)-2-oxo-2H-chromen-7-yl)oxy)acetoni trile 0358 Synthesis of 7-methoxy-2-oxo-2H-chromen-4-yl trifluoromethanesulfonate, 106 [Step 1]: A solution of 4-hydroxy-7-methoxy-2H- chromen-2-one (100, 500 mg, 2.6 mmol) in DCM (3 mL) was cooled to 0 o C and triethylamine (0.7 mL, 5.2 mmol) and trifluoromethanesulfonic anhydride (0.7 mL, 3.9 mmol) were added at 0 o C. The reaction mixture was allowed to warm to ambient temperature and stirred for another 3 h. The reaction mixture was quenched with water and extracted with DCM (3 x 50 mL). The organic layer was washed with water, brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by flash chromatography to afford 7-methoxy-2-oxo-2H-chromen-4-yl trifluoromethanesulfonate (106, 350 mg). LCMS (ESI) Calcd. for C 11 H 7 F 3 O 6 S: 324, found [M+H] + = 325. 1 H NMR (400 MHz, DMSO-d6) δ 7.61 (d, 1H), 7.19 (br s, 1H), 7.13-7.10 (m, 1H), 6.65 (s, 1H), 3.90 (s, 3H). 0359 Synthesis of 4-(2,6-dimethylphenyl)-7-methoxy-2H-chromen-2-one, 107 [Step 2]: To a stirred solution of K 3 PO 4 (420 mg, 2 mmol) and 7-methoxy-2-oxo-2H- chromen-4-yl trifluoromethanesulfonate (106, 100 mg, 0.3 mmol) in 1,4-dioxane-water (5 mL, 4:1) mixture was added (2,6-dimethylphenyl)boronic acid (70 mg, 0.5 mmol) and the reaction mixture was degassed with argon for 10 min. To the reaction mixture was added Pd-118 (20 mg, 0.03 mmol) and the reaction mixture was heated to reflux at 100 o C for 16 h. The reaction mixture was cooled, filtered through a celite bed, and the filtrate was evaporated under reduced pressure. The product was purified by flash column chromatography to afford 4-(2,6-dimethylphenyl)-7-methoxy-2H-chromen-2-one (107, 22 mg). LCMS (ESI) Calcd. for C18H16O3: 280, found [M+H] + = 281. 0360 Synthesis of 4-(2,6-dimethylphenyl)-7-hydroxy-2H-chromen-2-one, 108 [Step 3]: To a stirred solution 4-(2,6-dimethylphenyl)-7-methoxy-2H-chromen-2-one (107, 105 mg, 0.4 mmol) in DCM (3 mL) was added BBr 3 (1.1 mL, 1.1 mmol, 1M in DCM,) dropwise at 0 o C. The reaction mixture was allowed to warm to ambient temperature and stirred for 16 h. The mixture was concentrated under reduced pressure and quenched with methanol and ice cold water. The mixture was extracted with EtOAc (3 x 50 mL) and washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by flash column chromatography to afford 4-(2,6-dimethylphenyl)-7-hydroxy-2H-chromen-2-one (108, 92 mg). LCMS (ESI) Calcd. for C17H14O3: 266, found [M+H] + = 267. 0361 Synthesis of 2-((4-(2,6-dimethylphenyl)-2-oxo-2H-chromen-7- yl)oxy)acetonitrile, Example 107 [Step 4]: To a stirred solution of 2-bromoacetonitrile (55 mg, 0.5 mmol) and 4-(2,6-dimethylphenyl)-7-hydroxy-2H-chromen-2-one (108, 100 mg, 0.4 mmol) in DMF (2 mL) was added cesium carbonate (365 mg, 1.1 mmol) at ambient temperature and the reaction mixture was heated up to 100 o C for 16 h. The reaction mixture was quenched with water, extracted with EtOAc (3 x 30mL), washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford 2-((4-(2,6- dimethylphenyl)-2-oxo-2H-chromen-7-yl)oxy)acetonitrile (Example 107, 15 mg). LCMS (ESI) Calcd. for C 19 H 15 NO 3 : 305, found [M+H] + = 306. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.33-7.30 (m, 2H), 7.23-7.21 (m, 2H), 6.98-6.96 (m, 1H), 6.82-6.80 (d, 1H), 6.26 (s, 1H), 5.30 (s, 2H), 2.03 (s, 6H). Example 108: 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)acetamide 0362 Synthesis of ethyl 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)acetate, 110 [Step 1]: To a stirred solution of 7-hydroxy-4-(o-tolyl)chromen-2-one (Example 1, 250 mg, 1 mmol) and ethyl 2-hydroxyacetate (225 mg, 2.2 mmol) in THF (5 mL) was added PPh3 (780 mg, 3 mmol) and the mixture was cooled in an ice bath. DIAD (0.6 mL, 3 mmol) was added and the reaction mixture was allowed to warm up to ambient temperature and then gradually to 80 o C for 16h. The reaction mixture was diluted with ethyl acetate and washed with water, brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by combi-flash chromatography to afford ethyl 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)acetate (110, 270 mg). LCMS (ESI) Calcd. for C20H18O5: 338, found [M+H] + = 339. 1 H NMR (400 MHz, CDCl3) δ 7.39-7.29 (m, 3H), 7.16 (d, 1H), 6.98 (m, 1H), 6.83 (m, 1H), 6.76-6.73 (m, 1H), 6.16 (s, 1H), 4.66 (s, 2H), 4.30-4.23 (m, 2H), 2.14 (s, 3H), 3.09 (m, 1H). 0363 Synthesis of 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)acetic acid, 111 [Step 2]: To a stirred solution of ethyl 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)acetate (110, 270 mg, 0.8 mmol) in a mixture of THF (4 mL): water (1 mL) was added LiOH H2O (135 mg, 3.2 mmol) and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with water, acidified with 1N HCl and extracted with EtOAc (3 x 30 mL). The combined organic part was dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to afford 2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)acetic acid (111, 220 mg). LCMS (ESI) Calcd. for C 18 H 14 O 5 : 310, found [M+H] + = 311. 0364 Synthesis of 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)acetamide, Example 108 [Step 3]: A stirred solution of 2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)acetic acid (111, 230 mg, 0.7 mmol) in DMF (3 mL) was cooled to 0-5 °C and (NH4)2CO3 (355 mg, 3.7 mmol), DIPEA ( 0.64 mL, 3.7 mmol), and T3P (50% in EtOAc) (0.7 mL, 1.1 mmol) were added and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with ice-cold water, extracted with EtOAc, washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The product was purified by RP prep-chromatography and lyophilization to afford 2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)acetamide (Example 108, 40 mg). LCMS (ESI) Calcd. for C 18 H 15 ClFNO 4 : 309, found: [M+H] + = 310. 1 H NMR (400 MHz, DMSO-d6) δ 7.61 (br s, 1H), 7.45-7.33 (m, 4H), 7.25 (d, 1H), 7.05 (d, 1H), 6.93-6.87 ( m, 2H), 6.20 (s, 1H), 4.56 (s, 2H), 2.11 (s, 3H). Example 109: 4-(o-tolyl)-7-((1,1,1-trifluoropropan-2-yl)oxy)-2H-chromen-2 -one 0365 Synthesis of 4-(o-tolyl)-7-((1,1,1-trifluoropropan-2-yl)oxy)-2H-chromen-2 - one, Example 109: To a stirred solution of 7-hydroxy-4-(o-tolyl)-2H-chromen-2-one (Example 1, 150 mg, 0.6 mmol) in DMF (3 mL) was added K 2 CO 3 (205 mg, 1.5 mmol) and a DCM solution of (2,2,2-trifluoro-1-methyl-ethyl) trifluoromethanesulfonate (860 mg, 3.5 mmol) and the reaction mixture was stirred at 80 C for 16 h. The reaction was quenched with ice-cold water, extracted with EtOAc, washed with brine, dried over anhydrous Na2SO4, and purified by flash chromatography to afford 4-(o-tolyl)-7-((1,1,1- trifluoropropan-2-yl)oxy)-2H-chromen-2-one (Example 109, 140 mg). LCMS (ESI) Calcd. for C19H15F3O3: 348, [M+H] + = 349. 1 H NMR (400 MHz, DMSO-d6) δ 7.42- 7.32 (m, 4H), 7.25-7.23 (d, 1H), 7.00-6.98 (dd, 1H), 6.91-6.89 (d, 1H), 6.25 (s, 1H), 5.49-5.43 (m, 1H), 2.11 (s, 3H), 1.46-1.44 (d, 3H). Example 110: (R)-4-(2-chloro-4-fluorophenyl)-7-((1-(1,1-dioxidothiomorpho lino)-1- oxopropan-2-yl)oxy)-2H-chromen-2-one 0366 Synthesis of methyl (R)-2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H- chromen-7-yl)oxy)propanoate, 115 [Step 1]: To an ice-cold solution of 4-(2-chloro-4- fluorophenyl)-7-hydroxy-2H-chromen-2-one (Example 13, 1.0 g, 3.44 mmol), methyl (S)-2-hydroxypropanoate (0.5 mL, 5.2 mmol) and triphenylphosphine (1.4 g, 5.2 mmol) in THF (20 mL) was added diisopropyl azodicarboxylate (1.0 mL, 5.2 mmol), and the reaction mixture was stirred at 25 o C. After 16 h., the reaction mixture was concentrated under reduced pressure, and purified by column chromatography to afford methyl (R)-2- ((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)prop anoate (115, 1.0 g). LCMS (ESI) Calcd. for C 19 H 14 ClFO 5 : 376, found [M+H] + = 377. 1 H NMR (400 MHz, DMSO-d6) δ 7.71-7.69 (m, 1H), 7.58-7.55 (m, 1H), 7.46-7.42 (m, 1H), 7.04-7.03 (m, 1H), 6.96-6.94 (m, 1H), 6.90-6.87 (m, 1H), 6.33 (s, 1H), 5.25-5.20 (m, 1H), 3.70 (s, 3H), 1.54 (d, 3H). 0367 Synthesis of (R)-2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7- yl)oxy)propanoic acid, 116 [Step 2]: To a solution of methyl (R)-2-((4-(2-chloro-4- fluorophenyl)-2-oxo-2H-chromen-7-yl)oxy)propanoate (115, 150 mg, 0.4 mmol) in THF (2 mL)-water (0.5 mL) was added lithium hydroxide monohydrate (40 mg, 1.0 mmol) and the reaction mixture was stirred at 25 o C. After 16 h., the reaction mixture was concentrated under reduced pressure and was diluted with water, acidified with 1N HCl to pH 2, and extracted with 20% methanol in dichloromethane (twice). The combined organic extract was washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure to afford (R)-2-((4-(2-chloro-4-fluorophenyl)-2-oxo- 2H-chromen-7-yl)oxy)propanoic acid (116, 100 mg). LCMS (ESI) Calcd. for C18H12ClFO5: 362, found [M+H] + = 363. 0368 Synthesis of (R)-4-(2-chloro-4-fluorophenyl)-7-((1-(1,1- dioxidothiomorpholino)-1-oxopropan-2-yl)oxy)-2H-chromen-2-on e, Example 110 [Step 3]: To a stirred solution of (R)-2-((4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen- 7-yl)oxy)propanoic acid (116, 100 mg, 0.3 mmol) and thiomorpholine 1,1-dioxide (45 mg, 0.3 mmol) in DMF (3 mL) was added HATU (157 mg, 0.4 mmol) and DIPEA (0.1 mL, 0.7 mmol) successively at 25 o C. After 16 h., the reaction mixture was quenched with cold water, and extracted with ethyl acetate (twice). The combined organic extract was washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford (R)-4-(2-chloro-4-fluorophenyl)-7-((1-(1,1-dioxidothiomorpho lino)-1-oxopropan-2- yl)oxy)-2H-chromen-2-one (Example 110, 50 mg). LCMS (ESI) Calcd. for C 22 H 19 ClFNO 6 S: 479, found [M+H] + = 480. 1 H NMR (400 MHz, DMSO-d 6 ) (at 100 o C) δ 7.62-7.59 (m, 1H), 7.55-7.52 (m, 1H), 7.41-7.37 (m, 1H), 7.05-7.04 (m, 1H), 6.99-6.97 (m, 1H), 6.88-6.86 (m, 1H), 6.25 (s, 1H), 5.51-5.46 (m, 1H), 3.97-3.95 (m, 4H), 3.20-3.15 (m, 4H), 1.52 (d, 3H). Example 111: (R)-7-((1-(1,1-dioxidothiomorpholino)-1-oxopropan-2-yl)oxy)- 4-(o-tolyl)-2H- chromen-2-one
0369 Synthesis of methyl (R)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate, 120 [Step 1]: To an ice-cold solution of 7-hydroxy-4-(o-tolyl)-2H- chromen-2-one (Example 13, 1.0 g, 3.9 mmol), methyl (S)-2-hydroxypropanoate (0.6 mL, 5.9 mmol), and triphenylphosphine (1.6 g, 5.9 mmol) in THF (20 mL) was added dropwise diisopropyl azodicarboxylate (1.2 mL, 5.9 mmol). The reaction mixture was stirred at ambient temperature for 16 h., concentrated under reduced pressure, and purified by column chromatography to afford methyl (R)-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanoate (120, 800 mg). LCMS (ESI) Calcd. for C 20 H 18 O 5 : 338, found [M+H] + = 339. 1 H NMR (400 MHz, DMSO-d6) δ 7.43-7.39 (m, 2H), 7.37-7.33 (m, 1H), 7.25-7.23 (m, 1H), 7.02 (s, 1H), 6.90-6.84 (m, 2H), 6.21 (s, 1H), 5.22-5.20 (m, 1H), 3.70 (s, 3H), 2.12 (d, 3H), 1.54 (d, 3H). 0370 Synthesis of (R)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoic acid, 121 [Step 2]: To a solution of methyl (R)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanoate (120, 150 mg, 0.4 mmol) in THF (2 mL)-water (0.5 mL) mixture, was added lithium hydroxide monohydrate (45 mg, 1.1 mmol), and the reaction mixture was stirred at ambient temperature for 16 h. The mixture was concentrated under reduced pressure, acidified with 1N aqueous HCl to pH 2, and extracted with ethyl acetate (twice). The combined organic extract was washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure to afford (R)-2-((2-oxo-4-(o-tolyl)-2H- chromen-7-yl)oxy)propanoic acid (121, 120 mg). LCMS (ESI) Calcd. for C 19 H 16 O 5 : 324, found [M+H] + = 325. 0371 Synthesis of (R)-7-((1-(1,1-dioxidothiomorpholino)-1-oxopropan-2- yl)oxy)-4-(o-tolyl)-2H-chromen-2-one, Example 111 [Step 3]: To a stirred solution of (R)-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)propanoic acid (121, 100 mg, 0.5 mmol) in DMF (3 mL), was added HATU (265 mg, 0.7 mmol) followed by N,N- diisopropylethylamine (0.2 mL, 1.2 mmol) at 0 o C. After stirring for 10 min. at ambient temperature, thiomorpholine 1,1-dioxide (75 mg, 0.5 mmol) was added and the reaction mixture was stirred at ambient temperature for 4 h. The reaction mixture was diluted with ice-cold water, and extracted with ethyl acetate (twice). The combined organic extract was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford (R)-7-((1-(1,1-dioxidothiomorpholino)-1-oxopropan-2-yl)oxy)- 4-(o-tolyl)-2H-chromen-2- one (Example 111, 55 mg). LCMS (ESI) Calcd. for C 23 H 23 NO 6 S: 441, found [M+H] + = 442. 1 H NMR (400 MHz, DMSO-d6) δ 7.45-7.33 (m, 2H), 7.36-7.33 (m, 1H), 7.25-7.22 (m, 1H), 7.05-7.04 (m, 1H), 6.90-6.88 (m, 1H), 6.83-6.79 (m, 1H), 6.15 (s, 1H), 5.49-5.44 (m, 1H), 3.95-3.94 (m, 4H), 3.16-3.15 (m, 4H), 2.14 (s, 3H), 1.52 (d, 3H). Example 112: Synthesis of (R)-4-(2,6-dimethylphenyl)-7-((1-(1,1-dioxidothiomorpholino) -1- oxopropan-2-yl)oxy)-2H-chromen-2-one 0372 Synthesis of methyl (R)-2-((4-(2,6-dimethylphenyl)-2-oxo-2H-chromen-7- yl)oxy)propanoate, 125 [Step 1]: To an ice-cold solution of 4-(2,6-dimethylphenyl)-7- hydroxy-2H-chromen-2-one (108, 1.0 g, 3.8 mmol), methyl (S)-2-hydroxypropanoate (4, 0.5 mL, 5.6 mmol) and triphenylphosphine (1.5 g, 5.6 mmol) in THF (20 mL), was added diisopropyl azodicarboxylate (1.1 mL, 5.6 mmol) and the reaction mixture was stirred at ambient temperature. After 16 h., the reaction mixture was concentrated under reduced pressure, and purified by Combi-Flash column chromatography to afford methyl (R)-2- ((4-(2,6-dimethylphenyl)-2-oxo-2H-chromen-7-yl)oxy)propanoat e (125, 1.0 g). LCMS (ESI) Calcd. for C21H20O5: 352, found [M+H] + = 352. 0373 Synthesis of (R)-2-((4-(2,6-dimethylphenyl)-2-oxo-2H-chromen-7- yl)oxy)propanoic acid, 126 [Step 2]: To a solution of methyl (R)-2-((4-(2,6- dimethylphenyl)-2-oxo-2H-chromen-7-yl)oxy)propanoate (125, 200 mg, 0.57 mmol) in THF (4 mL)-water (1 mL) was added lithium hydroxide monohydrate (35 mg, 0.8 mmol), and the reaction mixture was stirred at ambient temperature. After 16 h., the reaction mixture was concentrated under reduced pressure, acidified with 1N aqueous HCl to pH 2, and extracted with 20% methanol in dichloromethane (twice). The combined organic extract was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford (R)-2-((4-(2,6-dimethylphenyl)-2-oxo-2H-chromen-7- yl)oxy)propanoic acid (126, 160 mg). The product was used in the next step without further purification. LCMS (ESI) Calcd. for C 20 H 18 O 5 : 338, found [M+H] + = 339. 0374 Synthesis of (R)-4-(2,6-dimethylphenyl)-7-((1-(1,1- dioxidothiomorpholino)-1-oxopropan-2-yl)oxy)-2H-chromen-2-on e, Example 112 [Step 3]: To a solution of (R)-2-((4-(2,6-dimethylphenyl)-2-oxo-2H-chromen-7- yl)oxy)propanoic acid (126, 160 mg, 0.5 mmol) and thiomorpholine 1,1-dioxide (77 mg, 0.6 mmol) in DMF (5 mL), was added HATU (270 mg, 0.7 mmol) followed by DIPEA (0.2 mL, 1.2 mmol), and the reaction mixture was stirred at ambient temperature. After 16 h., the reaction mixture was quenched with cold water and extracted with ethyl acetate (twice). The combined organic extract was washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC followed by lyophilization to afford (R)-4-(2,6-dimethylphenyl)-7-((1- (1,1-dioxidothiomorpholino)-1-oxopropan-2-yl)oxy)-2H-chromen -2-one (Example 112, 80 mg). LCMS (ESI) Calcd. for C24H25NO6S: 455, found [M+H] + = 456. 1 H NMR (400 MHz, DMSO-d 6 ) (at 100 °C) δ 8.05-8.03 (m, 1H), 7.33-7.31 (m, 1H), 7.21-7.19 (m, 2H), 7.12-7.09 (m, 2H), 6.27 (s, 1H), 5.51 (q, 1H), 3.98-3.95 (m, 4H), 3.16-3.14 (m, 4H), 2.27 (s, 6H), 1.53 (d, 3H). Example 113: Synthesis of 4-phenyl-7-propoxy-2H-chromen-2-one
0375 Synthesis of 7-propoxy-2H-chromen-2-one, 131 [Step 1]: To a solution of 7-hydroxy-2H-chromen-2-one (130, 1.0 g, 6.2 mmol) in acetone (30 mL) was added potassium carbonate (1.7 g, 12.3 mmol) followed by 1-iodopropane (0.7 mL, 7.4 mmol) at 25 °C, and the reaction mixture was stirring for 16 h. The reaction mixture was concentrated under reduced pressure, and purified on a silica gel column to afford 7- propoxy-2H-chromen-2-one (131, 1.0 g). LCMS (ESI) Calcd. for C 12 H 12 O 3 : 204, found [M+H] + = 205. 1 H NMR (400 MHz, DMSO-d6): δ 7.62 (d, 1H), 7.34 (d, 1H), 6.84-6.79 (m, 2H), 6.22 (d, 1H), 3.97 (t, 2H), 1.83 (sextet, 2H), 1.05 (t, 3H). 0376 Synthesis of 4-phenyl-7-propoxy-2H-chromen-2-one, Example 113 [Step 2]: To a mixture of 7-propoxy-2H-chromen-2-one (131, 200 mg, 1.0 mmol), phenylboronic acid (350 mg, 2.9 mmol), Pd(OAc)2 (22 mg, 0.1 mmol) and 2,2′-Bipyridyl (23 mg, 0.15 mmol) in dry DMF (2 mL) was bubbled O 2 gas, and the reaction mixture was stirred at 80 °C for 16 h. The resulting mixture was allowed to warm to ambient temperature, quenched with water, and extracted with EtOAc (x2). The organic layers were combined and washed with brine, dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The product was purified by RP prep-HPLC and lyophilized to afford 4-phenyl-7-propoxy-2H-chromen-2-one (Example 113, 49 mg, 0.2 mmol). LCMS (ESI) Calcd. for C 18 H 16 O 3 : 280, found [M+H] + = 281. 1 H NMR (400 MHz, DMSO-d6): δ 7.58-7.51 (m, 5H), 7.34 (d, 1H), 7.08 (d, 1H), 6.94 (dd, 1H), 6.23 (s, 1H), 4.06 (t, 2H), 1.76 (sextet, 2H), 0.99 (t, 3H). Example 114: Synthesis of chiral
0377 Synthesis of N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-3- (trifluoromethoxy)propanamide, 136 [Step 1]: In a sealed tube was added dry potassium fluoride (410 mg, 7.1 mmol), silver trifluoromethanesulphonate (1.5 g, 5.7 mmol), 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (1.0 g, 2.8 mmol) and 3-hydroxy-N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)propanamide (135, 500 mg, 1.4 mmol) under argon. To the mixture was added dry ethyl acetate (20 mL), 2-fluoropyridine (0.5 mL, 5.7 mmol) and (trifluoromethyl)trimethylsilane (0.8 mL, 5.7 mmol) under argon and the reaction mixture was stirred at ambient temperature for 40 h. The reaction mixture was diluted with ethyl acetate and filtered through a celite bed. The filtrate was dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The product was purified by column chromatography followed by RP prep-HPLC to afford N-methyl-2-((2-oxo-4-(o-tolyl)- 2H-chromen-7-yl)oxy)-3-(trifluoromethoxy)propanamide (136, 250 mg). LCMS (ESI) Calcd for C21H18F3NO5: 421, found [M+H] + = 422. 1 H NMR (400 MHz, DMSO-d6) δ 8.31 (br s, 1H) 7.46-7.34 (m, 3H), 7.24 (d, 1H), 7.15 (d, 1H), 6.99 (d, 1H), 6.91 (d, 1H), 6.24 (s, 1H), 5.23 (br s, 1H), 4.47 (br s, 2H), 2.65 (d, 3H), 2.12 (s, 3H). 0378 Synthesis of chiral N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)- 3-(trifluoromethoxy)propanamide, Example 114 and Example 115 [Step 2]: The racemic N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-3- (trifluoromethoxy)propanamide (136, 30 mg) was used for normal phase chiral HPLC separation to afford Peak 1 as chiral N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7- yl)oxy)-3-(trifluoromethoxy)propanamide (Example 114, 10 mg) and Peak 2 as chiral N- methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-3-(trifluo romethoxy)propanamide (Example 115, 11 mg). The absolute stereochemistries of these compounds were not determined. 0379 Example 114, N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-3- (trifluoromethoxy)propanamide, Peak 1: LCMS (ESI) Calcd. for C21H18F3NO5: 421, found [M+H] + = 422. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.30 (b rs, 1H), 7.43-7.41 (m, 2H), 7.37 (t, 1H), 7.24 (d, 1H), 7.15 (d, 1H), 6.99 (d, 1H), 6.91 (d, 1H), 6.23 (s, 1H), 5.23 (br s, 1H), 4.46 (br s, 2H), 2.65 (d, 3H), 2.12 (s, 3H). 0380 Example 115, N-methyl-2-((2-oxo-4-(o-tolyl)-2H-chromen-7-yl)oxy)-3- (trifluoromethoxy)propanamide, Peak 2: LCMS (ESI) Calcd. for C 21 H 18 F 3 NO 5 : 421, found [M+H] + = 422. 1 H NMR (400 MHz, DMSO-d6) δ 8.30 (br s, 1H), 7.44-7.39 (m, 2H), 7.35 (t, 1H), 7.24 (d, 1H), 7.15 (d, 1H), 6.99 (d, 1H), 6.91 (d, 1H), 6.23 (s, 1H), 5.23 (br s, 1H), 4.46 (br s, 2H), 2.65 (d, 3H), 2.11 (s, 3H). 0381 Prep Normal phase HPLC Chiral Method: Chiral separation was performed on an Agilent 1200 series instrument. Column was a CHIRALCEL OD-H (250 X 20 mm), 5µ, operating at ambient temperature and a flow rate of 18.0 mL/min. The mobile phase was mixture of 70% Hexane and 30% EtOH, held isocratic for 13 min. with detection at a wavelength of 322 nm. Biological/Biochemical Evaluation General protocol for in vitro analysis of compounds 0382 The inhibitory activity of the compounds of the present invention against POLRMT were determined by assays based on Bergbrede, T., et al., “An adaptable high- throughput technology enabling the identification of specific transcription modulators,” SLAC Discov., 22, 378–386 (2017). 0383 The ability of some compounds of the present invention to inhibit POLRMT were determined in a homogeneous TR-FRET Assay using high-throughput screening in a 384-well plate format. This method is used to monitor the activity of mitochondrial transcription through measurement of its product, a 407 bp long RNA transcript. Detection of the product is facilitated by hybridization of two DNA-oligonucleotide probes to specific and adjacent sequences within the RNA product sequence. Upon annealing of the probes, two fluorophores are coupled directly to an acceptor nucleotide probe (ATTO647, 5 ), or introduced via a coupled streptavidin with a biotinylated donor nucleotide probe (Europium cryptate) that is brought into sufficient proximity to serve as a fluorescence-donor-acceptor pair. Thus, a FRET signal at 665 nm is generated upon excitation at 340 nm. 0384 Proteins used as transcription factors (POLRMT: NP_005026.3, TFAM: NP_003192.1, TFB2M: NP_071761.1) are diluted from their stocks to working concentrations of 1 µM, 20 µM and 4 µM respectively, in a dilution buffer containing 20 mM Tris-HCI (pH 8.0), 200 mM NaCl, 10% (v/v) glycerol, 1 mM Dithiothreitol (DTT), 0.5 mM EDTA. 0385 DNA template is a pUC18 plasmid with the mitochondrial light strand promotor sequence (1-477) cloned between HindIII and BamHI sites. The DNA template is restriction linearized proximal to the promotor 3’-end (pUC-LSP). 0386 The reaction mixture (10 uL) containing 7.5 nM POLRMT, 15 nM of TFB2M, 30 nM of TFAM , 0.5 nM of DNA template and 500 µM nucleotide triphosphate mix (NTPs) in a reaction buffer (containing 10 mM Tris-HCI (pH 7.5), 10 mM MgCl2, 40 mM NaCl, 10 mM DTT, 0.005% (w/v) Tween-20, 160 units/ml Rnase inhibitor and 0.1 mg/mL BSA) are dispensed to compounds in microplates, using a Thermo Multidrop® dispenser, and incubated at 37 °C in a VWR INCU-Line incubator for 60 minutes after mixing. No nucleotide triphosphate mix is added to negative control samples. Microplates with compounds to be tested in the assay are prepared from 10 mM compound stocks in 100% DMSO, equal amounts of DMSO without any compound are added to positive control and negative control samples. 0387 During the incubation, a mix of the detection reagents is prepared in a buffer such that the enzymatic reaction is terminated due to chelating of Mg-ions and increased ionic strength, containing 50 mM Tris-HCl (pH 7.5), 700 mM NaCl, 20 mM EDTA, and 0.01% (w/v) Tween-20. Europium-streptavidin is pre-incubated with a 200-fold molar excess of a random sequence oligonucleotide to block unspecific binding of oligo, for two hours at ambient temperature in the dark. Afterwards, the blocked Europium-streptavidin is kept on ice until use. 0388 At the end of the enzymatic reaction time, 5 µL detection oligo mix in the detection buffer is added, and assay plates are mixed and kept at ambient temperature for one hour, protected from light. The concentration of the Acceptor nucleotide oligo (e.g., ATTO647N-5’-ACAAAGAACCCTAACACCAG-3’) and Donor nucleotide oligo (e.g., bio-5 -AACACATCTCT(-bio)GCCAAACCCCA-bio-3 ) in each assay well is 1 nM, and 3 nM, respectively. 0389 After incubation with oligo mix, 5 µL of pre-blocked Europium-streptavidin reagent is dispensed to each assay well, assay plates are again mixed and kept at ambient temperature for one hour, protected from light. 0390 The generated signal is measured with BMG Pherastar microtiter plate reader with a TRF light unit, using excitation at 340 nm, an integration time of 200 µs, and a delay time of 100 µs, before detection at 620 nm and 665 nm. The ratio of donor- and acceptor-fluorescence is used as a measure of the generated transcript product (i.e. enzymatic activity). 0391 The IC50 values are summarized in Table 1. Table 1. E E E E E E E E E E E E E E General protocol for in vivo AML (Acute Myeloid Leukemia) efficacy experiment Determination of maximum tolerated dose of test compound 0392 Immunocompromised mice (6–10-week-old, female NSG mice, strain NOD.Cg- Prkdc scid Il2rg tm1Wjl /Szj, Jackson Laboratories) are treated orally with test compound ranging from 75 to 150 mg/kg, once or twice per day for the duration of 14 days. Total body weight is measured, and the general condition of mice is monitored routinely. Mice with severe symptoms and moribund are excluded from study. Submental blood collection method (no anesthesia) is used for all samplings. Plasma levels of test compound are determined at intervals ranging from 0.5 to 4 hours post first and last doses in all dosing groups. From these data pharmacokinetic analysis are conducted. In vivo efficacy study in AML mouse model 0393 MV4-11 AML cell lines (ATCC) are labelled with luciferase tag by viral transduction procedure (MV4-11-luc). 0394 For an AML cell line xenograft efficacy experiment, female NSG mice are given intravenously ~1 × 10 7 MV4-11-luc cells. Mice are flux sorted and randomized into treatment groups 14 days post transplantation. Mice are then treated with vehicle (50 mM Na 2 HPO 4 ), or test compound at a tolerable dose determined from the above study, once or twice per day for 21 days. Tumor progression/regression is monitored by imaging of mice using luciferin as a substrate (150 mg/kg). Images are taken on a total of 9 time points i.e., one flux sort and once weekly to end date (8 time points). Imaging is performed under anesthesia and using in vivo imaging equipment IVIS. The treatment efficacy is also measured based on proportion of human AML cells, determined by flow cytometry analysis of viable human CD45 positive cell population in peripheral blood of mice one week post last dose. Plasma levels of test compound are determined at intervals ranging from 0.5 to 4 hours post last dose. Animals are monitored individually, and total body weight is measured routinely. The endpoint of the experiment is moribundity. In addition, mice demonstrating tumor-associated symptoms including impairment of hind limb function, ocular proptosis, and weight loss are considered for euthanasia. The remaining mice are euthanized on day 60 of the study.
Next Patent: HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT